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Prenatal Medicine.
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Current screening: age, ultrasound and serum proteins 
 
Cytogenetic disorders are present in about 1 % of live births, with an increased rate 
for pregnancies in women of advanced age. Avoidance of Down syndrome births is 
the principal aim of prenatal screening for aneuploidy. The historical indicator of risk 
was advanced maternal age. Serum screening of placental analytes and ultrasound 
examination, mainly the measurements of nuchual translucency and nasal bone length 
during the first and second trimester can be used in conjunction to adjust the age 
related risk(1-4). The detection rate of all chromosomal defects amounts to over 90 %, 
but the false positive rate is high with approximately 5 % of the total screenings (5). 
Consequently, a much greater number of invasive confirmatory tests are performed 
than actual diagnoses made. A great demand for more accurate and fast methods that 
can properly determine the risk of a fetus for having a chromosome anomaly exists. 
 
 
Invasive diagnosis 
 
Prenatal diagnosis of chromosomal anomalies and single gene disorders currently 
relies on invasive testing with chorionic villus sampling or amniocentesis in 
pregnancies considered to be at increased risk for these anomalies. As it is an invasive 
procedure it can cause a miscarriage in up to 1 % of pregnancies. 
Invasive testing is advised for pregnancies that bear a high risk of being affected by a 
chromosomal aberration from family and individual history. Furthermore, women 
identified as having an increased risk by first trimester screening can opt for genetic 
testing. 
Depending on the gestational age, the invasive procedure can be chorionic villi 
sampling (CVS) or amniocentesis. Following the sampling a full karyotype is 
established. This procedure requires an average duration of two weeks for cell culture. 
Developments in laboratory methods such as Fluorescent In-Situ Hybridization (FISH) 
and quantitative fluorescent PCR (QF-PCR) of short tandem repeats (STR) (6-8)  
allow to obtain a first diagnostic answer within 24 – 48 hours. To date, these rapid 
tests complement but do not replace the full karyotype analysis as they only provide an 
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answer for a limited number of numerical aberrations (13, 18, 21, X and Y), covering 
about 70 % of all pertinent aberrations. The diagnosis of major chromosomal 
abnormalities in this shortened period after the invasive procedure offers the 
possibility of quick intervention in case of adverse results confirming aberrant 
ultrasound findings. Additionally, it is discussed whether the rapid tests can fully 
replace karyotype analysis for pregnancies at a moderate risk for chromosomal 
aberration, since the tested aberrations amount to about 99.8  % of the disorders in this 
group (9). An overview of aneuploidy testing methods is presented in chapter 3. 
 
In the context of rapid testing I recently demonstrated that the precision of the TaqMan 
based multiplex real-time qPCR can be optimized to detect as low as 3:2 differences in 
template copy number, as is the case for the affected chromosome in fetal 
aneuploidies. These preliminary results were published in Clinical Chemistry and 
comprise chapter 4 of the thesis (10). The increased accuracy exceeding the 2:1 
difference measurable according to the manufacturers was achieved by implementing 
special experimental and analytical parameters.  
Similar parameters were adopted to enable the determination of rhesus D zygosity 
using real-time quantitative PCR, chapter 5, which appeared in Swiss Medical Weekly 
2003 (11). 
We were asked to contribute a book chapter on the method of trisomy detection by 
real-time PCR for the cutting edge 2nd Edition of “Diagnostic applications of PCR” by 
Dennis Lo, which appears as chapter 6. The initial investigation was extended by 
development of an assay for the simultaneous assessment of chromosomes 18 and 21.  
We then aimed to prove the diagnostic potential of the concept in a blinded large-scale 
retrospective study on clinical samples. The results (chapter 7) indicate that real-time 
quantitative PCR is a powerful tool for the prenatal diagnosis of aneuploidies. The 
method is straightforward and can produce results of diagnostic value within as little 
as two hours. With further development of the instrumentation and reagents the test 
can be easily optimized to a high-throughput method, which would save time and 
money and would allow to analyze an increased number of targets. Alternatively, the 
test can be amended to perform testing of the sample directly at the point of care, 
without the need for technical staff, and results would be available within one hour. 
The potential speed and simple test set-up of the novel real-time PCR approach are not 
matched by other rapid methods.  
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Non-invasive molecular methods for the prenatal diagnosis and 
screening 
 
As the invasive procedures bear a considerable risk for fetal loss, a long sought goal 
in prenatal medicine is the establishment of non-invasive tests that allow for prenatal 
genetic testing. The traditional strategy to accomplish this goal was the isolation of 
fetal cells found in the maternal circulation. The later discovery of fetal DNA 
circulating in the maternal plasma has shifted the attention towards this target, which 
can be found at higher numbers than the scarce cells.  
  
 
Fetal cells 
 
Fetal cells have been known to cross the placental barrier into the maternal circulation 
for a long time, but extensive attempts to use them for prenatal diagnosis have not had 
any consistent success. In a large multi-center trial investigating the approach of 
recovering fetal cells from the maternal circulation, the NIFTY study (National 
Institute of Child Health and Development Fetal Cell Isolation Study), various 
enrichment techniques using fluorescent-activated cell sorting (FACS) or magnetic 
activated cell sorting (MACS) coupled to FISH analysis have been evaluated for 
clinical use (15) in our laboratory. This approach has proven to be too labor intensive, 
with discouragingly low detection and high false positive rates. Although the biologic 
availability of fetal cells has been demonstrated, the development of practical 
technology still requires further developments. 
Also, attempts at selectively culturing viable fetal cells from maternal peripheral 
blood have been made. Cell culture could theoretically be used to expand the number 
of fetal cells for testing. At the beginning of my thesis, a high profile report by 
Tutschek (12) raised hopes that prenatal diagnosis might be possible by this strategy. 
We aimed to confirm the reported success of the culture of single clones of fetal 
progenitor cells from maternal blood. Hemopoietic progenitor cells were cultured 
from 16 blood samples obtained from women pregnant with a male singleton fetus 
and single colonies were isolated by micro-manipulation. Examination by multiplex 
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real-time PCR identified 1’648 as maternal and no colonies of fetal origin were 
detected. This lead to the conclusion that the clonal expansion of single fetal colonies 
from the maternal circulation is not feasible by current methods (13). My work, which 
is presented in chapter 2, as well as other reports, has shown, that the results of 
Tutschek were not reproducible and findings seem to originate from artefacts in the 
analysis rather than from cultured fetal cells (comment in Lancet. 2001; Mar 24; 
357(9260): 962). 
 
 
Cell-free circulatory DNA 
 
Until recently, all efforts for the non-invasive recovery of fetal genetic material were 
aimed at fetal cells. The discovery of significant quantities of circulating cell free 
DNA by Lo in the plasma of pregnant women opened a new window for diagnosis 
(14). The free extracellular DNA can be readily extracted from maternal plasma to 
high purity and quantified by real-time Polymerase Chain Reaction amplification.  
It has been suggested that the cell free fetal DNA originates from the placenta (15-18). 
 
 
Free circulatory DNA: diagnosis of sequences not present in 
maternal genome 
 
Since it’s discovery, the use of free fetal DNA has been limited to the detection of 
uniquely paternal sequences. The determination of fetal sex by the amplification of Y-
chromosome specific sequences has been implemented in the diagnosis of X-linked 
genetic disorders (19;20). With female fetuses being unaffected, it helps reducing the 
number of invasive procedures to 50 %. Similarly, the paternal contribution to the 
rhesus D status in pregnancies of rhesus D negative pregnant women is fairly easy to 
determine from plasma DNA(21) and is already offered by health services in Holland 
and Great Britain. The test helps to prevent the prophylactic administering of anti-D 
immunoglobulins in case of a rhesus D negative fetus (22). 
Several studies assess the sensitivity and specificity of fetal DNA detection by 
amplification of sequences specific to the Y-chromosome and the Rhesus D gene in 
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the first and second trimester maternal plasma (23). These studies report 95-100 % 
sensitivity and specificity. Between 1 and 5 % of the total maternal plasma DNA 
usually correspond to the fetus during the gestational age from 11-17 weeks. Lower 
amounts of fetal DNA are observed in the first trimester resulting in a reduced 
detection rate, but fetal DNA from plasma is available in every pregnancy by the 
second half of the first trimester. 
 
 
Free circulatory DNA in screening 
 
A current focus in research on cell free fetal DNA investigates it’s use as a maternal 
serum marker in early pregnancy for fetal Down Syndrome or other pregnancy related 
complications. The quantitative measurement of fetal DNA by real-time PCR may 
complement the major second trimester serum markers. By increasing the specificity 
of the screening it could help preventing a considerable amount of unnecessary 
invasive procedures. The median of fetal DNA concentration is reported to be 
approximately twofold higher in Down Syndrome compared with unaffected 
pregnancies, but the data is disputed by other reports (24-28). Elevated levels of fetal 
DNA in the maternal plasma were also reported in pregnancies with preeclampsia and 
polyhydramnios (29-34). Large sample numbers and meticulously accurate, 
standardized quantification are demanded to allow final conclusions. 
An impediment in the generation of accurate data is the low number of fetal 
sequences in the plasma, such that the samples quantified by the real-time PCR have 
copy numbers close to the detection limit, and the quantitative value of the results is 
reduced by increased variability of the method and sampling effects. As we could 
observe in a recent comparison study between five laboratories, even use of the 
identical sample material and implementation of the same DNA extraction and real-
time quantitative PCR procedures can result in major differences of the finalized data. 
In the comparison of numerical values from different studies using different protocols, 
major discrepancies can be expected (35). In the context of clinical application it will 
be important to standardize several procedural steps which otherwise can lead to 
variability of the quantitative data. Also, a more precise description of the 
quantification procedures needs to be included when reporting results.  
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In chapter 10 we present an approach to address one of the major hindrances in the 
generation of precise and relevant data, the scarce nature of the material to be 
quantified. We amended an existing but sub-optimal real-time quantitative PCR 
protocol specific to the multicopy locus DYS14 on the Y-chromosome and evaluated 
it’s performance in comparison to the currently used SRY targeting protocol. Our 
evaluation shows that the new assay performs with an increased precision and 
sensitivity. As most reports quantify samples surprisingly close to the theoretical 
detection limit, we tried to highlight several important points to generate accurate 
data. Furthermore we show that the assay can be used for sex determination by 
applying a cut-off to exclude false positive results. 
Most studies generate data from pregnancies with male fetuses, as sequences on the Y 
chromosome are unique DNA markers absent from the maternal genome. This 
approach is only applicable to the male 50 % of the pregnancies, but straightforward 
to perform. In order to use the fetal DNA as a screening marker, a gender-independent 
fetal DNA marker that can be assayed by real-time PCR is needed. Polymorphic 
sequences are presently used in the clinical samples that are investigated for fetal 
rhesus status to ascertain the presence of adequate amounts of fetal DNA (36). 
Although a number of sequences has to be examined in each pregnancy to ascertain 
distinction between fetal and maternal, this approach is still relatively facile to 
implement. 
 
 
Mutation detection with free DNA 
 
A caveat of the approach is that the DNA present in the circulation is predominantly 
of maternal origin and interferes with molecular analysis of the fetal DNA. Hence, 
only paternally inherited fetal loci that are clearly distinct from maternal genomic 
sequences can be readily examined. Paternally inherited mutant genes in compound 
heterozygous genetic disorders may also be detected if the paternal mutation is 
dissimilar from the maternal allele, as for example a four base deletion causing 
thalassemia (37). In general, the detection of fetal single gene disorders is at least 
cumbersome and often impossible with current methods. Likewise does the 
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determination of gross chromosomal abnormalities require another advancement in 
the technology before it is feasible in a non-invasive manner. 
I participated in the successful enrichment of fetal DNA as compared to the maternal 
fraction from plasma by agarose gel electrophoresis mediated size separation. By this 
approach, which is presented in chapter 8 (38), we were able for the first time to 
detect fetal STR-alleles in size-separated DNA isolated from maternal plasma. Very 
recently it has also been shown by Lo that the majority of the fetal circulatory DNA in 
the plasma of pregnant women is of short length, which is contrary to the much longer 
total circulatory DNA, confirming the validity of our approach (39). 
We applied the strategy of enriching the proportion of fetal DNA for the detection of 
point mutations in the beta-Globin gene causing thalassemia. Our successful analysis 
of 15 of 16 samples is presented in chapter 9. 
A recent report (40) claimed the recovery of increased proportions of fetal DNA from 
maternal plasma, rendering DNA extracts of in average 25 % fetal origin. The 
decreased levels of maternal DNA were claimed to be due to stabilzation of cells by 
formaldehyde at the time of blood sampling. However, when we tried to repeat the 
results, our quantification by real-time PCR could not confirm this massive increase 
of the fetal percentage (chapter11). 
 
 
Circulatory RNA: discovery, stability, promises 
 
The presence of cell free fetal DNA in maternal plasma has revealed significant 
clinical potential for the prenatal diagnosis of fetal genetic diseases and pregnancy-
associated complications. Extending beyond plasma DNA, a new field of 
investigation has opened by the demonstration of the cell free form of fetal RNA in 
maternal plasma, which is surprisingly stable and holds promise for non-invasive 
profiling of placental gene expression (41). As gender independent fetal DNA 
markers are laborious to implement, efforts to identify screening markers for 
pregnancy-associated disorders, such as preeclampsia or aneuploidy, now focus at 
identifying placentally expressed mRNA. To date only a few reports present 
quantitative data on this phenomenon. They indicate that mRNA from maternal 
plasma may be used as a gender independent marker group that provides a suitable 
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screening tool for pregnancy associated pathologies. Quantitative analysis of mRNA 
has proven to be very complicated in other fields of research, with great variability of 
the data due to the instability of the target molecules and variable efficiencies of the 
reverse transcription step. Also, plasma markers of fetal origin and clinical relevance 
await to be established. 
 
In summary, the present findings point mainly to the possible use of fetal DNA or 
RNA as additional screening analytes for chromosomal anomalies and other 
complications of pregnancy. The ultimate goal is to develop non invasive prenatal 
procedures that can be used for the diagnosis of chromosome and single gene 
disorders. 
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Abstract  
 
Objectives: To confirm the recent report of the culture of single clones of fetal 
progenitor cells from maternal blood.  
Methods: Hemopoietic progenitor cells were cultured from 16 blood samples 
obtained from women pregnant with a male singleton fetus. Single colonies were 
isolated by micro-manipulation and examined by multiplex real-time PCR.  
Results: Of a total of 1,674 colonies examined, 1,648 were identified as being 
maternal. No colonies were detected of fetal origin.  
Conclusions: The clonal expansion of single fetal colonies from the maternal 
circulation is not feasible by current methods.  
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Introduction  
 
The isolation of fetal cells, specifically fetal erythroblasts, from the blood of pregnant 
women offers a unique opportunity for the non-invasive risk-free examination of fetal 
genetic traits [1, 2]. Previous proof of concept studies have shown that both fetal 
aneuploidies as well as inherited single gene disorders can be detected by the analysis 
of such enriched fetal erythroblasts by either FISH (fluorescence in situ hybridisation) 
or PCR (polymerase chain reaction) [1, 2]. These pioneering studies have also 
indicated that the frequency of fetal cells in the maternal periphery is very low, being 
of the order of 1 in 106 to 1 in 107 maternal nucleated cells [3]. Due to their scarcity, 
only very few fetal cells are recovered from normal maternal blood samples, which 
implies that a diagnosis may be based on the analysis of one or two cells. Our own 
experience in the simple determination of fetal sex by the use of FISH for the X and Y 
chromosomes on enriched fetal erythroblasts has shown that optimal specificity is 
attained when 3 or more cells can be evaluated [4]. In a similar manner, it has been 
shown that the examination of single cells by PCR is also prone to several technical 
problems of which the most evident is allele dropout, a PCR phenomenon whereby 
only 1 allele of a particular locus is efficiently amplified [5, 6]. In this manner 
heterozygous loci could be incorrectly determined as either being homozygous 
wildtype or of greater concern as homozygous affected mutant [5]. An approach we 
have developed to counter this problem is the independent analysis of several 
candidate fetal cells by single cell PCR, by which means we have shown that 
diagnostic efficacies of almost 100% can be attained from the analysis of 4–5 fetal 
cells despite an allele dropout rate of over 40% [7]. The caveat of this approach is that 
it requires the reliable detection of at least 5 fetal cells, a feature we have not always 
been able to achieve, even when using a highly optimised enrichment protocol with 
normal maternal blood samples [8]. A further disadvantage of only being able to 
examine a few differentiated non-dividing cells is that it is impossible to obtain 
conclusive information regarding the entire fetal karyotype. For this reason, several 
researchers have attempted to culture fetal hemopoietic progenitor cells which have 
been enriched from the maternal circulation. Reports indicating that such approaches 
may be feasible have been made by Valerio et al. [9, 10] as well as by the group of Di 
Renzo [11]. In their studies these researchers have used either anti-CD34 or 
erythropoietin receptor based enrichment procedures in order to obtain sufficient fetal 
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progenitors which could then be amplified in culture. By these means Valerio et al. 
[12] have reported upon the successful identification of fetal aneuploidies. As these 
enrichment procedures and culture conditions are quite complex they are deemed as 
being too difficult to adapt to a routine clinical setting. In this regard, the recent report 
by Tutschek et al. [13] of the clonal expansion of fetal progenitors directly from non-
enriched maternal blood samples has considerably raised hopes that it may be possible 
to obtain sufficient fetal cells for complex genetic analyses by less technically 
challenging means. The aim of our experiments has been to confirm this observation 
in an independent manner.  
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Materials and Methods  
 
Blood Samples  
For this study we recruited 16 women with normal pregnancies between 13 and 41 
weeks of gestation who had been identified by routine ultrasound examination to be 
carrying a singleton male fetus. None of these women had an invasive prenatal 
diagnostic sample performed in this pregnancy prior to blood letting. The Institutional 
Review Board of the University of Basel granted approval for this study. Written 
informed consent was obtained in all instances.  
 
Isolation of Peripheral Blood Mononuclear Cells (PBMC)  
Isolation and culture conditions were used as described by Tutschek et al. [13]. In 
brief, 7-ml maternal blood samples were collected into a vacuum tube containing 
EDTA as an anticoagulant (Sarsted, Nümbrecht, Germany). The samples were all 
processed within 6 h. The mononuclear cells were separated by single-density 
gradient centrifugation (Ficoll-Paque, Amersham, Uppsala, Sweden), washed twice in 
phosphate-buffered saline (PBS) and resuspended at a density of 106 cells/ml in PBS.  
 
Semisolid Culture of Erythroid Progenitors  
The cells were cultured in 24-well plates, 0.8 ml per well, at densities of 0.15 million 
cells/ml, in a semisolid 1% methylcellulose medium for the assay of human 
clonogenic hematopoietic progenitors, containing 30% FBS, 1% BSA, 10–4 M 2-
mercaptoethanol, 2mM L-glutamine, 50 ng/ml rh SCF, 20 ng/ml rh GM-CSF, 20 ng/ 
ml rh IL-3, 20 ng/ml rh IL-6, 20 ng/ml rh G-CSF and 3 U/ml rh epo in Iscove’s 
modified Dulbecco’s medium (Methocult TM GF+ 4435, Stem Cell Technologies).  
 
Micromanipulation and Lysis  
After 10 days of cultivation, single colonies containing 150 cells were isolated by 
micro-manipulation: 100-µl glass micropipettes were drawn into fine micro-capillaries 
using a Leitz needle puller (Leica, Basel, Switzerland). Single colonies were drawn 
into these micro-capillaries under microscope guidance. Single colonies were 
transferred into a single PCR reaction vessel and lysed at 50°C for 1 h in 17 µM SDS 
containing 400 ng/µl proteinase K.  
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TaqMan Real-Time PCR  
The lysates were analysed in duplicates by the TaqMan real-time multiplex PCR, 
amplifying the SRY (sex determining region) locus on the Y-chromosome to identify 
male fetal clones, and the ubiquitous GAPDH (glyceraldehyde 3-
phosphodehydrogenase) gene on chromosome 12 as a positive internal control as 
described previously [14].  
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Results  
 
In this study, we examined 16 maternal blood samples from women pregnant with a 
singleton male fetus as identified by ultrasonography. Following culture under 
conditions optimised for the expansion of erythropoietic progenitor cells in semi-solid 
medium, single colonies were isolated by micro-manipulation. These were then 
examined by a real-time multiplex PCR assay, which permits the simultaneous 
detection of the male Y chromosome and the ubiquitous GAPDH gene. In this 
manner, it would be very easy to distinguish between cells of male fetal origin and 
those which are of maternal origin, as the former would be positive for both the Y 
chromosome and the GAPDH gene, whereas the latter would only be positive for the 
GAPDH gene. In our experiment we isolated a total of 1,674 individual colonies by 
micro-manipulation, varying from 50 cells to several thousand cells per colony. As 
these clones had been grown in semi-solid medium, they are completely clonal in 
origin having originated from a single cell. In our real-time PCR analysis of these 
single colonies we obtained efficient amplification in 1,648 clones (98.4%) (table 1). 
Only in 26 of the isolated colonies could we not obtain any reliable amplification 
(1.6%). All of the 1,648 tested colonies proved to be positive solely for the GAPDH 
control gene, but not for the male specific SRY locus. They were determined to be of 
maternal origin. We could detect one colonies which was clearly male and of fetal 
origin.  
 
Table 1. Examination of single culture colonies by multiplex TaqMan PCR 
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Discussion  
 
In this study we have attempted to confirm a recent report [13] regarding the very 
simple clonal expansion of fetal progenitor cells from maternal blood without the 
need for a specific enrichment step. In order to identify colonies of fetal origin, 
Tutschek and colleagues used a complex PCR assay for highly polymorphic 
microsatellite markers, also termed short tandem repeats (STRs). As this assay is quite 
tedious to perform, we have elected to use a simpler and more rapid method, namely 
real-time multiplex PCR for the male SRY locus and the ubiquitous GAPDH gene 
[14, 15]. Since we were only examining pregnancies with singleton male fetuses, any 
colonies of fetal origin would be positive for both the SRY locus and GAPDH gene. 
On the other hand, colonies derived from the mother would only be GAPDH positive. 
The advantages of this assay over the STR one is that it has a much higher throughput 
in that up to 96 different PCR reactions can be examined simultaneously. The 
TaqMan real time PCR system is also less prone to contamination as the PCR reaction 
is monitored directly in the reaction vessel on-line. There is, hence, no need to open 
the PCR reaction vessels in order to examine the PCR product. It is at this step that 
the contamination of subsequent reactions by the presence of highly amplified target 
DNA sequences is most likely to occur. Furthermore, since the assay is quantitative, 
purely fetal colonies will be expected to have the correct 1:2 gene dosage ratio of the 
SRY locus located on the single Y chromosome to the autosomal GAPDH gene 
located on chromosome 12. In this manner, we should be able to detect any 
contamination with PCR products or extraneous male DNA. In our study, which 
attempted to duplicate the report of Tutschek et al. [13] as closely as possible, we 
were unable to confirm the presence of any clonal colonies of fetal origin in maternal 
blood cultures. Since we have considerable experience with the culture of early fetal 
hemopoietic progenitor cells [16], it is unlikely that our lack of success is due to a 
technical deficit. Rather, our result may reflect upon some discrepancies in the initial 
publication which have recently been commented upon by the group of Fisk in 
London [17]. The chief criticism raised was that Tutschek and colleagues reported 
presence of colonies of mixed origin, a strange feature as colonies which are cultured 
in semisolid media arise from a single progenitor cell and are therefore truly clonal in 
origin. In our view, it appears that Tutschek and colleagues may have been misled by 
an error in the complex STR PCR assay they were using. Due to their highly 
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repetitive nature, usually consisting of a varying number of CG repeats, it frequently 
occurs that the PCR polymerase incorrectly amplifies the correct length of the STR 
marker under investigation [5, 7]. Under such conditions it is easy to misinterpret the 
incorrectly amplified allele and consequently regard it as being indicative of fetal 
rather than of maternal origin. An example of such an artefact is illustrated in figure 1, 
where two different microsatellite patterns are obtained from the same DNA source 
solely due to incorrect amplification of the polymorphic marker interrogated. Such 
incorrect amplifications frequently occur when dealing with small cell numbers [5, 7], 
as would be the case when dealing with single micro-manipulated colonies. Of further 
note is that Tutschek et al. [13] did not report the detection of any male colonies 
despite the use of a sex determining amelogenin specific PCR reaction. Therefore, our 
data suggest that the culture of fetal progenitor cells from the maternal circulation is 
not feasible by the described method, and that it would probably be best to involve 
some enrichment step, such as anti- CD34 [9–11], in order to obtain a higher 
proportion of fetal hemopoietic precursor cells.  
 
Fig. 1. PCR analysis of highly polymorphic microsatellite markers. In this PCR analysis of a highly 
polymorphic microsatellite marker two differently sized amplicons are obtained due to incorrect 
amplification of the allele investigated. Top: Alleles 1 and 2 are correctly amplified. Bottom: Allele 1 is 
amplified correctly, whereas allele 2 is incorrectly amplified and thereby yields a fragment of incorrect 
size (2a). This can easily be misinterpreted as being a different allele, e.g. of paternal rather than 
maternal origin.  
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In every pregnancy there is a risk that the fetus may have aneuploidy. Until about two 
decades ago this risk used to be assessed based on maternal age and family history 
only. Since then other factors, which affect this risk have been discovered and some 
of them have been introduced into clinical practice of genetic counseling. Currently 
the parameters that are employed for prenatal screening in the first trimester are: 
nuchal translucency (NT) measured by ultrasound (NT is on average increased in 
fetuses with trisomy 21), nasal bones presence assessed by ultrasound (nasal bones are 
absent in the majority of trisomy 21 first trimester fetuses), Pregnancy Associated 
Plasma Protein A (PAPP-A in maternal serum is on average reduced in trisomy 21 
fetuses), and free beta subunit of human chorionic gonadotrophin (free beta hCG in 
maternal serum is on average increased in trisomy 21 fetuses) measured in maternal 
serum. Deviations of the examined parameters from the median for the normal 
population are converted into a risk factor by which the a priori risk is multiplied so as 
to arrive at the final risk of fetal disorder. If the risk of fetal aneuploidy is high enough 
to justify an invasive test (usually the cut-off value for the risk of birth of a child with 
trisomy 21 is around 1 in 300 – equivalent to the risk in a 36 year old woman at birth), 
amniocentesis or chrionic villi sampling is advised.1 
Screening utilizing the above mentioned parameters in the first trimester to derive the 
risk is the most efficient way to screen for trisomy 21, trisomy 18 and 13, triploidy 
and monosomy X. This method of screening enables fairly good discrimination 
between healthy and aneuploid fetuses: in a general (low risk population) detection 
rates of the aforementioned aneuploidies (without nasal bones assessment) are close to 
90% with a false positives rate of 5%. Recent evidence shows that the addition of 
nasal bones assessment would either boost the sensitivity of trisomy 21 screening to 
around 97% at 5% false positives or at the sensitivity of 90% decrease the false 
positives rate to around 1%.2  
Screening is rational only when a large proportion of population is tested, which 
means that even with ideal implementation of the test, a large number of women will 
present with increased risk of the fetal disorder. This calls for a cytogenetic test, 
however, this is expensive and takes long time to obtain the result, which is 
unacceptable for many women. The most common procedures to obtain fetal tissues 
for cytogenetic testing are amniocentesis, chorionic villus sampling and fetal blood 
sampling. These procedures are connected to a small, but definite risk of fetal death.  
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Conventional cytogenetics using Giemsa banding of metaphase chromosomes has 
proven to detect a wide range of abnormalities with high trustworthiness, deserving 
the position of a gold standard in prenatal diagnosis. Because this technology is so 
reliable, it has not changed much for the last 30 years, even earning for this reason an 
affectionate name of “the alive fossil”. This conservatism in the era of rapidly 
evolving molecular methods is however not entirely kept, as cytogenetics has in 
recent years, combined with molecular biology, gone through renaissance with 
resulting development of FISH and CGH with all their varieties. The unique and 
unquestionable merit of classical cytogenetics is the ability to screen the whole 
genome in a “single test” and to detect balanced rearrangements. The resolution of 
classical cytogenetics is of the order of only 4 to 6 million base pairs, which 
constitutes one of the most serious drawbacks. Classical cytogenetics is subject to 
technical problems such as culture failure, external contamination and selective 
growth of maternal cells. Quantitative interpretation of banded karyotypes can be 
limited by cell-to-cell variability in chromosome condensation and staining 
characteristics. The subjective nature of the banded karyotype analysis also potentially 
complicates interlaboratory comparisons of the size or staining characteristics of 
specific lesions or polymorphisms.3 Among other earnest problems are high cost, low 
throughput, long turnaround time, limitations of suitable test material to viable, 
dividing cells and requirement for unique, highly qualified staff.  
Since balanced chromosomal rearrangements are usually associated with a normal 
phenotype, in prenatal diagnosis detection of unbalanced rearrangements and 
particularly autosomal trisomies is principal. 
Search for a molecular biology method that would replace or at least augment 
classical cytogenetics is underway because it is expected that DNA-based methods 
will be cheaper, faster and will have greater resolution. The time to result is a 
particularly important issue, since more and more women are referred for invasive 
prenatal diagnosis with very high risk after prenatal screening and the long time 
necessary for the classical cytogenetics is unacceptable for them.4,5,6 
There are many molecular techniques that potentially may be used to detect the 
underlying chromosome copy number changes in unbalanced rearrangements: 
fluorescent in situ hybridization (FISH), Southern blots, loss of heterozygosity (LOH) 
assays, microarray technology, comparative genomic hybridization, automated 
nuclear DNA cytometry, different modifications of quantitative polymerase chain 
reaction (Q-PCR). Nevertheless some of them are not practical in routine prenatal 
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diagnostic setting for different reasons: requirement for a large amount of DNA 
(Southern blot, LOH), high cost and labor-intensity (FISH, CGH, microarrays), 
inability to run in multiplex assay (FISH, LOH). 
In this article we will focus mainly on the PCR-based molecular methods, that may be 
expected to come into practice as they are amenable to automation and high 
throughput. 
 
 
Southern blotting 
 
In Southern blotting, DNA fragments separated by gel electrophoresis are transferred 
to the support membrane and the results can be analyzed spatially in terms of 
molecular weight or relative position. In quantitative Southern blotting copy number 
changes of specific DNA sequences are assessed by measuring the intensity of the 
bands by means of densitometry. Deletions or duplications can also be detected if they 
delete or duplicate a restriction site. Special equipment (e.g. phosphoimager), 
providing linear dose-response curve is necessary for quantitative measurements since 
classical photography provides non-linear curve. Quantitative blotting is a relative 
quantitation method and, therefore, relies on the inclusion of one or more internal 
controls or reference sequences; quantitation of DNA is relative to this reference 
sequence of known copy number. However quantitative inference can be undermined 
by several factors, e.g. densitometric measurement utilizing ethidium bromide can be 
complicated by irregular backgrounds and diffused bands7. 
Quantitative Southern blotting requires large amounts of DNA, therefore it is not 
suitable for prenatal diagnosis. The process is also cumbersome and requires strictly 
controlled conditions. 
 
 
 
Fluorescent in situ hybridization 
 
Fluorescent in situ hybridization (FISH) utilizes fluorescent-labeled probes, which are 
fluorescently stained single-stranded DNA segments complementary to regions of 
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individual chromosomes. These probes hybridize with target DNA sequences in the 
sample and can be identified using fluorescence microscopy. The light signals emitted 
by the fluorescent stain enable enumeration and spatial analysis of complementary 
sequences and identification of chromosomal abnormalities, such as trisomies, 
monosomies, and duplications.8 
DNA probes used in prenatal diagnosis of aneuploidy by FISH can be categorized in 
the following way:  
• probes consisting of tandemly repeated human DNA sequences, such as 
centromeric alpha satellite sequences, which are often used for identification 
and enumeration of specific chromosomes in interphase nuclei.  
• Unique sequence probes, which are used for identification of small regions of 
the genome which may be deleted or duplicated in certain syndromes and are 
often missed by conventional cytogenetics (e.g. Williams and DiGeorge 
syndromes). 
•  Mixtures of unique probes from the same chromosome or chromosome 
segment which are used to stain, or "paint," large sections of the entire 
chromosome. Such staining allows analysis of the chromosome number as 
well as identification of additions and translocations in metaphase cells.9 
 
Fluorescent in situ hybridization (FISH) studies of interphase cells avoids the need to 
culture cells and reduce the time required for the diagnosis. However, this technique is 
relatively labor intensive, requires intact cells and technical expertise, and is unable to 
detect balanced rearrangements and imbalanced aberrations involving chromosomal 
segments other than the sequences complementary to the probe set used. The major 
aneuploidies diagnosed prenatally by most often used probes set involve the 
autosomes 13, 18, 21, and sex chromosomes. FISH on interphase nuclei provides an 
initial rapid screen preceding the full cytogenetic evaluation.10 
 
 
PCR 
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PCR is the most widely used technique of genetic analysis, owing to the combination 
of the highly specific hybridization and exponential amplification of the target 
sequences. In quantitative PCR, the amount of PCR product is proportional to the 
quantity of the initial target sequence, as long as the reaction is stopped during the 
exponential phase. The product’s starting amount has to be  calculated from quantities 
of the exponential phase as end point measurements are not precise enough.  
Of the molecular methods amenable to quantitative study the polymerase chain 
reaction has several advantages: it is less labor intensive and more sensitive than in 
situ hybridization and, unlike Southern blot analysis, does not require transfer to a 
membrane and hybridization for quantitation. 
When using PCR for quantitative measurements, the following issues need to be kept 
in mind: 
• the measurement should be made during the reproducible exponential phase of 
the amplification. Consequently, the number of cycles may not be exceedingly 
high, as with very high cycle numbers the competing products and other 
factors decrease amplification efficiency, causing plateau effect. 
• the concentration of the starting DNA may not be very low, as with very low 
sequence copy numbers the early phase of amplification is stochastic in nature, 
(e.g. allele drop-out phenomenon) 
• In multiplex PCR presence of multiple primer pairs compromises the 
robustness of the reaction and reliability of quantitation.11  
• Comparisons “between wells” may not be valid, because of small deviations 
resulting e.g. from pipetting errors, alterations in polymerase activities etc. 
(This shortcoming would not be overcome even by post-run data analysis12,13.) 
Performing a quantitative PCR reaction to determine ploidy of the sample, an internal 
standard must be implemented, which enables relative quantitation. While diagnosing 
aneuploidy of a given chromosome, sequences specific for other autosomes may be 
chosen as such standard. The detection of fetal aneuploidy is a particularly difficult 
task, involving more precision than usual quantitative applications, because it requires 
unequivocal discrimination of quantities of the DNA being in the ratio of 3:2. Most of 
the described methods enable distinguishing between the quantities of the order of at 
most 2:1. 
The qPCR methods suitable for the detection of fetal aneuploidy may be divided in 
two groups: assays in which measurement is performed by measuring the amount of 
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products after additional analytical steps and assays in which measurement is 
performed during the very process of amplification. Quantitative fluorescent PCR, 
Multiplex Amplifiable Probe Hybridization (MLPH), Multiplex Probe Ligation Assay 
(MLPA) and melting curve of SNP after the PCR belong to the former and real-time 
quantitative PCR to the latter group. 
 
 
Quantitative Fluorescent PCR 
 
Historically the first attempt for PCR-based detection of aneuploidy involved PCR 
amplification of small-tandem-repeat (STR) markers located on a given chromosome, 
and analysis by fluorescence-based methods to identify the presence of an additional 
allele on the third copy of the chromosome or absence of the second allele, denoting 
its monosomy. This DNA approach was first used for the diagnosis of monosomy X, 
and has since been modified to include the identification of some other common 
trisomies. Many studies have assessed the clinical usefulness of this technique.14,15,16 
The main advantages of this approach for the prenatal diagnosis of trisomy 21 Down’s 
syndrome, on DNA extracted from uncultured samples of amniotic fluid, are the small 
amount of fluid required and the speed and accuracy with which the test can be done. 
The technique can be automated and 96 samples processed simultaneously, and 
results available within the same day. It is also objective, but requires special software 
for interpretation and the development of a set of markers designed particularly for 
this purpose.17 After amplification of chosen polymorphic sequences for a limited 
cycle number, the fluorescent labeled PCR products are analyzed by electrophoresis. 
Quantitative assessment of copy number can be performed by measuring the area 
under the curve of the specific peak on the electrophoregram. A normal result shows 
two different-sized alleles with peaks of equal intensity on electrophoregram. A 
trisomic sample shows either three different-sized alleles of equal intensity or two 
peaks with a ratio of 2/1. A single peak is equivocal: it could indicate the presence of 
either two or three chromosomes carrying the same size allele; thus a normal sample 
cannot be distinguished from that of a Down’s syndrome fetus with this marker and 
an analysis using a different, informative allele is necessary.  
Up to now, the STR-based strategy has been the method of choice for molecular 
detection of aneuploidies. Although attractive, this method has several disadvantages. 
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At least two highly heterozygous short tandem repeat (STR) markers are needed to 
determine trisomy 21 using QF-PCR with fluorescent STRs.18 In some cases, 3, 4 or 
more markers are used, increasing the complexity of the PCR19. Levett et al., in a large 
prospective study of 5000 amniotic fluids, were not able to conclude for 1 
chromosome in 2% of the samples because 7 out of 8 markers showed a homozygous 
peak.20 The major drawback here is the need for an informative polymorphism, as 
even when using multiple sequences, in a proportion of patients no informative 
sequences may be found. The polymorphic loci show different frequencies in different 
populations, as a result polymorphisms found to be optimal in one population may be 
ineffective in another population.21 A further Drawback of the assay is that polymerase 
stuttering can lead to products of false length which may lead to misdiagnosis. Certain 
polymorphisms are more prone to this error and usually replaced by better ones. 
Such approach can detect aneuploidy resulting from first or second meiotic divisions. 
This is a semi-quantitative test, with less need for precision than pure quantitative 
measurement. Summing up, to detect trisomy using polymorphic sequences one needs 
either 3 alleles of different length with equal amounts of products or a 2-allele pattern 
characterized by a 2:1 ratio.  
Maternal cell contamination is associated with additional peaks and distortion of the 
ratios of the QF-PCR peaks even if the maternal cells are present in low number. 
However, admixture of maternal cells can be confused with mosaicism irrespective of 
the method and constitutes a problem for all, not only PCR based techniques.22  
 
 
Multiplex ligation-dependent probe amplification (MLPA) 
Multiplex Amplifiable Probe Hybridization (MAPH) 
 
MLPA is a recently developed PCR-based quantitation technique, that enables robust 
quantitation of up to 40 sequences in a single test, using only one pair of primers. By 
using identical primers, the reaction efficiencies are equal for each target. In this 
approach, not sample DNA but probes added to the samples are PCR amplified and 
their amplification products quantitated. The template amplified in this reaction 
consist of two oligonucleotide probes, which after specific hybridization to a target 
sequence undergo ligation. One of these oligonucleotides  has a common sequence 
used as a primer for the PCR reaction at 5’ end and a specific sequence, hybridizing to 
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the target sequence at 3’ end. The other oligonucleotide consists of three parts: At the 
5’ end a sequence, that hybridizes to the target sequence adjacent to the sequence 
recognized by the former probe, a common sequence used for amplification at the 3’ 
end and a non-hybridizing so called “stuffer” sequence of variable length in between. 
During the reaction each oligonucleotide probe of a pair hybridizes to its target 
sequence adjacent to the target sequence of the second oligonucleotide and 
subsequently the two parts of the probe are ligated by a ligase, which is very sensitive 
to probe-target mismatches close to the ligation site. Then the DNA is melted, ligase 
inactivated and the PCR performed. The mismatch at, or very close to, ligation site or 
inability of one of oligonucleotides from the pair to hybridize prevents subsequent 
amplification. The lengths of the stuffer sequences and target sequences are chosen in 
such a way, that the resulting PCR products differ in size (by around 6 to 9 bp), 
permitting to distinguish the products originating from different sequences by their 
length. The PCR products subsequently undergo capillary electrophoresis and the 
fluorescent peaks are used for quantification. A relative probe signal is calculated for 
every probe (length) by dividing each individual peak area by the sum of the peak 
areas of all the probes in the sample and expressed as a multiple of the relative probe 
signal obtained in a control sample. The expected value for euploid sample is close to 
1 and for trisomic sample is close to 1,5. The first blind, prospective clinical trial 
found this new method robust and reliable. New trials are underway.23 
 
MAPH is another recently developed PCR-based quantitation technique enabling 
quantitation of multiple DNA sequences. In MAPH sample DNA is denatured and 
bound to a nylon membrane. In this technique, like in MLPA, not the sample DNA, 
but the probes, hybridizing to this DNA are amplified. The so called amplifiable 
probes used in this method are between 100 and 600 bp long. Their sequences 
correspond to the different loci tested and are flanked by the same primer-binding 
sequence. Amplifiable probes, matching the loci which are to be quantitated are 
hybridized to the immobilized DNA. Because the probes are in surplus, every 
sequence to be recognized in the sample DNA is occupied, so there is a direct relation 
between the copy number of the target sequences in the sample DNA and amount of 
the bound probe. The filter with bound sample DNA and hybridized probes is 
thoroughly washed, to remove any unbound probes. Then the filter is incubated at 
95oC to release the probes, which are subsequently amplified for around 20-25 cycles. 
The amplification is stopped during the exponential phase of PCR. One of the primers 
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is usually coupled to a fluorophore, to enable detection and measurement of band 
intensity after gel or capillary electrophoresis. To our knowledge MAPH has not been 
used yet to screen for aneuploidy, nevertheless potentially it is a method that in a 
single run could quantitate multiple (around 40) sequences from the genome, for 
example detecting common aneuploidies and microdeletion syndromes. 
Both MLPA and MAPH rely on sequence-specific probe hybridization to genomic 
DNA, followed by amplification of the hybridized probe, and semi-quantitative 
analysis of the resulting PCR products. The relative peak heights or band intensities 
from each target indicate their initial concentration. The two techniques differ in the 
ease with which probes can be generated in house, and the labor intensity of 
performing the assay.24  
 
 
Allele Quantification Combined with Melting Curves 
Analysis of Single-Nucleotide Polymorphism Loci 
 
In this technique PCR products amplified from the two different alleles of a pair of 
heterozygous chromosomes are distinguished by temperature-dependent loss of 
fluorescence by hybridization probes which is converted into two "melting peaks" 
centered on the melting temperature specific for each allele. In euploid DNA, for each 
heterozygous SNP, an allele ratio of 1:1 is anticipated, whereas in trisomic samples 
ratios of 1:2 are expected. The representation of each allele is estimated by the area 
under the curve of the derivative melting curve in a post-PCR melting step.25 The 
measurement can be performed in the same well and in a real-time PCR instrument, 
avoiding additional sample handling or processing. 
The disadvantage here is need for an informative polymorphism, as even when using 
multiple sequences, in a proportion of patients no informative sequences may be 
found.. In theory, a panel of six independent SNPs, each heterozygous in 50% of the 
population, provides an accuracy >98% if diagnosis is established with only one 
heterozygous locus. In a clinical test that would require confirmatory data from at 
least two SNPs, informative data would be obtained for more than 89% of the 
population. 
The assay is rapid, with little sample demand, but requires several control reactions 
due to variability between tests. 
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Real-time quantitative PCR (qPCR):  
 
One of the most robust and versatile tools for the measurement of the copy number of 
nucleic acid sequences that has recently been developed is real-time quantitative PCR. 
It gained popularity because it is more sensitive, specific and reproducible than 
previous techniques and owing to these features it has been employed for the analysis 
of gene expression, determination of gene deletions or duplications in various areas of 
research. It is worth to point out that recent instruments make it possible to obtain 
results of certain tests after 15 minutes. In comparison to conventional PCR, real-time 
PCR also offers a much wider dynamic range of up to 107-fold (compared to 1000-
fold in conventional qPCR). This means that a wide range of ratios of target and 
normaliser can be assayed with equal sensitivity and specificity.  
This technique requires a thermocycler combined with an optical device for excitation 
of fluorochromes and detection of emitted photons. Real Time qPCR, unlike 
“classical” PCR, enables monitoring of the accumulation of the product during the 
amplification process, which allows abandoning the gel separation phase. 
Consequently, the analysis is performed in a single well in a closed system without 
further sample handling. Accumulation of the product can be detected by several 
different fluorescence markers: intercalating dyes, molecular beacons, dual-labelled 
probes. Of these, intercalating dyes are the most prone to false results, because of the 
appearance of the non-specific double-stranded products. The TaqMan real-time 
qPCR is based upon fluorescence produced by the 5’ nuclease method: A so called 
TaqMan dual labelled probe with a fluorescent detector dye at the 5’ end and with a 
quencher at the 3’ end hybridises to a specific sequence between the two primers. The 
annealing temperature of the probe is higher than the melting temperature of the 
primers, guaranteeing that in every cycle a labelled probe hybridizes to every 
complementary sequence before primers bind. After the primers have bound to the 
DNA, the Taq polymerase starts elongation and at the same time, owing to its 
nuclease activity, nicks the 5’ end of the probe. This separates the detector from the 
quencher, which causes the detector dye to emit a characteristic fluorescence signal 
when excited by light. Because the cleavage of each dual labelled probe is the result 
of a single amplification event, the intensity of excited fluorescence is directly 
 36
proportional to the number of probes cleaved and the amount of PCR product 
synthesised.. 
It has recently been proven, that the accuracy of the Real Time qPCR is even superior 
to the specifications given by equipment manufacturers, in that it can detect as low as 
3:2 differences in copy number, whereas the lowest differences reported to date were 
2:1. Detection of the differences of the order of 3:2 is evidently a requirement when 
attempting to determine fetal aneuploidy. Achieving such high accuracy requires 
implementation of stringent experimental and analytical conditions. The quantitative 
PCR is based on comparable and stable PCR efficiencies for the target sequences, one 
located e.g. in the Down’s syndrome critical region and the others on different 
chromosomes.  
Currently spectral overlap of fluorophores limits the maximum possible number of 
simultaneous amplifications up to four sequences in existing Real Time qPCR 
machines, so potentially four sequences could be quantitated in a single test in one 
well.26 
There are significant advantages of Real Time qPCR in comparison to other systems: 
the closed system reduces the risk of contamination and saves space. There is no need 
for post PCR processing, which saves time and provides an elegant and reproducible 
assay. Data for analysis are collected not at the arbitrarily chosen end of the 
experiment, but accumulate during the amplification, and the optimal point (or 
multiple points) for analysis may be chosen retrospectively, depending on the 
characteristics of the amplification profile. The shape of the amplification curve per se 
provides means of quality control of the analysis. The technique is amenable to 
automation and high throughput and the sample demand is little. Also, as it targets 
non-polymorphic sequences, a once established assay should be applicable to all 
patients, and multiple loci only need to be examined for security purposes. 
However there are some disadvantages too: the cost of the reagents surpasses the 
conventional assays and only up to four sequences can be examined in multiplex. The 
fact, that the control sequences come from other chromosomes of the same sample 
implies that real-time quantitative PCR cannot distinguish triploidy 69,XXX from 
normal 46,XX. 
 
 
Discussion 
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We are still at an early stage of development of molecular techniques for the detection 
of fetal aneuploidy. We may even hypothesize, that trustworthiness of classical 
cytogenetics hampered the development of competitive molecular methods. Recently 
the main source of increased demand for faster, molecular methods is a large 
proportion of fetuses that are karyotyped because of the very high risk after efficient 
non-invasive screening. Up to now however, most prenatal laboratories do not 
perform these tests in all patients and there is no uniform agreement which of these 
methods will become a method of choice. 
DNA sequence based methods provide a means for the detection of autosomal trisomy 
in one of the following ways:  
• Detection of polymorphisms. Making use of highly polymorphic sequences, 
detection of three allelic variants of a sequence in a sample indicates trisomy 
of the putative chromosome. Detection of two allelic polymorphic sequences 
does not exclude trisomy. If one of them is present in a second copy from a 
surplus chromosome, detection of a 2:1 ratio is possible, denoting trisomy. 
Methods based on this phenomenon PCR of STR, melting analysis of SNP 
• Detection of abnormal sequence or chromosome dosage is based on the 
number of sequence copies specific for the target chromosome relative to 
another sequence on another chromosome. This approach requires precise 
quantitation, because the proportion of target sequence copy number in the 
trisomic cells is 3:2 – euploid is 2:1. Methods using this are real-time PCR, 
MLPA, MAPH,  
 
It seems probable that the choice of the molecular method for the detection of 
aneuploidy will depend on the indications for the test. If such test is to be performed 
in a low risk patient just for early reassurance, screening of the sequences only from 
the chromosomes that are most often engaged in aneuploidy would be recommended. 
In a patient at high risk of aneuploidy because of suspicious US/biochemical findings 
a more detailed analysis, comprising also common microdeletion syndromes, would 
seem justified. In future, molecular methods could also screen the subtelomeric 
regions, if current presumptions about their association with mental retardation are 
confirmed. 
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Current molecular methods do not provide a means for genome-wide-screening, 
although their resolution is considerably superior to classical cytogenetics. At present 
maximally about 40 sequences can be examined in one test, which does not compare 
favorably with the figure of 500 bands, easily achievable by classical cytogenetics, 
which simultaneously surveys ploidy of all chromosomes, whereas analysis directed 
at specific alleles is constrained to the targeted regions. The molecular methods 
however concentrate on particular “hot spots” i.e. critical regions, associated with 
specific, relatively common pathologies, their results are unequivocal, and lesions 
beyond the resolution of cytogenetics may be detected. The future therefore seems to 
belong to the molecular approach.  
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The detection of gross chromosomal abnormalities is a major focus of invasive 
prenatal diagnosis testing, of which the most common cytogenetic anomaly in live 
births is trisomy 21 (Down syndrome). Classically these examinations are lengthy 
procedures relying on karyotypic analysis of cultured amniocytes or chorionic 
mesenchyme. More rapid alternatives, such as fluorescence in situ hybridization and 
quantitative fluorescent PCR on uncultured cells, are time- and labor-intensive. Here 
we describe a novel real-time PCR (1, 2) assay for the detection of trisomy 21 that is 
readily amenable to automation and high-throughput screening.  
Real-time PCR can determine subtle alterations in gene dosage, such as hetero- or 
homozygosity of the RhD locus (3) and protooncogene amplification in breast cancer 
patients (4). We examined whether a real-time PCR assay could determine 
chromosomal ploidy, in particular for the prenatal detection of Down syndrome 
(trisomy 21). We examined the coamplification of a genetic locus (amyloid gene) in 
the Down’s region of chromosome 21 and a control locus [glyceraldehyde 3-
phosphate dehydrogenase (GAPDH)] on chromosome 12. The amyloid gene locus on 
chromosome 21 was chosen because aberrant expression of this protein has been 
implicated in the physiologic lesions associated with Down syndrome (5). 
Furthermore, use of this locus should enable the detection of unbalanced Robertsonian 
translocations involving the Down’s region of chromosome 21, which occur in ~ 4% 
of Down syndrome cases (6). No such cases were available during in this pilot study.  
We used a multiplex real-time PCR assay in which amplification of both loci was 
simultaneously monitored in the same reaction vessel. In this way, we could be sure 
that any alterations were not attributable to well-to-well variation. The following 
primers and probe were used for the amyloid gene on chromosome 21: forward, 5’-
GGG AGC TGG TAC AGA AAT GAC TTC-3’; reverse, 5’-TTG CTC ATT GCG 
CTG ACA A-3’; and probe, 5’-(FAM) AGC CAT CCT TCC CGG GCC TAG G 
(TAMRA)-3’, where FAM is 6-carboxyfluorescein, and TAMRA is 6-
carboxytetramethylrhodamine. The sequences for the GAPDH primers and the probe 
were as follows: forward, 5’-CCC CAC ACA CAT GCA CTT ACC-3’; reverse, 5’-
CCT AGT CCC AGG GCT TTG ATT-3’; and probe, 5’-(VIC) AAA GAG CTA 
GGA AGG ACA GGC AAC TTG GC (TAMRA)-3’. In the TaqMan analysis, we 
used 25-µL reaction volumes containing 2 µL of the extracted DNA, 300 nmol/L each 
of the primers, 150 nmol/L each of the dual-labeled TaqMan probes, and further 
components supplied in the TaqMan Universal PCR Master Mix (Perkin-Elmer), 
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corresponding to 3.5 mmol/L MgCl2, 100 µmol/L dNTPs, 0.025 U/µL AmpliTaq 
Gold, and 0.01 U/µL Amp Erase. Cycling conditions were as follows: incubation for 2 
min at 50 °C, to permit Amp Erase activity, and for 10 min at 95 °C for AmpliTaq 
Gold activation and DNA denaturation, followed by 40 cycles of 1 min at 60 °C and 
15 s at 95 °C.  
In proof-of-principle experiments we examined DNA extracted from amniocyte 
cultures obtained from 10 trisomy 21 fetuses. As controls we used DNA samples 
obtained from 11 apparently healthy individuals. These samples included peripheral 
blood as well as amniocyte cultures. DNA was extracted from 400-µL samples, using 
the QIAamp DNA Blood Mini Kit according to the manufacturer’s recommendations 
(Qiagen). We included several dilutions of these DNA samples because we were 362 
Technical Briefsconcerned that the assay should be applicable over a broad range of 
DNA concentrations. In this small series of experiments we were able to show that the 
ratio of the two loci in these samples, as determined by the difference in threshold 
cycle value ( CT), distinguished trisomy 21 from karyotypically normal tissue (Fig. 1). 
Furthermore, we ascertained that clear segregation of karyotypically normal and 
trisomic samples was possible over a wide sample concentration range, in that we still 
observed optimal results when we used 10-fold diluted DNA samples and DNA 
concentrations as low as 10 mg/L.  
 
Figure 1. Clear segregation of trisomy 21 samples from those with a normal karyotype by a 
multiplex real-time PCR assay that is able to accurately assess the ratio for a chromosome 21-specific 
locus and a control locus on chromosome 12. 
Differences in threshold cycle numbers (∆CT) greater than +0.2 are indicative of a trisomy 21 
karyotype, whereas differences less than -0.4 indicate a normal karyotype. 
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We required that the following two conditions be met: that efficient amplification of 
both loci examined occurred and that both loci were amplified with equal efficiency 
over the entire exponential phase of the PCR. For this purpose we examined, on the 
one hand, the amplitude of the amplification curve ( RN). Because this parameter is 
indicative of amplification efficiency and template concentration, it can be considered 
a rather basic endpoint measurement for quality surveillance. In our pilot study we 
arbitrarily selected a RN cutoff value of 0.7. It is possible that another cutoff value 
may be obtained in a larger series of experiments. For the second step, which was to 
ensure that both loci had been amplified with equal efficiency, we examined their 
ratio at three separate points (bottom, middle, top) along the exponential phase of the 
amplification reaction. Samples in which a deviation was found were disregarded.  
Using this approach, we were able to correctly determine the ploidy in 9 of 11 cases 
with normal karyotype. Our analysis included six diluted samples in which the ploidy 
was also identified correctly. In the 10 samples from trisomy 21 fetuses, we were able 
to determine the ploidy correctly in 9 samples and in 10 separate dilutions. In those 
cases where we could not reliably determine fetal ploidy, we were alerted to incorrect 
amplification either by a RN value _0.7 or by an inconsistency in the ratio of the two 
loci examined at the three thresholds selected over the exponential phase of the 
amplification. In one case of trisomy 21, an outlier was recorded with a CT of almost 
0.8. This sample was almost 3 years old. Interestingly, in two dilutions of this 
extraction, we obtained the expected CT values for trisomy 21.  
These added precautions prevented incorrect determination of the ploidy in this series. 
A recent study regarding the detection of single-nucleotide polymorphisms by real-
time PCR indicated that relying solely on CT values may lead to erroneous results, 
which could be averted by examining the corresponding RN values (7). Our 
smallscale pilot study, therefore, suggests that real-time PCR technology can be used 
for the rapid determination of trisomy 21. This technology could be easily extended to 
examine the most common fetal aneuploidies (13, 16, 18, X, and Y). Because real-
time PCR permits the analysis of numerous samples in an automated manner, this 
technology may be more suited to this task than current molecular or cellular 
cytogenetic methods because these are considerably more time- and labor-intensive. 
In a largescale setting, this method may also compare favorably with a fluorescent 
PCR-based approach or fluorescence in situ hybridization analysis regarding speed 
and price.  
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We caution against premature use of the described method for routine prenatal 
diagnosis of trisomy 21. The feasibility of this method must be explored in a large-
scale prospective study before it is applied to a routine diagnostic setting.  
 47
References  
 
1. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. 
Genome Res 1996;6:986–94.  
2. Zhong XY, Hahn S, Holzgreve W. Prenatal identification of fetal genetic traits. 
Lancet 2001;357:310–1.  
3. Chiu RW, Murphy MF, Fidler C, Zee BC, Wainscoat JS, Lo YM. Determination 
of RhD zygosity: comparison of a double amplification refractory mutation 
system approach and a multiplex real-time quantitative PCR approach. Clin Chem 
2001;47:667–72.  
4. Bieche I, Olivi M, Champeme MH, Vidaud D, Lidereau R, Vidaud M. Novel 
approach to quantitative polymerase chain reaction using real-time detection: 
application to the detection of gene amplification in breast cancer. Int J Cancer 
1998;78:661–6.  
5. Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St. George-Hyslop P, van Keuren 
ML, et al. Amyloid _ protein gene: cDNA, mRNA distribution, and genetic 
linkage near Alzheimer locus. Science 1987;235:880–4.  
6. Mutton D, Alberman E, Hook EB. Cytogenetic and epidemiological findings in 
Down syndrome, England and Wales 1989 to 1993. National Down syndrome 
cytogenetic register and association of clinical cytogeneticists. J Med Genet 
1996;33:387–94.  
7. Oliver DH, Thompson RE, Griffin CA, Eshleman JR. Use of single nucleotide 
polymorphisms (SNP) and real-time polymerase chain reaction for bone marrow 
engraftment analysis. J Mol Diagn 2000;2:202 
 
 
 48
Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Determination of RHD Zygosity
Using Real-Time Quantitative PCR.
Ying Li, Bernhard Zimmermann, Xiao Yan Zhong,
 Anurag Kumar Gupta, Wolfgang Holzgreve,
Sinuhe Hahn
Laboratory for Prenatal Medicine, University Women’ s Hospital / 
Department of Research, University of Basel, Switzerland. 
Published in: Swiss Medical Weekly 2003; 133: 442 - 445
 49
Summary 
 
At present RHD incompatibility is still an obstetric problem despite prophylactic 
treatment. A very welcome recent technical advance has now made it possible to 
determine the foetal RHD status in a non-invasive risk-free manner using cell free 
foetal DNA in maternal plasma. In some cases, however, where there is a high risk 
that the foetus may be affected by HDN (haemolytic disease of the newborn), it may 
be of interest to determine whether the father is hetero- or homozygous for the RHD 
gene, since in the former instance there is only a 50% chance that the pregnancy is 
affected. It has recently been shown that quantitative PCR assays, in particular real-
time Taqman PCR, can be used to determine the RHD gene dosage, and also to 
determine foetal aneuploidies. We demonstrate that the same real-time Taqman PCR 
assay we had previously developed for non-invasive analysis of the foetal RHD gene 
and the foetal Y chromosome from maternal plasma can be used to determine the 
paternal RHD genotype. 
 
Key words: RHD; paternal genotype; prenatal diagnosis; real-time PCR 
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The determination of RHD zygosity has until recently been a tedious procedure and is 
usually inferred from the serotype, family history and / or complex PCR-based RFLP 
assays [1–3]. To address this issue, two recent publications have shown that 
quantitative PCR assays can be used to accurately genotype the predominant 
Caucasian RHD locus. In the first instance, Chiu and colleagues determined RHD 
zygosity using a real-time Taqman PCR assay in which the dosage of the RHD gene 
was compared with a control locus, namely the albumin gene [4]. In the second 
approach, described by Pertl and colleagues, a quantitative fluorescent PCR assay 
compared the dosage of the RHD gene to that of the related RhCE gene locus [5]. A 
further development of the real-time PCR approach by our group has shown that this 
technology is sufficiently sensitive to detect even smaller differences in gene dosage, 
namely those which occur in foetal aneuploidies, in which instance only a 50% 
increase in gene copy number occurs and not 100% as is the case for the RHD gene 
[6]. 
Since it is only of interest to determine the RHD genotype of the male partner (the 
mother by definition being RHd), we were curious as to whether a real-time Taqman 
PCR assay we had previously developed for another purpose, non-invasive risk-free 
determination of foetal RHD status and sex from maternal plasma [7], could be used 
for the determination of RHD zygosity. 
The Taqman® real-time PCR assay centres upon the detection of a fluorescent signal 
generated from the cleavage of a target sequence specific probe by the Taq 
polymerase during each cycle of the PCR reaction [8]. As this signal is directly 
proportional to the PCR product being amplified, it permits very precise quantitation 
of the amount of initial input template. This is ascertained from the so-called 
threshold cycle, also termed the CT value, the point where the exponential phase of the 
amplification curve crosses a defined threshold line. As this CT value is a reflection of 
the number of PCR cycles required to reach this threshold, the lower the CT value is, 
the higher is the concentration of input target template.  
By using a real-time PCR assay in which two genetic loci are amplified 
simultaneously in a multiplex reaction, it is possible to determine the relative ratio of 
these two loci by subtracting their respective CT-values, e.g.: 
 
∆∆CT = CT (target A) – CT (target B) = CT (RHD) – CT (SRY) 
 
 51
Since 1 cycle entails a doubling of the PCR product, the ratio of RHD: SRY = 2-(∆∆CT).  
Hence, if both the RHD and SRY genes are present with the same gene dosage, e.g. 1 
copy (heterozygous RHD/RHd), the difference in threshold cycle number (∆∆CT) will 
be 0 cycles, whereas if 2 copies of the RHD gene are present (homozygous 
RHD/RHD) the difference in threshold cycle number (∆∆CT) will be 1 cycle. It 
should be noted that these are theoretical values and that slight differences are bound 
to occur due to minor variations in the PCR assay, especially if one reaction proceeds 
with slightly greater efficiency than the other.  
These minor deviations are bound to occur even if considerable care has been taken to 
optimise the paired PCR reactions in such a manner that no significant difference is 
discernible between their efficiencies, as measured by the slope of the PCR assays [4, 
6]. 
Precautions which need to be taken in order to obtain a correct result include the use 
of multiplex PCR reactions whereby both target gene sequences are analysed 
simultaneously in the same reaction vessel, as well as the inclusion of genotypically 
defined samples in each analysis [4, 6, 9]. By using such precautions it has previously 
been shown by Chiu and colleagues [4] that realtime PCR can be used to determine 
the paternal RHD genotype. More recently we have shown that real-time PCR can 
also be used to detect more subtle increments in gene dosage (only 50%), such as 
those occurring in foetal trisomies [6]. 
To test the possibility that the real-time PCR assay we had previously developed for 
analysis of the foetal RHD and SRY genes in maternal plasma [7] could be used to 
determine the paternal RHD genotype, we examined 39 DNA samples obtained from 
males who had been serologically typed to be RHD (Swiss Red Cross Blood Bank, 
Basel, Switzerland). To confirm the accuracy of our assay we also determined RHD 
zygosity in these samples using a modification of the real-time PCR described by 
Chiu and colleagues [4]. In our investigation the dosage of the RHD gene was 
compared to another control locus, which in our case was the GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase) gene and not the albumin gene. The 
reason for this modification was that we have previously described the use of the 
Taqman real-time PCR assay for this GAPDH control locus in a number of studies, 
using either cell free DNA [7, 10] or genomic DNA [6]. In our analysis, all samples 
were run in triplicate. 
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The results of our analysis indicated that the samples in our investigation clustered 
into two specific groups, one having a median of almost 0 and the other of 
approximately 1 (see Figure 1A). 
To ascertain the genotype of these two groups we also tested our samples using a 
modification of the assay described by Chiu and colleagues [4], whereby we 
compared the dosage of the RhD gene with that of the GAPDH gene [6]. Here we 
would expect an opposite pattern, as the GAPDH gene is normally present in 2 copies, 
i.e. the RHD/RHD genotype should yield a ∆∆CT value of 0, whereas the RHD/RHd 
genotype should differ by 1 cycle from the CT value for the GAPDH reference. In this 
analysis we again found that the samples clearly clustered into two groups, one with a 
median ∆∆CT value of approximately –0.5 and the other a median ∆∆CT value of 
approximately 0.5 (see figure 1B). It is of interest that a 100% concordance was 
observed between the 2 groups of samples in both assays. 
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Interpretation of the results, however, is not as straightforward as it would seem, due 
to a significant deviation from the expected ∆∆CT values. In this manner, even though 
the expected ∆∆CT values in the first SRY:RHD assay would be –1 for the RHD/RHD 
genotype and 0 for the RhD/Rhd genotype, it is apparent that the PCR reaction for the 
SRY gene has proceeded with slightly better efficiency than that for the RHD gene. 
Consequently the expected RHD:SRY ∆∆CT value in the case of the RHD/RHD 
genotype has shifted up from the theoretical value of –1 to almost 0, whilst that for the 
RHD/RHd genotype has similarly also been shifted up by 1 cycle from the theoretical 
value of 0 to almost 1. 
In an analogous manner the GAPDH PCR reaction has proceeded slightly more 
efficiently than that for the RHD gene, resulting in a shift in the expected 
RHD:GAPDH ∆∆CT value. In this case the ∆∆CT value for the homozygous 
RHD/RHD genotype has shifted down by almost half a cycle from the theoretical 
value of 0 to almost –0.5. Equally, that for the heterozygous RHD/RHd genotype has 
been shifted down by 0.5 cycles from the theoretical value of 1 to almost 0.5. 
We have previously indicated that to counter these unwanted shifts it is possible to 
use ∆∆CT values, whereby the CT value of the sample being analysed is compared to a 
mean CT value comprised of the analysis of a large number of samples of known 
genotype [6, 9]. Furthermore, these drifts in ∆∆CT values stress the importance of 
including samples of known genotype in each analysis, to counter inter-run variations 
[4, 6, 9]. It is also imperative to analyse the samples in a multiplex manner whereby 
both target genes are analysed simultaneously in the same reaction vessel, and not to 
attempt this type of analysis by comparing the assessed gene dosage against a 
standard curve [4, 6, 9]. 
An important feature that is evident from our analysis is that the two groups can be 
segregated with 100% accuracy by the use of particular cutoff values. With regard to 
the RHD/SRY assay, we determined that a cut-off ∆∆CT (CT RHD – CT SRY) value of 
0.5 could be used to distinguish between the heterozygous (RHD/RHd) and 
homozygous (RHD/RHD ) genotypes, in that the values for the RHD/RHd genotype 
had ∆∆CT values which clustered around 1, while RHD/RHD genotype had ∆∆CT 
values which clustered around 0 (Figure 1A). No overlap between the two groups was 
found to occur. 
Similarly, for the RHD/GAPDH assay, a ∆∆CT (CT RHD – CT GAPDH) cut-off value 
of 0.0 could be used to distinguish the homozygous RHD/ RHD genotype form the 
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heterozygous RHD/ RHd one. In this test the heterozygous (RHD/ RHd ) genotypes 
have ∆∆CT values above 0.0, while the homozygous (RHD/RHD ) genotype had 
∆∆CT values below 0.0 (Figure 1B). Once again, no overlap between the two groups 
was found.  
As explained previously, the reason for the difference in the ∆∆CT cut-off values 
between these two assays is that for the RHD/GAPDH assay the RHD gene is 
compared with both alleles of the GAPDH gene on chromosome 12, whereas for the 
RHD/SRY assay, the dosage of the RHD gene is compared to the single SRY allele 
on the Y chromosome. 
The validity of our analysis is underscored by our subsequent examination of 3 
samples known to be from RHD heterozygous males, in which case we were able to 
determine the correct genotype in a blinded manner (data not shown). 
In the sample cohort of 39 samples we determined that 26 (66%) were heterozygous 
for the RHD gene (RHD/RHD) and 13 (34%) were homozygous (RHD/RHD). Once 
again there was complete concordance between the 2 assays. Although the expected 
frequency of RHD heterozygosity would be 56% [1], it is probable that our results are 
slightly skewed by the small number of cases examined. 
Although our data obtained by the use of two independent real-time PCR assays do 
serve to indicate that this technology can potentially be used for the determination of 
RHD zygosity, we have also shown that the employment assays and their subsequent 
analysis require considerable experience if a correct diagnostic outcome is to be 
achieved. Furthermore, the data also emphasise the importance of running 
genotypically well defined control samples in parallel with the sample being analysed, 
as the theoretically expected ∆∆CT values cannot be used. Our study also indicates the 
usefulness of running two independent analyses in parallel as a potential safeguard 
against erroneous results, a feature we have also observed previously when attempting 
to discern foetal trisomies by the use of real-time PCR [6, 9]. 
Despite these promising results we caution against the premature clinical use of these 
assays, since their efficacy has not yet been determined in large scale studies, nor is it 
yet known how they may be influenced by the RHD polymorphisms [1–3] prevalent 
in many ethnic populations. 
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Abstract 
 
With the advent of real-time PCR it is now possible to measure nucleic acid 
concentrations with an accuracy that was not deemed possible only a few years ago. 
Examples are the analysis of gene expression or gene duplications / losses, where 
two-fold differences in nucleic acid concentration have routinely been determined 
with almost 100% accuracy. As our primary interest is in prenatal diagnosis, we have 
investigated whether real-time PCR could be used for the diagnosis of chromosomal 
anomalies, in particular the aneuploidies such as trisomy 21, where the difference in 
copy number is only 50 %. The feasibility of such an approach was first tested in a 
pilot study, in which we were able to demonstrate that trisomy 21 samples could be 
detected with 100 % specificity. We have recently modified this test in order to permit 
the simultaneous analysis of trisomies 18 and 21 and have in a large scale analysis 
demonstrated that our approach can be used for the highly reproducible and robust 
detection of only 1.5 fold differences in gene copy number. 
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1. Introduction 
 
1.1 Background 
 
The detection of gross chromosomal abnormalities is a major focus of prenatal 
diagnostics, of which the most common cytogenetic anomaly in live births is trisomy 
21, also known as Down’s Syndrome. Other fetal aneuploidies frequently detected 
involve chromosomes 13, 16, 18 and both sex chromosomes (X and Y). Currently, 
prenatal diagnosis of genetic anomalies relies on invasive procedures such as 
amniocentesis and chorionic villus sampling (CVS), from which the full fetal 
karyotype is usually determined using cultured cells. The two weeks period needed 
for cultivation and subsequent analysis has proven to be associated with considerable 
parental anxiety and medical problems in those situations requiring therapeutic 
intervention. 
In order to address these needs, more rapid methods for the prenatal diagnosis of fetal 
chromosomal aneuploidies have recently been developed and implemented. The first 
of these to be commercially introduced was multi-colour fluorescence in-situ 
hybridisation (FISH) for uncultured cells. Although this method is very reliable and 
has proven in large-scale studies to be very accurate, it is a time and labour intensive 
procedure. Furthermore, as this method requires intact cells, it can only be used on 
fresh or specially stored samples [1-4]. The next method that has seen widespread 
clinical application, particularly in the UK, is quantitative fluorescent PCR analysis of 
short tandem repeats (STR) [5-8]. This method has also proved itself to be rapid and 
reliable, once the initial problems with polymerase stuttering and amplification failure 
of the highly repetitive loci had been overcome.  
An important point to bear in mind regarding both of these rapid diagnostic tests is 
that they currently only permit a result regarding the most common fetal aneuploidies 
(chromosomes X, Y, 13, 18 and 21). Hence, it is still necessary to resort to the normal 
2-week cell culture-based analysis in order to obtain a full karyotype. Maternal blood 
contamination of the amniotic fluid or chorionic villus sample, although infrequent 
(less than 2% of samples collected), can interfere with either method of analysis, as 
the results cannot be distinguished from cases of fetal mosaicism. 
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The recent development of real-time PCR has rapidly emerged as a powerful tool for 
the accurate and precise determination of template copy numbers, and has found 
wide-spread applicability in the analysis of gene expression, cell free DNA in body 
fluids, as well as for measuring gene duplications or deletions in cancer research [9-
13]. The precision of current assays and technology, however, was not thought to 
permit analyses of less than two fold differences of target template concentrations. 
As our primary interest is in the development of new methods for prenatal diagnosis, 
we were interested in whether this new technology could be used for the 
determination of fetal trisomies. This would, however, entail the resolution of less 
than 2 fold increments in target gene copy number, as in these instances there is only a 
50% increase present in the amount of a particular chromosome.  
The reason for choosing a real-time “Taqman” PCR approach is that we have 
considerable experience with the methodology [14-17], especially in the quantitation 
of trace quantities of cell free fetal DNA in the maternal circulation. To test the 
feasibility of this approach we first performed a small-scale study involving trisomy 
21, as this is the most common aneuploidy in live births. In our study we compared 
the gene dosage of a sequence on the Down’s critical region on chromosome 21 to a 
control locus on chromosome 12. Our analysis indicated that by using such an 
approach of comparative quantitation it was indeed possible to discern karyotypically 
normal samples from trisomic ones, provided that certain criteria concerning quantity 
and quality of DNA and replicate reaction uniformity were met [18]. After successful 
completion of this pilot study, we have now extended this method for the 
simultaneous detection of trisomy 18 and trisomy 21. In this analysis the two 
chromosomes being interrogated are quantified relative to each other. 
Future developments would include the development of a test in which the other 
common fetal aneuploidies (chromosomes 13, 16, X, Y) would be analysed in a 
matrix-type assay. By using such a matrix approach, whereby the dosage of each 
chromosome is measured relative to the other chromosomes, an automatic system of 
“checks and balances” would be implemented, thereby helping to reduce the potential 
error rate considerably.  
The use of the real-time PCR assay need not be restricted solely to the detection of 
aneuploidies, but can also be applied for the discernment of translocations and for the 
distinction of these from chromosomal trisomies. This can be achieved by amplifying 
sequences critical to the region translocated, such as those located in the Down’s 
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region of chromosome 21, which should enable the detection of those unbalanced 
Robertsonian translocations which occur in approximately 4% of Downs’ syndrome 
cases. It has to be noted however, that the design of the assay does not permit to detect 
triploidies, since the chromosomal balance is equal to a normal karyotype.  
Advantages of the real-time PCR test for prenatal diagnosis are that it is insensitive to 
maternal blood contamination of samples where the maternal DNA is present at a 
small percentage (about 20% or less of the total DNA in the sample). On the other 
hand, this test will not be able to detect low level chimerism. Akin to the PCR 
amplification of STRs, the real-time PCR test also can be used on a wide variety of 
sample materials and does not require fresh or specially stored cells, since it only 
requires genomic DNA.  
Furthermore, the assay is readily amenable to automation, and by making use of the 
current real-time PCR 96 or 384 well formats, it also facilitates high throughput. In 
addition, by making use of a closed system, whereby the samples are analysed directly 
in the PCR reaction vessel during the amplification and do not need to be opened for 
analysis as is the case for the analysis of STRs, the assay is also less prone to 
contamination. 
 
1.2 The principle of relative quantification by real-time PCR in 
relation to the determination of chromosome ploidy. 
 
Real-time PCR is based upon the detection and quantitation of a fluorescent signal 
that is directly proportional to the PCR product being generated during each cycle of 
the PCR. In our assay the fluorescence is generated by the 5’ nuclease method: A so 
called TaqMan probe hybridises specifically to one strand of the DNA sequence 
between the two primers. The probe is labelled with a fluorescent detector dye at its 5’ 
end and with a quencher dye at its 3’ end. The annealing temperature of the probe is 
10 °C higher than the annealing temperature (TA) of the PCR reaction, which is the 
melting temperature of the primers. This ensures that in each cycle of the reaction a 
probe binds to every target sequence before primers anneal. When the primer binds to 
the target, the Taq polymerase immediately starts extending the primer and by its 
nuclease activity cleaves the 5’ end of the probe. This nucleolytic activity separates 
the detector dye from the quencher dye, thereby permitting the detector dye to emit a 
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characteristic fluorescence signal when excited by an appropriate light source. As the 
displacement of each probe molecule is the result of a single template amplification, 
the amount of fluorescent signal measured is therefore directly proportional to the 
number of probes cleaved and the amount of PCR product synthesised.  
For the correct analysis of such real-time PCR assays several parameters have been 
devised. The first of these is the CT-value, or threshold cycle, is defined as the cycle 
number at which point the amplification curve crosses the threshold line in semi-log 
view of the amplification plot (refer to figure 1). 
Although the CT-value is the chief factor used in most real-time PCR analyses, in our 
experience another important parameter, especially for the analysis of discrete 
template increments, is the normalised final fluorescence, ∆Rn. This ∆Rn-value, a 
measure of the accumulation of specific fluorescence, is indicative of the 
amplification efficiency and initial template concentration (refer to figure 1). 
 
Figure1. Amplification plot of the real-time PCR data. 1: Phase of observed background 
fluorescence. 2: Observable exponential phase. 2a: Measurements are close to the detection limit. Due 
to the high contribution of the background fluorescence to the total fluorescence measured, replicate 
curves can deviate (as seen in the blue curves). 2b: Influence of background fluorescence minimal. 3: 
Linear and plateau phases of the amplification with decreasing amplification efficiencies. 
Displayed are triplicate amplifications of a sample with trisomy 21. The red curves represent data from 
chromosome 21 (FAM dye), the blue curves from chromosome 18 (VIC dye). 
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As our real-time PCR test for fetal aneuploidy entails the simultaneous amplification 
of two chromosomal loci (e.g. chromosome 21 vs. chromosome 12 or chromosome 21 
vs. chromosome 18) in a multiplex reaction, their product formation is detected by 
two different fluorescent dyes. As each of these reporter dyes has a discretely 
different emission spectrum, and as the amount of each dye measured is proportional 
to the relevant target template, this enables the relative quantification of both 
chromosomes.  
 
This can be calculated by using the ∆CT, which is the difference of the CT-values of 
the first ( e.g. chromosome 18, VIC dye) and the second amplified sequence (e.g. 
chromosome 21, FAM dye) in one reaction well (refer to figure 2): 
 
∆CT  = CT (target A) – CT (target B) 
= CT (VIC, Chromosome 18) – CT (FAM, Chromosome 21) 
 
In order for this analysis to be accurate it is important that the co-amplification of two 
sequences occurs in the same reaction vessel, this guarantees that no well to well 
variation occurs between the two amplified targets [19]. In this regard, it is important 
to realise that the analysis cannot be carried out in a singleplex manner. As any small 
well to well deviations resulting from minute pipetting errors, alterations in 
polymerase activity, temperature or illumination gradients, as well as unequal reagent 
depletion, will lead to an inaccurate assessment of the target chromosome ploidy. In a 
similar manner it is not possible to determine the ploidy of a sample by referring to a 
standard curve, as this analysis to will be mislead by the same factors affecting 
singleplex analyses, a facet which is not alleviated by post-run data analysis [22-25]. 
In order to balance small fluctuations and ensure that the amplification of both target 
sequences has proceeded with similar efficiency, we have devised the following 
analytical aid: instead of a solitary CT-value, 3 to 4 points are chosen along the linear 
phase of the amplification plot (refer to figure 2). Those samples in which a deviation 
is found to occur at these points are either discarded or re-analysed. If this proviso has 
been made, then the fluorescent signals from both amplifications will be detected 
simultaneously if the sample is karyotypically normal i.e., both chromosomes being 
interrogated have the same copy number (refer to figure 3). In case of a trisomy, the 
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chromosome present at 3 copies per cell will be detected at a lower (earlier) CT-value 
than the other will.  
 
 
Figure 2. ∆CT in the amplification plot (magnification of figure 1). The ∆CTs of the four thresholds, 
indicated by double-headed arrows. 
 
 
Figure 3. Linear regression of fluorescence data: The CT-values of the trisomy 21 sample 
measured in triplicate for thresholds 0.2, 0.3 and 0.45 were fitted in a linear regression [23]. The slope 
for the amplification of chromosome 18 (VIC dye) is –3.27, the slope for chromosome 21 (FAM dye) 
is –3.54. The amplification efficiencies (E = 10^(1/-slope)-1) for both chromosomes are greater than 
0.90 but clearly different with this method of efficiency determination: E (chromosome18, VIC) = 1.02 
and E (chromosome 21, FAM) = 0.92. This can be a result of the probe and dye properties or the “C0t 
effect” [26]. With the standard curve method, the amplification efficiencies determined are equal. 
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The measured differences in CT ( the ∆CT) between the two target chromosomes can 
be converted into a ratio [20]: 
 
target A / target B = 2-(∆CT) = Chromosome 18 / Chromosome 21 
 
In theory the difference in threshold cycle number (∆CT) for a normal (and for a 
triploid) karyotype will be 0 cycles, for a trisomic sample it will be ±0.58 cycles, 
since 2-(0.58) = 1.5 
 
To correct for slight differences in reaction efficiencies and detector dye intensities, 
the ∆∆CT method can be used which relies on the analysis of a reference or calibrator 
sample [21]. Normally the reference or calibrator sample is a sample of known 
(preferably normal) karyotype. The ∆CT of the reference sample is subtracted from 
the ∆CT of the sample, and then the corrected ratio of the target sequences in the 
sample can be calculated as follows: 
 
   ∆∆CT calibrated = ∆CT (sample) - ∆CT (calibrator) 
(target A / target B)calibrated = 2-(∆∆CT calibrated) 
 
Even though this method is more reliable than solely relying on the ∆CT-value(s) of 
the analysed sample, the use of a single reference sample can nevertheless introduce a 
small source of error. This may be caused by minute deviations in the amplification 
and signal generation, which may in turn lead to the misinterpretation of the sample 
analysed. In this regard it is worth noting that a seemingly small shift in the reference 
∆CT-value of only +0.15 cycles from its “real” value may result in misdiagnosis of a 
sample with a similarly small deviation of –0.15 cycles. 
For this reason we recommend that for the reliable determination of ploidy an 
adaptation of the ∆∆CT method be used, whereby the samples being analysed are 
quantified relative to a reference ∆CT-value determined from the average ∆CT-values 
of all karyotypically normal samples tested previously. Furthermore, if this analysis 
suggests that a particular sample is aneuploid, then an added precaution may be to 
analyse this sample using a reference comprised of similar aneuploid samples. In this 
manner an opposite pattern to that normally expected will emerge, in that the ∆∆CT 
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analysis using a normal ploidy reference should be close to the theoretical value of 
±0.58 cycles, whereas the ∆∆CT comparison using a matched aneuploid reference 
standard should be close to 0.  
In reality, however, the experimentally measured differences in ∆∆CT between normal 
and trisomic karyotypes is not 0.58, but ranges from 0.47 to 0.55 depending on 
threshold-value set and the type of trisomy. As a consequence the calculated 
chromosome ratios will average 1.4 rather than 1.5 for a trisomic sample. Although 
the exact reason for this small anomaly is unclear, it is likely to be attributable to 
minor differences in amplification efficiencies or incomplete spectral separation of the 
dyes [26].  
Since the ∆∆CT-values themselves are indicative of the karyotype i.e. close to 0 for 
normal and ±0.58 depending on the type of trisomy, it is not actually necessary to 
determine the ratio. This is particularly evident when taking an average ∆∆CT-value 
taken at the 4 independent threshold points (refer to table 2). Alternatively it is 
possible to add these 4 independent ∆∆CT-values. In this manner, a normal karyotype 
will have a value close to 0, whereas a trisomy 21 sample will be of the order of 2 and 
a trisomy 18 sample will have a value of approximately –2. 
In this manner it is possible to determine the samples’ karyotype with a minimum of 
post-run work by setting the cut-off range around the average ∆∆CT of a given 
karyotype. In our analyses, we therefore, set a cut-off range of 0.25 cycles around the 
average measured ∆∆CT of a given karyotype, since the measured ∆∆CTs between 
normal and trisomic are around ±0.5. In this regard, the ∆∆CT calibrated of karyotypically 
normal samples will have a range of 0.00 +- 0.25. The accuracy of the test result can 
be confirmed by re-analysing the suspected trisomic sample in comparison to a 
reference-value made up of matched aneuploid samples. Furthermore, the test can be 
made more stringent by defining a smaller range. 
 
An example of such a ∆∆CT analysis, where trisomy 18 and 21 samples could be 
discriminated from each other as well as samples with normal ploidy for these 
chromosomes is illustrated as a scatter plot in Figure 4. This figure shows the clear 
segregation of the three different karyotypes. In addition, the manner by which the 
averaged ∆CT-values of all relevant control samples can serve as calibrator or 
reference values are displayed in table 2. In our hands this simple procedure (and its 
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modifications as described in the methods section) has been shown to be most 
reliable, producing consistent results over several experiments and months. 
 
Figure 4. Scatter plot of control DNAs for a threshold of 0.45. Depicted are replicate averages per 
sample. The ∆CT-values of all samples with normal karyotype group between –0.22 and +0.10, all 
trisomy samples lie outside of this area (trisomy 21 are above, trisomy 18 are below). The average 
∆CT-value of the normal samples is –0.09. This value is used as the ∆CT (calibrator) for samples with a 
normal karyotype at the threshold of 0.45 (refer to table 2). 
 
 
1.3 Differences between the use of the SDS 7700 and SDS 7000 real-
time PCR “Taqman” instruments 
 
In our proof of principle study for the detection of trisomy 21 using real-time PCR we 
used the Applied Biosystems Sequence Detection System 7700 (SDS 7700) 
instrument which uses a complex laser-array for the excitation of the fluorescent-
labelled reporter molecules. In this study, in which we only examined a small number 
of samples (n=21), we were able to correctly determine the karyotype in 10 of the 11 
trisomy 21 samples analysed. The analysis also included 10 dilutions of the trisomy 
21 samples. In two of the control samples and in 1 sample with trisomy 21 no 
definitive assessment was possible, due to poor quality or inadequate quantity of the 
DNA sample analysed. 
In the interim period Applied Biosystems has introduced the smaller, less costly and 
user-friendlier SDS 7700 onto the market. This instrument obviates the need for a 
complex laser-based system, instead employing a halogen lamp for the excitation of 
fluorescent probes. After careful appraisal of this instrument, in which we determined 
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it to be as robust, reliable and as accurate as the more sophisticated and larger SDS 
7000, we then adapted our assay in such a manner that it would permit the 
simultaneous analysis of trisomies 18 and 21. 
 
This was achieved by replacing the chromosome 12 (GAPDH gene) control amplicon 
of the original trisomy 21 assay by a sequence on chromosome 18. In order to 
increase the specificity of our new assay, we also examined the influence of various 
other parameters such as PCR reaction mix composition, primer sequences and purity, 
as well as different probe chemistries. These studies were undertaken to ensure that 
the amplification efficiencies of the two reactions (chromosome 18 and 21) were 
equal. 
As described above, reference calibration values for the two chromosomes being 
interrogated were determined by examining DNA samples with either normal, trisomy 
18 or trisomy 21 karyotype (refer to table 2). Once we had established these reference 
calibration values, we next performed a large-scale study of almost 100 clinical 
amniotic fluid samples, in which we examined the ploidy for these two chromosomes 
in a blinded manner (Zimmermann et al., manuscript in preparation). In over 86% of 
the cases was a correct analysis regarding the ploidy for these two chromosomes 
possible. In those instances where we were not successful, the analysis was either 
hindered by inadequate concentrations of template DNA or by the presence of 
inhibitors in the original DNA preparation (see note 7).  
These results clearly demonstrate the diagnostic potential of real-time PCR, whether 
for prenatal diagnosis or for other analyses involving gene-duplications or loss, such 
as are frequently found in cancer. 
It is worth noting that although the Quantitative Fluorescent PCR analysis of STR has 
been established and clinically implemented for the rapid prenatal analyses of the 
most common aneuploidies, the use of real-time PCR does have a few advantages, in 
that it is more amenable to automation and, by being a closed system is less prone to 
contamination. 
 
 68
2. Materials 
 
2.1 DNA extraction 
1. For the extraction of DNA from the amniotic fluid samples, Chelex 100 resin 
(biotechnology grade 100 – 200 mesh sodium form) from Biorad (Reinach, 
Switzerland, cataloque number 142-1253) was used. 
2. It is recommended to use a highly pure water source such as Analar water 
(molecular biology grade, VWR International). Alternatively Milli-Q water de-
ionised with the Elgastat Maxima (Kleiner AG, Wohlen, Switzerland) can be 
used. 
 
2.2 Performing real-time PCR 
1. For our real-time PCR analysis we used an ABI PRISM 7000 Sequence Detection 
System (SDS7000) (Note 1). 
2. For the PCR reactions we used MicroAmp Optical 96-well reaction plates 
(Applied Biosystems, Switzerland, Cat 4306737) and the ABI PRISM Optical 
adhesive covers (Cat 4311971) (Note 2). 
3. The reactions were carried using the TaqMan Universal PCR master mix (Cat 
4304437) containing Amplitaq Gold DNA Polymerase, AmpErase UNG, dNTPs 
with dUTP and passive Reference 1 (ROX fluorescent dye) (Note 3). 
4. Primer and probe sequences are listed in Table 1 (Note 4).  
5. The best results were obtained using TaqMan MGB probes (Cat 43160324) from 
ABI. These are 3’-labelled with a Minor Groove Binder (MGB) and a Non-
Fluorescent quencher (Note 5). The Chromosome 18 probe is 5’-labelled with the 
fluorescent dye VIC, the chromosome 21 probe is 5’-labelled with FAM. It is 
advisable to store 5 µM aliquots at – 20 °C, where they are stable for over 1 year. 
If used rapidly (within 1 month), the probes can be stored at 4 °C. In this case, 
aliquots of both probes should be are used and stored in parallel. Avoid exposure 
to light. 
6. In our experience, the best results were obtained using HPLC purified primers 
(Microsynth, Switzerland) (Note 6). These can be stored as 10 µM aliquots at –20 
°C. Primers stored at 7 °C are stable for several months. 
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Chromosome 
location 
accession 
GenBank 
Gene Name Fluorescent 
dyes 5'-3' 
Sequence of primers primer location 
bases 
18p11.32 D00596 TYMS Chr_18_F  TGACAACCAAACGTGTGTTCTG 2910 - 2931 
   Chr_18_R  AGCAGCGACTTCTTTACCTTGATAA 2961 - 2985 
   Chr_18_P_MGB VIC-NFQ GGTGTTTTGGAGGAGTT 2933 - 2959 
   Chr_18_P_dual VIC-TAMRA AAGGGTGTTTTGGAGGAGTTGCTGTGG 2930 - 2966 
21q21.3 D87675 APP Chr_21_F  CCCAGGAAGGAAGTCTGTACCC 7764 - 7785 
   Chr_21_R  CCCTTGCTCATTGCGCTG 7826 - 7843 
   Chr_21_P_MGB FAM-NFQ CTGGCTGAGCCATC 7788 - 7801 
   Chr_21_P_dual FAM-TAMRA AGCCATCCTTCCCGGGCCTAGG 7795 - 7816 
TYMS: Thymidylate Synthetase; APP: Amyloid Precursor Protein; NFQ: Non-FluorescentQuencher, MGB probe 
 
Table 1: Primer and probe sequences for the real-time amplification of chromosomes 18 and 
21. Probes used were the MGB probes Chr_18_P_MGB and Chr_21_P_MGB. The Sequences for dual 
labelled probes are included (see Note 5). 
 
 
 
2.3 Analysis of real-time PCR data 
1. No material required. 
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3. Methods 
 
3.1 DNA extraction of amniotic fluid samples  
 
1. Spin 1ml of amniotic fluid at 13,000 rpm in a bench top micro-centrifuge for 15 
seconds to pellet the amniotic cells.  
2. Discard the supernatant and re-suspend the cell pellet in 500 µl of water.  
3. Wash once by centrifuging the cells as in step 1. Discard the supernatant  
4. Add 60 µl of Chelex 100 resin to the pellet and re-suspend the cells by vortexing. 
5. Incubate the samples for 20 minutes at 57 ºC. 
6.  Following this, incubate the samples in a dry heat block at 100 ºC for 8 minutes. 
7.  Next, prepare the sample for use in the real-time PCR analysis by heating to 95 
ºC for 5 minutes. Following this spin the samples at 13,000 rpm in a bench top 
micro-centrifuge for 2 minutes to pellet the resin. Carefully remove the aqueous 
DNA solution, taking care not to disturb the resin pellet (Note 7).  
8. Use 2 µl of this DNA solution in a final reaction volume of 25 µl for the PCR 
analysis. (Notes 8 and 9). 
 
3.2 Performing real-time PCR 
 
1. It is advisable to include at least one control sample of known karyotype in the 
analytic run (Note 10). 
2. Each sample should be analysed at least in triplicate (Note 11). 
3. The preparation of the real-time PCR reactions should be carried out on ice.  
4. The real-time PCR amplification is carried out in a total volume of 25 µl (Note 
12), containing 2 µl of the sample DNA solution (Note 13), 300 nM of each 
primer (Note 14) and 200 nM of each probe (Note 15) at 1 x concentration of the 
Universal PCR reaction mix. 
5. This is prepared by first pipetting the PCR reaction mixture into the reaction 
wells, following this add 2ml of the sample DNA solution (Note 16). Carefully 
seal the reaction plate with the optical adhesive cover. Centrifuge at 1400 rpm at 4 
ºC for 1 minute to spin down any droplets and remove air bubbles. 
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6. Immediately start the real-time PCR cycler with the emulation mode off (Note 
17). 
7. Following an initial incubation at 50 ºC for 2 minutes to permit Amp Erase 
activity, 10 minutes at 95 ºC for activation of AmpliTaq Gold and denaturation of 
the genomic DNA, use the following cycle conditions: 40 cycles of 1 minute at 60 
ºC and 15 seconds at 95 ºC. 
 
3.3 Analysis of real-time PCR data 
 
8. Perform the experimental analysis with a baseline setting of 3 – 22 cycles (Note 
18). Check the replicate curves for uniformity in the amplification plot view (Note 
19) and for final fluorescence (Note 20). 
9. Analyse 4 different thresholds at Rn-values of: 0.2 / 0.3 / 0.45 / 0.625, as indicated 
in Figure 2 and Table 2. (Note 21). Export the CT result files and examine the data 
using an Excel spreadsheet.  
10. In our experience, CT-values from 25.0 to 29.0 (for a threshold of 0.2) will yield 
good results. CT-values of higher than 29.0, are associated with inadequate 
quantities of DNA, which are too low to guarantee that preferential amplification 
of one of the multiplexed reactions does not take place (Note 22). 
11. For every replicate calculate the ∆CT for each of the four thresholds (refer to Table 
2 and Figure 2). 
12. For every replicate and for all three ploidies that can be distinguished, calculate 
the ∆∆CT for each of the 4 thresholds: 
∆∆CT calibrated = ∆CT (sample) –∆CT (calibrator) 
13. Calculate for every replicate, with respect to a normal karyotype, to trisomy 18 
and to trisomy 21, the average of the four ∆∆CT-values. 
14. The analysis of one replicate that gives the value closest to 0 for the averaged 
∆∆CT is indicative for the chromosomal status. This value should be smaller than 
+-0.25 (Note 23), that is e.g.:  
∆∆CT calibrated (trisomy 18 sample) = ∆CT–∆CT (calibrator trisomy 18) = 0 +- 0.25 
15.  If the results of all 3 replicates are indicative of the same chromosomal balance, 
the ploidy of the sample is that of the matched reference ∆CT calibrators; 
otherwise the result is not conclusive but rather is suggestive (Note 24). 
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16. Alternatively it is possible to add the 4 calibrated ∆∆CT-values. In this manner, a 
normal karyotype will have a value close to 0, whereas a trisomy 21 sample will 
be of the order of 2 and a trisomy 18 sample will have a value of approximately 
minus 2. 
 
 
 ∆CT calibrator values 
Threshold 0.2 0.3 0.45 0.675 
Trisomy 18 -0.52 -0.55 -0.68 -0.73 
Normal 0.01 -0.03 -0.09 -0.11 
Trisomy 21 0.48 0.45 0.44 0.42 
 
Table 2: The calibrator values for the three karyotypes and the four 
thresholds used. The average ∆CT values of the control sample measurements 
for each karyotype are the respective calibrator values. 
 
 
 
 
 Sample 1 Sample 2 Sample 3 
Threshold 0.2 0.3 0.45 0.675 0.2 0.3 0.45 0.675 0.2 0.3 0.45 0.675 
CT (chromosome 18) 27.83 28.47 29.25 30.17 27.91 28.47 29.17 29.96 27.21 27.81 28.45 29.28 
CT (chromosome 21) 28.07 28.66 29.34 30.15 28.53 29.24 30.00 31.01 26.65 27.28 28.01 28.80 
∆CT -0.24 -0.19 -0.09 0.02 -0.62 -0.77 -0.83 -1.05 0.56 0.53 0.44 0.48 
∆∆CT (Normal) -0.20 -0.10 0.06 0.25 -0.58 -0.68 -0.68 -0.82 0.60 0.62 0.59 0.71 
∆∆CT (Trisomy 18) 0.30 0.40 0.61 0.79 -0.08 -0.18 -0.13 -0.28 1.10 1.12 1.14 1.25 
∆∆CT (Trisomy 21) -0.68 -0.57 -0.45 -0.30 -1.06 -1.15 -1.19 -1.37 0.12 0.15 0.08 0.16 
Avg ∆∆CT (Norm) 0.00 -0.69 0.63 
Avg ∆∆CT (T 18) 0.53 -0.17 1.15 
Avg ∆∆CT (T 21) -0.50 -1.19 0.13 
 
Table 3: Experimental data and analysis of 3 samples (single replicates). The Average ∆∆CT-
values of the determined karyotypes are in bold. Sample 3 is one of the replicates depicted in figures 1 
to 3. From this table it is apparent that sample 1 has a normal karyotype, sample 2 is of trisomy 18 and 
sample 3 is trisomy 21 (it is one of the replicates depicted in figures 1 to 3). 
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4. Notes 
 
1. In order for this assay to function, the main requirement for the real-time PCR 
instrument is that the fluorescence data is normalised to the passive reference dye, 
such as the ROX dye used by ABI. Any instrument that offers this feature should be 
suited for the test. In a previous study we used the ABI PRISM 7700 Sequence 
Detection System successfully. 
 
2. The optical covers have a high light transmission capacity, a necessity for highly 
precise measurements. Although optical caps should also work (according to the 
manufacturers’ technical support), our experience shows that the automatic data 
collection adjustments of the SDS7000 do not suffice to achieve the accuracy needed. 
For the laser illuminated SDS7700 the covers and caps work fine. However, it is 
advisable to always use the same covering for the reaction wells, since it has an 
influence on the measured fluorescence.  
 
3. The use of AmpErase UNG is absolutely required to avoid amplification of any 
miss-primed non-specific products formed prior to specific amplification. If this step 
is omitted, the balance of the two multiplexed reactions can be lost and one of the 
sequences will be amplified with a greater efficiency, resulting in false results. For the 
same reason use of a Taq- Polymerase activated by a hot start is required. 
 
4. To match the two assays a variety of primer combinations for the chromosome 21 
were tested. For the sake of expedience we have listed only the most efficient ones as 
well as the pertinent MGB probes (refer to Table 1).  
 
5. MGB probes emit lower background fluorescence than dual labelled probes. This is 
mainly due to more efficient quenching because the probes are shorter. As a result, 
MGB probes have a longer observable exponential phase, and this permits the use of a 
wider range for the thresholds. Dual labelled probes may also be used, but the 
measurements are slightly inferior in terms of final accuracy.  
It is also important to be aware, that the use of different batches of the same probes 
can result in differences in measurement due to minor differences in quality. 
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 6. It is highly recommended to use HPLC purified primers, as these are not subject to 
artefacts that non-purified primers are prone to, such as the formation of unspecific 
products by the presence of shorter unspecific primer fragments, which have an 
adverse effect on the reaction efficiency. Non-purified primers are also subject to 
greater batch-to-batch variation than HPLC purified ones.  
 
7. It is very important that the Chelex resin suspension is heated prior to 
centrifugation and separation of the DNA from the resin pellet. If not, re-adsorption of 
the DNA by the resin can occur, thereby removing a major amount of the DNA from 
the solution. This adsorption process may also lead to an imbalance of the ratio of the 
two target chromosomes. It is also important that no resin is transferred to the PCR as 
this will adversely affect amplification. 
 
8. DNA concentrations need not to be quantified. The Amount of DNA needed for 
highly reproducible results ranges from 5 ng to 80 ng. The protocol will usually 
produce a DNA solution in the required concentration range. Because of the limited 
quantity of sample material available, it should not be used for concentration 
measurements. The additional working step is not necessary. 
By co-amplifying a reference sample of known amount of DNA, which is the usual 
practice, the concentration of the sample can be determined with the following 
equation: 
concentration of sample = 2-(∆CT) / concentration reference sample 
 
9. Any kind of genomic DNA where the chromosomal ratio is preserved can be used. 
Next to the chelex extracted amniotic fluids we also tested extractions with the high 
pure PCR template kit from Roche and with the QIAmp blood kits from Qiagen. 
Cellular materials used were whole blood, monocytes from blood, cultured cells from 
blood and from amniotic fluid. 
 
10. Use of a reference sample of known quantity allows quantification as mentioned 
in Note 8. If the sample and a dilution of it are amplified, the sequence detection 
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software can determine the concentration of all samples tested with two standard 
curves (one for each chromosome).  
In theory these curves would permit karyotyping of the samples, however the results 
are not good enough. 
 
11. It makes sense to amplify a sample and a dilution of it. Sometimes in the original 
sample PCR inhibitors are present, that are diluted with the DNA. This added 
precaution makes it possible to observe reaction efficiencies for a sample via a 
standard curve and thus reveal the presence of inhibitors. 
 
12. Reaction volumes tested were 20 µl to 50 ul. Using 20 µl works, but the deviations 
are increased. A volume of 50 µl of course works fine, but it is not at all necessary to 
use such a big volume. Very small differences in collected data might occur, if the 
reaction volume is different from the volume that the assay is characterised for. 
 
13. If the concentration of the DNA is too low, up to 4 µl chelex extracted solution 
can be used. If the concentration is still too low, DNA has to be up-concentrated by 
for example evaporation, precipitation or extraction into a smaller volume using a kit. 
To save DNA and for highly concentrated samples, smaller volumes or dilutions in 
water can be used. 
 
14. Higher primer concentrations result in a decrease of the reaction efficiency in the 
multiplex assay. This can be attributed to an increase of unspecific reactions. Also 
higher concentrations of genomic DNA disturb the reaction. 
 
15. Probe concentrations of 100 uM also work fine, but a little accuracy may be lost, 
especially at the threshold of 0.675. 
 
16. Sample set-up on ice is important to reduce non-specific product formation to a 
minimum. The reaction plate should be kept on ice at all times prior to starting the 
real-time PCR. 
 
 76
17. Run the program always at the same heating and cooling rates. Differences in the 
temperature program will result in slight differences of the final CT and ∆CT-values. 
We use the emulation off setting, because it is faster. 
 
18. The baseline setting is very important to achieve optimal results in the analysis. It 
is used to separate unspecific fluorescent signal from the signal generated by the 
reaction. If the baseline is too far away from the amplification curve, many results of 
especially the lower thresholds will be affected by noise. 
Setting the baseline too close will skew the amplification curves and change the ∆CT 
to smaller values. 
 
19. In the amplification plot view check if the amplification curves of both dyes look 
normal and parallel for all three replicates. If the three replicates do not look very 
similar something might be wrong with at least one of the reactions. This can be due 
to contamination with DNA (pipetting errors), dirt or fluorescence source other than 
the dyes, leakage of the well, presence of an inhibitor or other reasons. If the curves 
do not resemble each other closely, the test should be re-run. 
 
20. After 40 cycles of amplification the ∆Rn will usually be between 2.0 and 3.0. Data 
from runs with a final ∆Rn of less than 1.5 is of poor quality. 
If using dual labelled probes, the ∆Rn will be smaller than when using MGB probes. 
This is a result of less efficient quenching and resulting higher background 
fluorescence in the longer dual labelled probes. 
 
21. The use of several thresholds increases the accuracy of the method. By using the 
four proposed thresholds, fluorescence data collected during 3 or 4 cycles is used 
compared to data from only 2 cycles when using only 1 threshold. A threshold of 0.1 
sometimes contains a good amount of unspecific signal. To exclude that possibility, 
the minimal threshold setting used is 0.2. The maximum threshold of 0.675 still gives 
good data, although the reaction is at the end of the exponential phase and efficiencies 
decreasing. 
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22. At DNA concentrations that result in a CT of 30.0 or higher (at the threshold of 
0.2), deviations occur in the amplifications, sometimes resulting in ∆CT-values 
uncharacteristic for the sample karyotype. Using a cut-off of 29.0 is a security 
measure to guarantee balanced amplification of both targets. 
The cut-off of 25.0 is a result of the baseline setting. Also the amplification of 
genomic DNA of very high concentrations can result in lower and varying 
efficiencies. None of the 100 amniotic fluid samples tested had a high enough 
concentration to result in such a low CT. 
 
23. To make the test more stringent, the maximum average ∆∆CT-value can be set to a 
smaller value. Alternative stringency requirements can be to demand that the results 
of a minimal number of thresholds per sample are indicative of the normal karyotype 
or one of the trisomies (e.g. 10 of total 12 values per triplicate). 
  
24. It is usually possible to exclude one of the three karyotypes. 
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Abstract 
 
Objective:  We  report  the  results  of  the  first  large  scale  study  using  a  novel  
real-time  quantitative  PCR  (real-time  qPCR)  method  for  the  detection  of  fetal  
trisomies.  The  multiplex  real-time  TaqMan  assay  was  performed  on  97  clinical  
amniotic  fluid  samples  which  were  analysed  in  a  blinded  manner.  Results  were  
compared  to  those  obtained  by  quantitative  fluorescent  PCR  (QF-PCR)  of  short  
tandem  repeats  (STRs)  in  a  diagnostic  laboratory.  The  aim  of  this  study  was  
to  evaluate  the  diagnostic  potential  of  the  new  real-time  qPCR  method. 
Results:  The  ratio  between  the  copy  numbers  of  chromosomes  18  and  21  was  
assessed  by  multiplex  real-time  qPCR.  In  our  analysis,  eight  samples  had  to  be  
excluded  as  the  sample  volume  was  too  small.  Our  analysis  of  the  remaining  
89  samples  resulted  in  a  specificity  of  94%.  The  five  false  diagnoses  were  due  
to  incorrect  sample  handling.  Upon  identification  of  the  source  of  error,  this  
was  readily  addressed  leading  to  a  correct  re-examination  of  these  samples. 
Our  data,  therefore,  demonstrate  that,  with  certain  precautions,  the  new  real-
time  qPCR  assay  allows  the  determination  of  fetal  aneuploidies  with  100%  
specificity. 
Conclusion:  The  real-time  qPCR  is  a  rapid  and  straightforward  method  for  the  
detection  of  prenatal  aneuploidies  and  is  highly  amenable  to  automation  at  
comparable  costs  and  sample  requirements  as  conventional  QF-PCR. 
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Introduction 
 
Prenatal  diagnosis  of  chromosomal  abnormalities  is  currently  accomplished  by  
invasive  techniques,  such  as  amniocentesis  and  chorionic  villus  sampling.  
Following  these  sampling  methods  a  complete  karyotype  is  established,  a  
procedure  that  takes  on  average  two  weeks  for  cell  culture.  This  period  of  
considerable  parental  anxiety  led  to  the  need  for  faster  methods.  Newer  
laboratory  techniques  such  as  Fluorescent  In-Situ  Hybridisation  (FISH)  and  QF-
PCR  of  STRs  (Mansfield 1993);  (Pertl et al. 1999),  (Levett, Liddle, and Meredith 
2001)  can  be  used  to  obtain  a  rapid  preliminary  diagnostic  answer  within  24  –  
48  hours.  To  date,  these  methods  complement  but  do  not  replace  full  
karyotypic  analysis  as  they  only  provide  an  answer  for  a  limited  number  of  
numerical  aberrations  (13,  18,  21,  X  and  Y),  which  cover  about  70%  of  all  
pertinent  fetal  chromosomal  aberrations  (Evans et al. 1999).  The  ability  to  
rapidly  determine  major  chromosomal  abnormalities  in  less  than  two  days  after  
the  invasive  procedure  offers  the  possibility  of  quick  intervention  in  case  of  
adverse  results.  Recent  studies  have  indicated  that  of  the  two  approaches  the  
FISH  method  is  expensive  and  labour  intensive  (Eiben et al.),  while  QF-PCR  is  
more  suited  for  high  throughput  analysis.  However,  since  special  technical  
expertise  and  equipment  are  needed,  QF-PCR  remains  confined  to  laboratories  
with  methodological  experience  and  with  access  to  specialised  software  for  the  
data  analysis  (Hulten, Dhanjal, and Pertl 2003). 
In  the  past  decade,  real-time  qPCR,  employed  as  the  5’-nuclease  TaqMan  
assay,  has  emerged  as  a  very  powerful  tool  for  the  measurement  of  the  copy  
number  of  nucleic  acid  sequences.  The  method  is  more  sensitive,  specific  and  
reproducible  than  previous  approaches.  It  has  consequently  found  a  wide  spread  
application  in  the  analysis  of  gene  expression,  determination  of  gene  deletions  
or  duplications  in  cancer  research  as  well  as  in  the  quantitation  of  circulating  
nucleic  acids  in  body  fluids  for  prenatal,  viral  and  cancer  diagnosis  and  
prognosis.  Newly  developed  instruments  permit  certain  assays  to  be  performed  
within  15  minutes. 
Although  manufacturers  generally  state  that  current  instrumentations  allow  only  
the    determination  of  2-fold  differences  in  template  concentration,  we  have  
recently  shown,  that  multiplex  real-time  qPCR  assays  can  be  optimised  to  
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detect  as  low  as  50%differences  in  template  copy  number.  This  is  a  
prerequisite  when  attempting  to  determine  fetal  aneuploidies  (Zimmermann et al. 
2002).  This  increased  accuracy  was  achieved  by  implementing  special  
experimental  and  analytical  parameters. 
We  have  now  extended  upon  this  preliminary  investigation  by  developing  the  
assay  further,  permitting  the  simultaneous  assessment  of  chromosomes  18  and  
21,  and  have  tested  the  diagnostic  potential  of  the  assay  in  a  blinded  large-
scale  retrospective  study  of  clinical  samples.  Our  results  indicate  that  real-time  
qPCR  is  a  powerful  tool  for  the  prenatal  diagnosis  of  aneuploidies. 
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Material  and  Methods 
 
Clear  amniotic  fluid  samples  from  97  pregnant  women  were  collected  and  
DNA  extracted  and  analysed  by  QF-PCR  for  STRs  at  the  Cytogenetic  DNA  
Services  Ltd.,  London  (Levett, Liddle, and Meredith 2001).  Small  aliquots  of  the  
archived  DNA  samples  were  coded  and  sent  to  Basel  for  blinded  real-time  
qPCR  analysis.   
Washed  cells  from  1ml  of  amniotic  fluid  were  suspended  in  60  µl  of  a  10%  
suspension  of  chelex  100  resin  in  water  (biotechnology  grade  100  –  200  mesh  
sodium  form,  Biorad,  UK)  and  incubated  for  20  minutes  at  57ºC,  then  for  8  
minutes  at  100°C.  The  resin  was  pelleted  at  13000  rpm  for  2  minutes  and  the  
aqueous  DNA  solution  used  for  PCR  analysis.   
For  control  purposes,  DNA  was  extracted  from  400  µl  amniocytes  cultures  
using  the  QIAmp  DNA  Blood  Mini  Kit  according  to  the  manufacturer’s  
recommendations  (Qiagen,  Switzerland).  In  addition,  already  diagnosed  samples  
were  re-examined. 
 
Karyotype  determination  by  real-time  qPCR 
The  multiplex  real-time  qPCR  analysis  for  sequences  on  chromosomes  18  and  
21  was  performed  in  the  ABI  PRISM  7000  Sequence  Detection  System  
(Applied  Biosystems  (ABI),  Switzerland).  Primers  and  TaqMan  MGB  probes  
were  designed  to  amplify  a  sequence  of  the  amyloid  precursor  protein  gene  in  
the  Down’s  region  of  chromosome  21  and  of  the  thymidylate  synthetase  gene  
on  chromosome  18.  Sequences  for  chromosome  21  were:  Primers  5’-CCC AGG 
AAG GAA GTC TGT ACC C-3’  and  5’-CCC TTG CTC ATT GC GCT G-3’,  and  
probe,  5’-CTG GCT GAG CCA TC-3’,  with  Minor  Groove  Binder  (MGB)  and  
labelled  with  FAM  fluorescent  dye.  Chromosome  18  sequences  for  primers  5’-
TGA CAA CCA AAC GTG TGT TCT G-3’  and  5’-AGC AGC GAC TTC TTT 
ACC TTG ATA A-3’,  and  the  VIC-labelled  MGB  probe  5’-GGT GTT TTG GAG 
GAG TT-3’. 
Patient  DNA  in  volumes  of  2  µl  was  amplified  in  triplicate  in  25  µl  reactions  
containing  300  nM  of  each  primer  (HPLC  purified,  Microsynth,  Switzerland),  
200  nM  of  each  MGB  probe  (ABI),  and  1  x  concentration  of  the  TaqMan  
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Universal  PCR  master  mix  (ABI).  The  reactions  were  prepared  on  ice  and  
cycling  conditions  were  as  follows:  2  min  at  50°C  and  10  min  at  95°C  for  
initial  denaturation  of  the  genomic  DNA  and  polymerase  activation,  followed  
by  40  cycles  of  1  min  at  60°C  and  15  s  at  95°C. 
The  real-time  qPCR  analysis  was  performed  with  a  baseline  setting  of  3  –  22  
cycles.  Amplifications  with  a  final  normalised  fluorescence  (∆R
n
)  smaller  than  
1.50  were  excluded  from  the  karyotype  determination  due  to  insufficient  
amounts  or  quality  of  DNA. 
Each  reaction  curve  was  analysed  at  4  different  thresholds  at  ∆R
n
-values  of:  
0.2  /  0.3  /  0.45  /  0.625,  with  an  increase  in  fluorescence  intensity  of  1.5  fold  
between  thresholds.  Amplifications  with  CT-values  from  25.0  to  29.0  (for  a  
threshold  of  0.2),  corresponding  to  approximately  700  –  10000  genome  
equivalents  per  PCR,  were  valid  for  diagnosis.  Samples  with  values  outside  of  
this  range  were  re-tested  either  in  dilution  or  with  a  larger  sample  input  
volume. 
For  the  three  replicates  the  ∆CT  and  the  ∆∆CT  for  each  of  the  four  thresholds  
was  determined,  leading  to  12  single  ∆∆CT  values  per  sample: 
  ∆CT  =  CT  (Chromosome  18)  –  CT  (Chromosome  21) 
∆∆CT,calibrated  =  ∆CT  (sample)  –∆CT  (calibrator) 
The  ∆CT  (calibrator)  is  the  average  ∆CT  of  the  reference  samples  of  normal  
karyotype.  In  this  analysis,  we  averaged  the  ∆CT-values  of  all  valid  reference  
DNAs.   
For  the  determination  of  a  sample  karyotype  the  following  criteria  had  to  be  
met:   
1. At  least  nine  of  the  twelve  single  ∆∆CT,calibrated  values  had  to  be  in  the  range  
from  -0.25  to  +0.25.   
2. The  averaged  ∆∆CT-values  of  each  of  the  three  replicates  had  to  be  in  the  
range  from  -0.25  to  +0.25.   
If  the  sample  karyotype  was  not  normal,  the  same  calculations  were  performed  
with  ∆CT  (calibrator)  values  derived  from  the  trisomy  controls.  If  the  results  
were  not  indicative  of  any  karyotype,  the  sample  was  retested. 
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Results 
 
Our  analysis  indicated  that  for  a  reliable  assay  the  sample  input  needs  to  be  
within  a  certain  concentration  range.  We  found  that  between  700  and  10000  
GE  are  optimal  for  diagnosis.  Most  of  our  samples  contained  this  amount  in  2  
µl,  the  usual  input  volume.  Amplification  of  standard  samples  in  fourfold  
dilutions  in  this  range  showed  equal  and  optimal  efficiencies,  indicating  
accurate  and  reproducible  assay  performance  [figure  1]. 
 
Figure  1:  Amplification  plot  of  the  real-time  PCR  data. Triplicate amplifications of  a  
normal  karyotype  sample  in  fourfold  dilution.  The  red  curves  represent  data  from  chromosome  
21,  the  blue  curves  from  chromosome  18.  The  four  thresholds  used  in  analysis  are  represented  
by  yellow  lines.  The  efficiencies  determined  for  chromosome  18  were  between  1.95  and  1.98  
for  the  four  selected  thresholds,  for  chromosome  21  between  1.93  and  1.96. 
 
 
Analysis  of  standard  samples,  which  included  cases  of  trisomy  21  and  18,  
confirmed  that  the  ∆CT-values  of  the  amplified  samples  cluster  in  three  specific  
groups  depending  on  their  karyotype  [figure  2].  By  defining  a  cut-off  region  of  
±  0.25  cycles  around  the  ∆CT(calibrator)  of  each  ploidy,  the  ∆CT  of  a  sample  
allows  to  assess  its  karyotype.  The  ∆CT-values  were  stable  over  several  
experiments,  as  is  evident  from  the  analysis  of  normal  samples  in  9  
consecutive  experiments  [Figure  3]. 
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Figure  2:  Scatter  plot  of  the  ∆CT-values  of  the  control  DNA  samples  for  the  threshold  
of  0.45.  Depicted  are  replicate  averages  per  sample.  The  ∆CT  -values  of  all  samples  with  
normal  karyotype  group  between  -0.22  and  +0.10,  all  trisomic  samples  lie  outside  of  this  area.  
The  average  of  the  normal  samples  is  -0.12,  this  is  the  ∆CT  (calibrator)  for  normal  karyotype  
at  threshold  0.45. 
 
Figure  3:  Box  plot  of  CT-values  in  9  experiments  of  all  samples  of  normal  karyotype  at  
the  threshold  0.45.  Numbers  on  X-axis  indicate  number  of  measurements  per  experiment.  The  
cut-off  lines  for  normal  karyotype  are  at  -0.37  and  0.13,  the  median  line  at  -0.12.  A  few  
points  are  outside  of  the  cut-offs,  but  replicate  amplifications  and  values  from  other  thresholds  
prevent  misdiagnosis. 
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In  our  study  we  examined  97  samples,  of  which  8  had  to  be  excluded  due  to  
too  small  sample  volume.  Our  blinded  analysis  of  the  remaining  89  samples  
indicated  that  the  method  could  be  reliably  used  for  the  analysis  of  fetal  
aneuploidies,  as  we  were  able  to  correctly  diagnose  all  11  cases  with  trisomy  
21  and  all  4  with  trisomy  18.  68  samples  of  normal  and  one  of  triploid  
karyotype  were  correctly  determined  as  chromosomal  balanced.  It  is  an  intrinsic  
feature  of  this  real-time  qPCR  assay  that  it  cannot  distinguish  triploid  from  
normal  karyotype  samples,  as  the  chromosome  ratios  are  equal.  In  our  blinded  
study,  5  samples  with  a  normal  karyotype  were  misdiagnosed. 
The  analysis  of  aneuploid  samples  indicated  that  these  could  be  detected  with  
a  sensitivity  of  100%  (15/15),  and  a  false  negative  rate  of  0%.  In  contrast,  our  
study  showed  that  the  false  positive  rate  of  25%  (5/20)  was  very  high.  As  we  
repeatedly  observed  erroneous  results  from  these  samples,  we  hypothesised  that  
this  error  may  be  due  to  an  artefact  introduced  during  sample  processing,  such  
as  aberrant  adsorption  to  the  resin  used  in  the  DNA  purification  procedure.  We  
re-extracted  the  DNA  from  the  resin  of  three  such  previously  misdiagnosed  
samples  by  addition  of  40  µl  water  and  heating  to  95  ˚C  for  5  minutes.  The  
reanalysis  showed  that  the  fetal  ploidy  could  subsequently  be  correctly  
determined  [figure  4].  Unfortunately  we  could  not  re-examine  the  other  two  
samples  which  had  yielded  erroneous  results,  due  to  insufficient  amounts  of  
material  remained  for  reanalysis.  We  conclude,  that  the  error  was  introduced  
during  sample  handling.  Following  purification  with  conventional  resin  based  
technology,  storage  and  shipment,  the  recovery  of  DNA  from  these  samples  
was  poor.  This  source  of  error  could  be  excluded  by  re-solubilizing  the  DNA  
under  heat.  The  improved  recovery  of  DNA  was  also  observed  in  samples  with  
initially  insufficient  amounts  of  DNA. 
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Figure  4:  The  corrected  CT-values  of  3  false  samples.  Experiments  7  and  8  are  the  results  
from  the  re-solubilized  resins.  CT-values  between  -0.25  and  0.25  indicate  that  the  normal  
karyotype  is  determined  correctly.  CT=  CT(sample)  - CT(calibrator). 
 
The  real-time  qPCR  assay  per  se  is  highly  robust,  but  it  needs  sufficiently  
concentrated  and  pure  DNA.  Further  indication  is  presented  by  the  
measurements  of  the  control  samples:  These  DNA  solutions  were  extracted  to  
high  purity  by  silica  membrane  technology  and  optimally  suited  for  the  real-
time  qPCR  assay.  Resulting  deviations  of  the  ∆CT-values  are  clearly  smaller  
than  for  the  clinical  samples:  we  plotted  the  ∆CT  against  the  ratio  of  the  
chromosomes  and  fitted  an  exponential  curve.  Excluding  the  five  false  samples,  
all  replicates  of  the  study  give  R2  values  of  0.74  to  0.80,  depending  on  the  
threshold.  Plotting  the  values  of  all  reference  samples  results  in  R2  values  of  
0.89  to  0.95. 
In  conclusion,  using  only  1  assay,  we  were  able  to  determine  the  karyotype  in  
84  of  89  fetal  samples,  with  a  combined  false  negative  rate  of  0%  and  a  false  
positive  rate  of  25%  for  both  trisomies.  The  specificity  of  94%  (84/89)  
underestimates  the  accuracy  of  the  method  considering  the  finding  of  DNA  
adsorption  by  the  extraction  resin.  Upon  analysis  of  re-solubilized  DNA  we  
improved  the  specificity  to  100%. 
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Ratio  determination 
The  use  of  a  ∆CT-  or  ∆∆CT-value  is  not  demonstrative  for  the  diagnostic  
application,  as  the  analyst  should  be  supplied  with  a  value  concerning  the  
actual  chromosomal  copy  numbers.  For  this  reason,  converting  the  amplification  
data  into  a  ratio  of  chromosome  copy  numbers  is  desirable,  such  that  the  
diagnostic  answer  of  the  assay  will  be  easy  to  understand  and  output  values  
linear  (Livak and Schmittgen 2001).  A  proviso  for  the  ratio  determination  by  the  
∆∆CT-method  is  that  both  targets  are  amplified  with  equally  optimal  
efficiencies.  We  showed  earlier  that  this  condition  is  met,  consequently  the  
ratio  between  the  two  chromosomes  can  be  calculated  by  the  following  
formula: 
 
Chr21/Chr18  =  2  –(∆∆CT)  =  2  ( CT,sample-  CT,calibrator)   
 
We  applied  the  averaged  ∆∆CT  values  of  all  measurements  as  calibrator-values.  
The  resultant  ratios  for  normal  karyotype  samples  are  averaging  1.00  at  every  
threshold  [table  1].  The  ratios  calculated  for  the  trisomy  samples,  however,  are  
closer  to  1.00  than  would  be  expected.  Consequently,  when  using  the  values  of  
the  calculated  ratios  for  diagnosis,  one  needs  to  adjust  the  cut-off  values  for  
this  bias. 
 
Sample  
karyotypes 
Replicates ∆CT      
(threshold  0.2) 
∆CT      
(threshold  0.3) 
∆CT      
(threshold  0.45) 
∆CT      
(threshold  0.675) 
Average  
∆∆CT 
Average 
Ratio 
Trisomy  18 62 -0.53 -0.59 -0.68 -0.78 -0.55 0.69 
balanced 358 -0.01 -0.06 -0.12 -0.19 0.00 1.00 
Trisomy  21 103 0.45 0.40 0.37 0.33 0.48 1.40 
Table 1: Average ∆CT  values  of  all  measurements separated by karyotype. The  average  ∆∆CT  
values are calculated in comparison to the balanced samples’ ∆CT  values. These values are used for the 
ratio determination. 
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Discussion 
 
In  the  past  decade,  QF-PCR  of  STRs  has  emerged  as  the  prime  PCR  method  
used  for  the  rapid  detection  of  chromosomal  aneuploidies.  Recently  we  
presented  an  alternative  PCR  approach  for  the  detection  of  trisomy  21  
(Zimmermann et al. 2002),  which  is  based  on  real-time  PCR.  In  this  assay,  a  
sequence  in  the  Down’s  syndrome  critical  region  of  chromosome  21  and  a  
control  sequence  from  the  GAPDH  gene  on  chromosome  12  are  simultaneously  
amplified.  Our  analysis  indicated  that  trisomy  21  samples  could  be  reliably  
distinguished  from  karyotypically  normal  specimen  according  to  the  resulting  
∆CT.  This  report  represented  the  first  instance  that  real-time  qPCR  could  be  
used  with  a  sensitivity  that  demonstrated  a  3:2  difference  between  gene  loci  
(Armour et al. 2002).  Also  other  PCR  methods  have  been  presented  to  avoid  the  
use  of  polymorphic  sites,  which  is  encumbered  with  small  disadvantages  that  
restrict  it’s  application  to  experienced  laboratories  (Mann et al. 2001).  The  
suggested  alternatives  involve  the  QF-PCR  comparative  quantification  of  non-
polymorphic  loci  (Lee et al. 1997);  (Rahil et al. 2002),  allele  quantification  by  
melting  curve  analysis  of  SNPs  (single  nucleotide  polymorphisms)  (Pont-
Kingdon G. and Lyon 2003)  and  multiplex  ligation  dependent  probe  amplification  
(MLPA)  (Slater et al. 2003). 
We  modified  our  initial  assay  to  quantify  chromosome  21  in  relation  to  
chromosome  18  and  thus  test  for  two  of  the  most  prevalent  fetal  aneuploidies.  
The  advantage  of  the  multiplex  PCR  set-up  is  that  it  circumvents  problems  
associated  with  well  to  well  variations  between  the  amplification  targets  caused  
by  reaction  set-up,  by  the  thermocycler  or  by  the  changing  conditions  during  
the  reaction  (Li et al. 2003).   
 
Assay  validation 
The  major  preconditions  to  achieve  the  highest  degree  of  reproducibility  and  
precision  are  stable  and  optimal  amplification  efficiencies  (Tichopad, Dzidic, and 
Pfaffl 2003).  In  the  present  study  we  showed  equal  efficiencies  for  both  targets  
amplified  in  multiplex  over  a  wide  range  of  concentrations  and  fluorescence  
intensities.  This  was  ascertained  by  a  series  of  standard  dilution  curves. 
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Our  studies  indicate  that  the  following  specifications  are  critical  for  optimal  
performance:  purified  primers  are  an  absolute  prerequisite  for  high  accuracy  in  
PCR,  while  being  a  negligible  cost  factor.  Also,  the  properties  of  the  TaqMan  
MGB  probes  allow  very  accurate  fluorescence  measurements.  The  MGB  probes  
generate  a  low  background  fluorescence,  which  results  in a  long  observable  
exponential  phase  of  the  PCR  reactions.  This  is  especially  important  in  
multiplex  experiments,  where  the  total  fluorescence  is  increased  by  the  presence  
of  more  than  one  labelled  probe.  
In  order  to  level  out  small  fluctuations  and  to  ensure  equal  amplification  of  
both  sequences  in  each  analysis,  4  thresholds  along  the  linear  phase  of  the  
amplification  plot  are  chosen  for  the  ploidy  determination.  This  approach  is  
more  accurate  than  the  use  of  a  single  threshold,  which  can  be  vitiated  by  
background  fluorescence  at  low  thresholds  and  plateau  effects  at  high  
thresholds,  in  addition  to  the  common  fluctuations  in  the  fluorescence  
measurements. 
The  use  of  a  single  sample  as  reference  is  not  reliable  and  may  result  in  an  
erroneous  diagnostic  result.  This  caveat  can  be  overcome  by  basing  the  
calculations  on  the  control  measurements  of  several  experiments.  This  procedure  
increases  the  accuracy  of  the  ∆CT(calibrator)  value.  As  long  as  identical  
reaction  conditions  are  ensured,  the  generated  data  is  very  stable  and  
reproducible  (Rutledge and Cote 2003). 
 
PCR  bias 
We  observed  that  the  multiplex  amplification  suffers  from  ∆CT-shifting  when  
the  targets  are  present  in  similar  concentrations.  This  bias  against  the  more  
abundant  locus  towards  the  PCR  product  ratio  of  1:1  was  already  observed  in  
our  previous  pilot  study  (data  not  published)  and  has  been  reported  for  the  
later  PCR  cycles  (Suzuki and Giovannoni 1996; Mathieu-Daude et al. 1996).  Data  
from  the  recently  reported  MLPA  describes  an  even  more  decreased,  non-linear  
relationship  between  chromosome  dosage  and  the  mean  peak  ratios  of  PCR  
products  with  unclear  cause.  We  suggest  that  the  rate  of  amplification  of  the  
more  abundant  PCR  product  declines  faster  than  that  of  the  less  abundant  one  
because  of  the  self-hybridisation  of  PCR  products,  thus  preventing  primer  
annealing  to  a  fraction  of  the  template.  The  higher  self-inhibition  during  all  
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PCR  cycles  for  the  more  abundant  product  results  in  a  successive  decrease  of  
the  original  difference.   
 
Aneuploidy  detection  by  real-time  qPCR 
Our  findings  demonstrate  that  real-time  qPCR  can  be  a  fast  and  reliable  
method  for  the  diagnosis  of  the  major  chromosomal  abnormalities.  During  this  
study,  we  were  alerted  to  pitfalls  of  PCR-based  methods.  Main  concerns  in  the  
clinical  application  are  DNA  quality  and  quantity.  DNA  adsorption  by  the  
extraction  resin  led  to  erroneous  diagnosis  of  five  samples.  This  can  be  
prevented  by  using  freshly  extracted  DNA,  resolubilising  stored  samples,  or  by  
using  a  different  DNA  extraction  method. 
Our  study  also  indicated  that  a  minimum  template  concentration  in  the  reaction  
mixture  is  required  to  ensure  equal  amplification.  The  amount  necessary  is  
usually  present  in  1  ml  of  amniotic  fluid  and  comparable  to  the  requirement  
for  QF-PCR  based  assays.  Advantages  of  the  real-time  method  in  this  regard  
are  that  the  assay  is  valid  for  concentrations  ranging  over  more  than  one  order  
of  magnitude  and  that  the  CT-value  of  the  amplification  directly  indicates  
insufficient  template  quantity.  As  such,  the  accurate  determination  of  template  
concentration  is  possible  without  additional  work  or  sample  demand. 
It  should  be  kept  in  mind,  that  the  precision  of  the  PCR  for  high  copy  
numbers  is  better,  as  low  amounts  of  DNA  cause  a  higher  degree  of  
variability.  Preferential  amplification  (Findlay et al. 1998)  and  statistical  variation  
due  to  sampling  become  important  impediments  (Niesters 2001).  We  observed  
that  700  GE  per  reaction  are  sufficient  to  assure  optimal  assay  performance.  
However,  the  lower  limit  of  sample  material  was  not  explored  extensively,  but  
good  sample  quality  and  smaller  reaction  volumes  can  improve  the  assay  
performance  further. 
Several  quality  control  measures  are  integrated  in  the  real-time  qPCR  set-up  
and  permit  monitoring  of  the  efficacy  of  the  assay.  These  are  available  without  
any  additional  hands-on  time,  and  include  the  final  fluorescence  ( R
n
),  the  
slopes  of  the  amplification  curves  and  uniformity  of  replicates.  Abnormalities  in  
these  parameters  allow  to  identify  samples  that  are  inadequate  to  guarantee  
accurate  assay  performance. 
The  absence  of  post-PCR  processing  saves  substantial  time  and  the  closed  tube  
system  effectively  eliminates  the  risk  of  carry-over  contamination,  a  vitally  
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important  factor  for  the  clinical  setting.  This  consequently  reduces  the  demand  
on  space  and  equipment,  as  separate  locations  for  PCR  product  handling  are  
not  necessary.   
Akin  to  other  PCR  based  methods,  real-time  qPCR  is  a  suitable  tool  for  the  
diagnosis  of  the  most  common  chromosomal  aberrations,  in  our  case  
specifically  for  the  aneuploidies  of  the  chromosomes  21  and  18.  The  assay  can  
be  readily  extended  for  the  analysis  of  the  other  common  fetal  aneuploidies  of  
chromosomes  13,  X  and  Y.  One  shortcoming  of  the  method  is  that  triploidies  
cannot  be  detected,  as  these  result  in  an  analysis  indicating  chromosomal  
balance.  It  will  only  be  possible  to  detect  these  if  one  or  two  Y  chromosomes  
are  present,  that  is  69XXY  or  69XYY.  As  triploidy  is  almost  always  
ascertained  by  ultrasound  examination,  this  is  not  a  major  concern. 
To  date,  the  real-time  qPCR  method  is  limited  in  the  number  of  loci  that  can  
be  analysed  in  one  well,  in  that  only  five  different  fluorophores  can  be  
monitored  simultaneously.  Other  methods  exhibit  a  much  greater  multiplexing  
capacity,  for  example  QF-PCR  of  STRs  allows  to  target  up  to  12  loci  and  
MLPA  even  40  in  one  reaction.  On  the  other  hand,  in  the  real-time  PCR  
assay  only  one  locus  per  chromosome  needs  to  be  examined.  Additionally,  the  
system  and  data  analysis  are  very  amenable  to  automation.  Currently  a  384  
well  format  is  available  requiring  as  little  as  5  –  10  µl  reaction  volume,  which  
allows  a  very  cost-effective  and  flexible  throughput. 
A  further  advantage  is  that  the  real-time  qPCR  is  the  fastest  assay  reported  to  
date.  With  rapid  cycling,  analysis  times  shorter  than  half  an  hour  are  easily  
possible,  and  an  adapted  software  could  make  data  analysis  almost  
instantaneous.  By  automating  DNA  extraction  and  the  subsequent  amplification,  
the  real-time  qPCR  test  can  conducted  in  as  much  as  no  laboratory  training  is  
necessary  to  conduct  the  test.  This  potential  to  obtain  a  diagnostic  result  within  
a  few  minutes  at  the  site  of  the  invasive  sampling  procedure  cannot  be  
matched  by  other  methods. 
In  addition,  it  is  possible  to  combine  the  assay  with  ancillary  methods  for  the  
detection  of  aneuploidies,  such  as  SNP  based  melting  curves  and  even  QF-
PCR.  As  there  is  a  trend  to  use  molecular  methods  as  stand  alone  tests  for  
women  who  are  at  relatively  low  risk  for  having  a  baby  with  a  chromosome  
disorder  (Hulten, Dhanjal, and Pertl 2003),  it  seems  advisable  to  combine  
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methods  that  can  be  carried  out  simultaneously  to  complement  individual  
advantages. 
In  summary,  we  report  the  first  large  study  using  real-time  qPCR  for  detection  
of  fetal  aneuploidies.  The  accuracy  and  precision  of  the  real-time  technique  is  
clearly  evident.  Our  study  also  indicates  that  the  method  is  straightforward  and  
that  it  can  produce  results  of  diagnostic  value  within  as  little  as  two  hours. 
With  further  development  of  the  instrumentation  and  reagents  the  test  can  be  
easily  optimised  to  a  high-throughput  method,  which  would  save  time  and  
money  and  would  allow  to  analyse  an  increased  number  of  targets. 
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ABSTRACT 
 
Background:  Circulatory  fetal  DNA  in  maternal  plasma  has  rapidly  been  
introduced  as  a  new  method  for  non-invasive  prenatal  diagnosis,  particularly  for  
the  analysis  of  fetal  genetic  traits,  which  are  absent  from  the  maternal  genome,  
e.g.  RHD  or  Y  chromosome  specific  sequences.  Currently,  the  analysis  of  other  
fetal  genetic  traits  has  proven  to  be  more  problematic,  due  to  the  
overwhelming  presence  of  maternal  circulatory  DNA  sequences.  We  have  
examined  whether  different  biochemical  properties  can  be  discerned  between  
fetal  or  maternal  circulatory  DNA.   
 
Methods:  Circulatory  plasma  DNA  was  examined  by  agarose  gel  
electrophoresis.  The  fraction  of  fetal  and  maternal  DNA  in  size  fractionated  
fragments  was  determined  by  real-time  PCR.  The  determination  of  paternally  
and  maternally  inherited  fetal  genetic  traits  was  examined  using  highly  
polymorphic  chromosome  21  specific  microsatellite  markers.   
 
Results:  Size  fractionation  of  circulatory  DNA  indicated  that  the  major  portion  
of  cell  free  fetal  DNA  had  an  approximate  molecular  size  of  less  than  0.3  kb,  
whereas  maternally  derived  sequences  were  on  average  considerably  larger  than  
1  kb.  Analysis  of  size  fractionated  DNA  (≤  0.3  kb)  from  maternal  plasma  
samples  facilitated  the  more  ready  detection  of  paternally  and  maternally  
inherited  microsatellite  markers. 
 
Conclusions:  Circulatory  fetal  DNA  can  be  enriched  for  by  size  selection  of  
fragment  sizes  of  less  than  approximately  0.3kb.  Such  selection  permits  more  
ready  analysis  of  both  paternally  and  maternally  inherited  DNA  polymorphisms.  
(222  words) 
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INTRODUCTION 
 
Since  it’s  discovery  in  1997  by  Lo  and  colleagues  (1),  circulatory  fetal  DNA  
in  maternal  plasma  or  serum  has  rapidly  emerged  as  the  prime  strategy  for  the  
development  of  risk  free  methods  for  prenatal  diagnosis  of  fetal  genetic  traits  
(2,  3).  Indeed,  due  the  relative  abundance  of  this  fetal  genetic  material,  which  
is  several  orders  of  magnitude  higher  than  that  of  trafficking  fetal  cells  (4),  the  
determination  of  fetal  genetic  loci  which  are  totally  absent  from  the  maternal  
genome  has  proven  to  be  relatively  facile.  Consequently  the  analysis  of  
circulatory  fetal  DNA  in  maternal  plasma  is  already  being  offered  clinically  by  
several  centres  for  the  determination  of  the  fetal  RHD  status  in  pregnancies  
with  a  Rhesus  constellation,  or  the  determination  of  fetal  sex,  via  the  detection  
of  Y  chromosome  specific  sequences  in  pregnancies  at  risk  for  an  X-linked  
disorder  (e.g.  Haemophilia,  Fragile  X  syndrome)  (3). 
Quantitative  analysis  of  this  new  found  fetal  analyte  using  real-time  PCR  
strategies  have  also  indicated  that  the  concentration  of  circulatory  fetal  DNA  
were  elevated    under  a  variety  of  pregnancy  related  pathologies  including  
preeclampsia  (5,  6),  preterm  labour  (7,  8),  hypermesis  gravidarum  (8)  and  in  
pregnancies  with  fetal  aneuploidies,  most  notably  trisomy  21  (9,  10).  These  
studies  have  suggested  that  fetal  DNA  concentrations  may  serve  as  a  new  
screening  marker  for  such  pregnancy  related  anomalies  (11). 
A  caveat  of  current  investigations  is  that  the  overwhelming  amount  of  
circulatory  DNA  in  the  maternal  circulation  is  of  maternal  origin  (>90%)  (4),  
which  has  rendered  the  discrimination  of  more  subtle  genetic  differences  
between  mother  and  child  considerably  more  difficult  (2,  3).  This  is  generally  
true  for  Mendelian  genetic  disorders  involving  point  mutations  (12),  or  those  
instances  where  both  parents  are  carriers  for  the  same  disease  allele,  as  well  as  
for  the  examination  of  DNA  polymorphisms  (13,  14),  which  could  be  used  for  
the  determination  of  fetal  ploidy  (15).  Consequently  few  reports  exist  regarding  
the  successful  use  of  circulatory  fetal  DNA  for  such  applications  (12,  16-18). 
To  date  few  studies  have  addressed  the  biochemical  properties  of  circulatory  
fetal  DNA  (19,  20).  In  the  most  recent  of  these  Chan  and  colleagues  (20)  
used  differently  sized  PCR  amplicons  to  discern  the  respective  size  distributions  
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of    circulatory  fetal  and  maternal  DNA  species,  which  indicated  that  fetal  
DNA  molecules  are  generally  smaller  than  comparable  maternal  ones.  As  this  
approach  only  permitted  a  precise  delineation  of  rather  small  DNA  species  
(<800bp),  we  have  examined  this  facet  using  a  combination  of  agarose  gel  
electrophoresis,  Southern  blotting  and  real-time  PCR,  as  this  would  permit  an  
analysis  of  large  DNA  molecules  (>  10  to  20  kb).  Our  studies  have  shown  
that  circulatory  DNA  has  apoptotic  characteristics,  displaying  a  typical  ladder  
obtained  by  nucleosomal  cleavage.  We  also  observed  that  circulatory  fetal  DNA  
is  generally  of  a  smaller  size  than  maternally  derived  cell  free  DNA  fragments,  
a  feature  which  is  in  good  agreement  with  recent  observations  (20).  By  
exploiting  this  observation,  we  have  now  shown  that  even  a  simple  strategy,  
such  as  size-separation  using  conventional  agarose  gel  electrophoresis  and  
subsequent  PCR  analysis  (21),  can  lead  to  the  selective  enrichment  of  
circulatory  fetal  DNA  sequences.  These,  in  turn  can  be  used  for  the  
determination  of  DNA  polymorphisms  that  are  masked  by  maternal  sequences  
in  the  native  plasma  sample. 
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MATERIALS  AND  METHODS 
 
Southern  Blot    Analysis 
 
Plasma  sample  collection:  Following  approval  by  the  Cantonal  Institutional  
Review  Board  of  Basel,  Switzerland,  18ml  peripheral  blood  was  obtained  after  
written  informed  consent  from  pregnant  women.  EDTA  (Sarstedt  Movovette  
tubes;  Sarstedt,  Sevelen,  Switzerland)  was  used  as  anti-coagulant.  The  blood  
samples  were  first  cleared  by  centrifugation  at  1600g  for  10  minutes,  following  
which  the  plasma  was  further  subjected  to  a  second  centrifugation  step  of  
16000g  for  10  minutes.  Plasma  was  immediately  used  for  DNA  extraction  in  
each  analysis.   
Southern  hybridisation:  Circulatory  DNA  was  extracted  from  approximately  7-
10ml  maternal  plasma  (gestational  age  11-17  weeks)  and  18ml  cord  blood  
plasma  using  a  conventional  phenol-chloroform  procedure,  with  a  slight  
modification  in  that  the  plasma  sample  was  first  treated  with  a  chaotropic  
Guanidium  Isothiocyanate  solution  to  denature  any  nucleases  (Qiagen,  Basel,  
Switzerland)  (22).  As  a  control,  we  used  plasma  from  non-pregnant  women. 
The  extracted  DNA  was  separated  on  a  1.0%  agarose  gel.  A  100bp  ladder  and  
Hind  III  digested  Lambda  phage  DNA  were  used  to  estimate  molecular  size  
(New  England  Biolabs,  USA).  DNA  was  transferred  onto  nylon  membranes  
(Roche,  Basel,  Switzerland)  with  20xSSC  using  standard  capillary  transfer  
method  (22). 
Detection  of  transferred  DNA  was  performed  using  the  Roche  ®  DIG  labelling  
and  detection  system  according  to  the  manufacturer’s  instructions  (Roche,  
Switzerland).    The  highly  repetitive  Alu  sequence  was  used  as  a  hybridisation    
probe,    and  was  directly  DIG-labelled  by  PCR  process  using  PCR  DIG  Probe  
Synthesis  Kit    (Roche,  Switzerland).  The  primer  of  the  Alu  sequence  is  as  
follows:  ATC  TCG  GCT  CAC  TGC  AA.  Prehybridization  was  carried  out  at  
42°C  in  DIG  Easy  Hyb  solution  (Roche,  Switzerland).  Hybridization  was  
performed  at  42°C  overnight  and  washed  at  high  stringency  and  incubated  with  
the    chemiluminescent  alkaline  phosphatase  substrate  (CSPD)  according  to  the  
manufacturer’s  instructions  and  the  resulting  blot  was  exposed  on  X-ray  film. 
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Determination  of  the  size  distribution  of  circulatory  fetal-derived  
DNA  in  maternal  plasma   
 
Circulatory  DNA  preparation:  Plasma  samples  were  prepared  as  described  
above.  Peripheral  blood  was  collected  from  the  pregnant  women  carrying  a  
singleton  male  fetus.  Six  samples  were  obtained  early  in  pregnancy  (median  
gestational  age = 13+2  weeks)    and  8  samples  were  collected  in  third  trimester  
(median  gestational  age =  34+4  weeks).  Blood  from  three  non–pregnant  women  
and  three  healthy  males  was  used  as  controls.  Routinely  5-7  ml  plasma  was  
used  for  DNA  extraction,  using  a  combination  of  the  Roche  ®  High  Pure  
Template  DNA  Purification  Kit  (Roche,  Switzerland)  and  a  custom  made  
vacuum  pump  for  the  isolation  of  the  circulatory  plasma  DNA.  In  brief,  as  
described  by  the  manufacturer,  the  plasma  sample  was  incubated  with  binding  
buffer  and  proteinase  K  at  70°C  for  10minutes  after  which  the  required  
volume  of  isopropanol  was  added  and  the  sample  was  passed  through  the  
Roche  ®  column  under  the  application  of  vacuum.  Following  this,  the  column  
was  washed  with  inhibitor  removal  buffer  and  twice  with  wash  buffer,  
respectively,  as  recommended  by  the  manufacturer.  The  column  bound  
circulatory  DNA  was  eluted  in  40µl  elution  buffer.   
   
Gel  electrophoresis  and  isolation  of  circulatory  DNA  fragments:  The  total  
circulatory  DNA  was  subjected  to  agarose  gel  electrophoresis  using  a  1.0%  
agarose  gel  (Invitrogen,  Basel,  Switzerland)  containing  0.5ug/ml  ethidium  
bromide  (Sigma,  USA).  Size  markers  were  100bp  ladder  and  HindIII  digested  
Lambda  phage  DNA  (New  England  Biolabs,  USA).  Electrophoresis  was  carried  
out  at  80V  for  1h.  Each  lane  of  the  gel  containing  circulatory  DNA  was  then  
cut  using  a  sterile  scalpel  blade  into  six  discrete  fragments  using  the  molecular  
weight  markers  as  a  guide.  The  size  of  the  fragments  were  0.09-0.3kb,  0.3-
0.5kb,  0.5-1.0kb,  1.0-1.5kb,  1.5-23kb,  and  greater  than  23kb.  As  the  23  kb  
marker  is  imprecise  in  1%  gels,  it  can  only  be  used  as  a  rough  guide  to  
estimate  the  size  of  DNA  fragments  which  have  sizes  greater  than  10  kb.  The  
circulatory  DNA  was  extracted  from  the  agarose  sections  using  a  QIAEX®II  
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Gel  Extraction  Kit  (Qiagen,  Basel,  Switzerland)  and  eluted  in  40µl  sterile  
10mM  Tris-HCl  (pH  8.0).  Numerous  anti-contamination  procedures  were  used  
during  these  experiments  including:  UV  irradiation  of  the  gel  tray  and  tank,  
fresh  buffers  with  each  electrophoretic  run,  as  well  as  the  examination  of  
plasma  samples  from  women  carrying  female  fetuses  (n=2),  and  blank  gel  
slices  (n=  14)  examined  parallel  with  each  analysis.  In  no  instance  were  any  
false  positive  results  recorded. 
 
Determination  of  the  proportion  of  circulatory  fetal  and  total  DNA:  The  
relative  proportions  of  fetal  and  total  circulatory  DNA  eluted  from  the  
individual  agarose  gel  sections  were  determined  using  a  well  established  
Taqman  ®  real  time  PCR  assay  for  the  SRY  gene  on  the  Y  chromosome  and  
the  ubiquitous  GAPDH  gene  (6).  The  only  modifications  being  that  a  new  
generation  Perkin  Elmer  Applied  Biosystems  7000  Sequence  Detector  was  used  
and  that  MGB  (minor  groove  binding)  probes  were  used,  instead  of  the  
previous  TAMRA  conjugated  probes  (Applied  Biosystems,  Rotkreuz,  
Switzerland).  The  PCR  reactions  were  carried  out  in  a  final  reaction  volume  of  
25 µL,  which  consisted  of  6µL  eluted  DNA,  300nmol/L  of  each  primer,  
150nmol/L  of  each  probe  and  2xTaqMan  Universal  PCR  Master  Mix  (Applied  
Biosystems,  Rotkreuz,  Switzerland).  PCR  was  carried  out  using  an  initial  
incubation  at  50ºC  for  2  minutes  to  activate  Uracil-N-glycosylase,  then  
incubation  at  95ºC  for  10  minutes  and  followed  by  40  cycles  of  95ºC  for  15  
seconds  and  60ºC  for  1  minute.  This  analysis  permitted  the  determination  of  
the  total  amount  of  DNA  present  in  each  fraction  by  the  use  of  the  GAPDH  
specific  assay,  and  the  fraction  of  that  which  was  fetal  using  the  SRY  specific  
assay.  The  relative  proportions  of  each  have  been  expressed  as  percentages. 
 
 
Detection  of  highly  polymorphic  microsatellite  markers   
 
Sample  preparation:  18ml  maternal  blood  was  collected  from  three  third  
trimester  pregnancies,  and  cord  blood  was  collected  subsequently  after  delivery.  
Following  plasma  separation  by  high-speed  centrifugation,  the  buffy  coat  was  
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collected,  washed  with  PBS  (phosphate  buffered  saline)  and  used  for  the  
preparation  of  maternal  genomic  DNA.  Fetal  genomic  DNA  was  prepared  
similarly  from  the  cord  blood  sample.    In  order  to  verify  that  this  same  
approach  can  also  be  used  to  examine  clinically  relevant  samples,  we  examined  
4  samples  taken  early  in  pregnancy  (median  =  13+5  weeks).  In  this  instance  
the  fetal  genotype  was  determined  from  archived  amniocyte  or  chorionic  villus  
cultures.  One  of  these  samples  was  obtained  from  a  trisomy  21  fetus.   
 
Fluorescent  PCR  analysis  of  highly  polymorphic  microsatellite  markers:  
The  same  standardized  fluorescent  PCR  assay  for  highly  polymorphic  short  
tandem  repeat  (STR)  markers  on  chromosome  21  as  used  previously  for  our  
analysis  of  urinary  DNA  was  used  (24).  The  fetal  and  maternal  genomic  DNA  
sources  were  used  to  determine  which  short  tandem  repeat  (STR)  makers  on  
chromosome  21  were  informative.  These  informative  STR  markers  were  then  
used  for  the  detection  of  paternally  and  maternally  inherited  fetal  alleles  in  
total  maternal  plasma  circulatory  DNA,  as  well  as  in  size-separated  circulatory  
DNA  fractions.  The  preparation  of  the  low  molecular  weight  circulatory  DNA  
fraction  was  carried  out  as  described  above. 
As  the  concentration  of  circulatory  DNA  following  size  fractionation  was  very  
low,  use  had  to  be  made  of  a  semi-nested  PCR  assay,  as  described  previously  
(24).The  PCR  products  were  analysed  by  capillary  electrophoresis  on  a  ABI  
310  gene  analyser  (Applied  Biosystems).  For  the  analysis  of  the  samples  taken  
early  in  pregnancy,  where  the  concentration    of  circulatory  fetal  DNA  has  been  
shown  to  be  lower  than  at  term,  our  investigation  showed  that  the  PCR  
procedure  had  to  be  modified  in  order  to  obtain  optimal  results.  For  this  
reason,  we  used  a  “touch-down”  PCR  method  instead  of  our  conventional  
semi-nested  PCR  method  described  above.  In  this  procedure,  a  total  of  50  
cycles  were  run,  using  PCR  reactions  containing  3ul  of  10X  buffer;  3.5mM  
MgCl2;  160µM  dNTPs;  0.1µM  each  of  forward  and  reverse  primers  (24)  (one  
primer  of  each  set  was  fluorescent  labelled);  1U  of  AmpliTaq  Gold  polymerase  
and  3µL  of  DNA  in  final  30µL  volume.  After  incubation  at  95ºC  for  10min,  
10  cycles  (95ºC  for  15s,  65ºC  for  15s,  72ºC  for  30s)  of  thermal  cycling  were  
carried  out  whereby  the  annealing  temperature  was  decreased  1ºC  every  cycle.  
This  was  then  followed  by  40  further  cycles  of  95ºC  for  15s,  56ºC  for  15s,  
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and  72ºC  for  30s.  The  PCR  terminated  following  an  extension  phase  at  72ºC  
for  7min.  As  described  above,  the  PCR  products  were  analysed  by  capillary  
electrophoresis  on  a  ABI  310  gene  analyser  (24). 
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RESULTS 
 
Circulatory  DNA  has  been  proposed  to  exhibit  apoptotic  hallmarks  such  as  
oligonucleosomal  laddering  and  nucleosome  association  (25,  26).  In  our  initial  
investigation  we  attempted  to  determine  whether  circulatory  DNA  in  pregnant  
women  also  displayed  such  characteristics.  For  this  examination  we  used  
Southern  blot  analysis  of  total  circulatory  plasma  DNA  that  had  been  subjected  
to  agarose  gel  electrophoresis.  The  analysis  of  such  blots  using  the  ubiquitous  
highly  repetitive  Alu  sequence,  indicated  that  oligonucleosomal  fragments  could  
indeed  be  detected,  and  were  present  in  all  three  of  the  plasma  sources  
examined:  maternal  blood,  non-pregnant  female  control  and  cord  blood  (refer  to  
figure  1).  This  examination  also  indicated  that  a  significant  proportion  of  the  
circulatory  DNA  had  a  molecular  size  of  larger  than  10  or  even  23  kb  (refer  
to  figure  1).  The  presence  of  such  high  molecular  weight  DNA  species  cannot  
be  attributed  to  the  plasma  sample  being  contaminated  by  maternal  cells,  as  
extreme  care  was  taken  to  obtain  cell  free  plasma  samples.  It  is  of  interest  
that  these  high  molecular  weight  DNA  molecules  are  quite  similar  to  those  the  
very  large  ones  we  observe  in  terminally  differentiated  erythroblasts  prior  to  
enucleation  (Hristoskova  et  al.,  manuscript  in  preparation). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Southern blot analysis of 
plasma circulatory DNA, using a 
highly repetitive Alu probe. 
 
Lane 1, plasma from cord blood; 
lane 2, maternal plasma (13 weeks 
of gestation);  
lane 3, plasma from nonpregnant 
woman. 
 
200bp
500bp— 
1.0k — 
2.0k — 
23kb — 
4.3kb — 
1 2   
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Unfortunately  we  were  not  able  to  determine  the  characteristics  of  circulatory  
fetal  DNA  in  the  samples  obtained  from  pregnant  women,  as  the  concentrations  
of  fetal  DNA  proved  to  be  too  low  to  be  detectable,  even  when  using    a  very  
high  copy  (DYS14)  probe  specific  for  the  Y  chromosome. 
As  we  were,  however,  able  to  detect  circulatory  apoptotic  DNA  fragments  in  
our  Southern  blot  analysis,  we  used  an  alternative  strategy  to  determine  
whether  circulatory  fetal  DNA  displayed  a  similar  pattern.  For  this  analysis,  we  
used  an  approach  that  had  previously  been  successfully  used  for  the  
characterisation  of  rare  linear  extra-chromosomal  DNA  species  (21).  In  this  
procedure,  the  circulatory  DNA  was  first  subjected  to  agarose  gel  
electrophoresis  following  which  individual  gel  fragments  containing  the  size-
fractionated  DNA  were  examined  by  PCR.  For  our  examination,    following  
electrophoresis,  the  agarose  gel  was  cut  into  six  discrete  fragments  having  
approximate  sizes  of  <0.3kb,  0.3  –  0.5kb,  0.5-1.0  kb,  1.0  –  1.5kb,  1.5  –  23.0  
kb  and  >  23  kb.  Once  the  circulatory  DNA  was  extracted  from  these  gel  
fragments,    the  proportion  of  fetal  and  maternal  DNA  in  these  fractions  was  
then  determined  using  well  established  real-time  PCR  assays  for  the  SRY  locus  
on  the  Y  chromosome  and  the  ubiquitous  GAPDH    (glyceraldehyde  3–
phosphate  dehydrogenase)  gene  (6).  To  ensure  that  we  were  not  being  mislead  
by  any  PCR  artefacts,  we  included  numerous  anti-contamination  procedures  in  
our  study,  including  plasma  samples  from  women  pregnant  with  female  fetuses  
(n=2)  and  the  parallel  examination  of  blank  gel  slices  in  each  analysis  (n=14).  
No  false  positive  results  were  recorded  in  any  of  these  instances. 
Our  examination  of  plasma  samples  from  third  trimester  pregnancies  with  a  
male  fetus  indicated  that  the  vast  proportion  of  circulatory  fetal  DNA,  as  
detected  by  the  SRY  specific  PCR  assay,  had  an  approximate  molecular  size  
of  less  than  300bp  (refer  to  table  1  and  figure  2),  with  very  little  or  no  fetal  
DNA  having  a  molecular  size  of  greater  than  1  kb.  Maternally  derived  
sequences,  as  determined  by  the  GAPDH  specific  PCR  assay,  on  the  other  
hand  were  estimated  to  be  larger  than  0.5  to  1.0  kb  and  included  molecular  
weight  species  larger  than  10  to  20  kb.  A  similar  pattern  for  both  fetal  and  
maternal  circulatory  DNA  was  also  observed  in  plasma  samples  obtained  early  
in  the  second  trimester  of  pregnancy  (table  2,  figure  3).   
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With  regard  to  the  size  distribution  of  total  circulatory  DNA,  we  determined  
that    the  pattern  we  had  observed  in  pregnant  women  was  very  similar  to  that  
observed  in  samples  taken  from  non-pregnant  women  as  well  as  healthy  male  
volunteers  (figure  4).  In  none  of  these  analyses  were  we  able  to  detect  large  
amounts  of  DNA  with  a  molecular  size  greater  than  that  indicated  by  the  23kb  
molecular  weight  marker,  in  contrast  to  what  we  observed  in  our  Southern  blot  
analysis  (figure  1).  The  reason  for  this  anomaly  may  be  that  these  large  
fragments  are  not  easily  eluted  from  the  agarose  gel  under  the  conditions  we  
are  using,  unlike  in  the  Southern  blotting  where  the  DNA  is  first  treated  with  
alkali  in  order  to  generate  the  small  fragments  required  for  efficient  capillary  
transfer. 
 
 
Our  data  also  indicated  that  by  examining  DNA  fragments  of  a  size  less  than  
approximately  300bp,  a  selective  enrichment  of  circulatory  fetal  DNA  sequences  
may  be  possible  to  achieve.  Our  next  step  was,  therefore,  to  determine  whether  
such  size  dependent  separation  would  facilitate  the  determination  of  more  
subtle  fetal  genetic  traits. 
For  this  purpose,  we  examined  whether  both  paternally  and  maternally  inherited  
DNA  polymorphisms  could  be  discerned  from  such  size  fractionated  circulatory  
DNA.  For  our  analysis  we  used  highly  polymorphic  short  tandem  repeat  
(STRs)  sequences  on  chromosome  21,  which  have  previously  been  
demonstrated  to  be  suitable  for  the  reliable  distinction  of  mother  and  child  
(24).    In  order  to  test  the  feasibility  of  this  approach  we  first  examined  
 112
samples  taken  close  to  term,  as  here  the  concentration  of  circulatory  fetal  DNA  
is  at  a  maximum,  and  since  it  was  readily  possible  to  obtain  the  fetal  
genotype,  a  prerequisite  for  such  studies,  from  a  cord  blood  sample  after  birth.  
In  this  manner,  we  could  select  easily  discernible  polymorphic  markers  between  
mother  (Fig  5a)  and  fetus  (Fig.  5b). 
 
 
In  this  analysis,  the  benefits  of  selectively  enriching  for  circulatory  fetal  DNA  
species  becomes  readily  apparent,  in  that  the  paternally  inherited  STR  allele  
(with  a  size  of  228bp)  is  barely  detectable  in  total  plasma  extracted  DNA  
(figure  5C),  but  is  clearly  present  in  the  DNA  fraction  with  a  size  of  less  than  
300bp  (figure  5D).  Furthermore,  the  maternally  inherited  STR  allele  (with  a  
size  of  232bp)  cannot  be  distinguished  from  the  predominantly  maternal  pattern  
obtained  from  the  analysis  of  total  plasma  extracted  DNA  (figure  5C).  This  
fetal  allele  can,  however,  be  detected  in  the  analysis  of  the  DNA  fraction  with  
a  size  of  less  than  300bp  (figure  5D),  as  here  the  peak  for  that  STR  allele  
has  a  much  greater  area  than  either  the  paternally  inherited  fetal  allele  (228bp)  
or  the  solitary  maternal  allele  (234bp).  This  indicates  that  both  fetal  and  
maternal  loci  are  contributing  to  the  presence  of  this  particular  PCR  product.  
Similar  results  were  obtained  in  the  analysis  of  the  DNA  fraction  with  a  size  
between  300  to  500bp,  although  the  results  in  this  instance  were  less  refined  
(data  not  shown).  The  reproducibility  of  this  approach  was  verified  in  the  
analysis  of  a  further  2  samples,  which  were  analysed  at  a  number  of  different  
polymorphic  loci,  where  analogous  results  were  obtained  (refer  to  table  3). 
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In  order  to  determine  whether  this  approach  could  also  be  applied  to  clinically  
relevant  samples,  we  also  examined  four  samples  taken  early  in  the  second  
trimester  of    pregnancy.  In  these  analyses  the  fetal  genotype  was  determined  
from  archived  amniocyte  or  chorionic  villus  cultures.  One  of  these  samples  was  
from  a  fetus  affected  by  Down’s  syndrome  (trisomy  21).  This  is  evident  from  
our  microsatellite  analysis  for  the  D21S1432  marker,  where  three  equivalent  
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peaks  with  sizes  of  133,  137  and  141bp  respectively  are  recorded  (Fig  6b),  
implying  that  the  fetus  has  inherited  a  copy  of  each  of  the  maternal  
chromosome  21’s,  in  addition  to  the  paternally  inherited  chromosome  21.    In  
our  analysis  of  the  total  circulatory  cell  free  DNA  in  the  maternal  plasma  
sample,  only  the  two  maternal  markers  can  be  readily  discerned  (133  and  
141bp)  (Fig  6c),  whereas  our  analysis  of  size  –  fractionated  DNA  having  an  
approximate  size  of  less  than  300bp  facilitates  the  ready  detection  of  the  
paternally  inherited  137bp  marker  (Fig  6d).  A  similar  feature  was  observed  
when  examining  this  sample  for  a  different  microsatellite  marker,  namely  
D21S1270  (Table  4).  In  this  instance,  it  was  not  possible  to  determine  whether  
the  maternally  inherited  polymorphisms  could  be  detected,  as  the  fetus  has  the  
same  pattern  as  the  mother  for  both  loci.  In  the  three  other  cases,  which  had  
a  normal  karyotype,  we  were  in  all  three  cases  readily  able  to  detect  the  
paternally  inherited  polymorphic  locus  in  the  size  fractionated  DNA  sample  
(Table  4).  However,  only  in  one  instance  could  we  discern  the  presence  of  the  
maternally  inherited  locus  (Case  3;  Table  4).  In  case  2,  this  was  not  possible  
as  the  mother  was  homozygous  for  the  locus  interrogated,  whereas  in  the  other  
cases  (case  2:  D21S1435  and  case  4:  D21S1440),  the  maternal  locus  which  
had  not  been  inherited  by  the  fetus  appeared  to  have  been  preferentially  
amplified  (Table  4). 
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DISCUSSION 
 
Our  investigation  supports  the  current  hypothesis  that  circulatory  DNA  has  
apoptotic  attributes  (25,  26),  in  that  we  can  readily  discern  oligonucleosomally  
cleaved  fragments  using  Southern  blot  analysis.  Our  analysis  also  indicates  that  
a  significant  proportion  of  the  circulatory  DNA  has  a  very  large  molecular  size  
of  greater  than  20  kb.  Independent  investigations  in  our  laboratory  indicate  that  
these  large  circulatory  DNA  species  may  be  derived  from  the  erythropoietic  
system,  in  that  DNA  isolated  from  terminally  differentiating  erythroblasts  
exhibits  similar  characteristics  (Hristoskova  et  al.,  manuscript  in  preparation).  It  
is  currently  unclear  whether  these  large  DNA  molecules  are  subsequently  
cleaved  into  smaller  oligonucleosomal  fragments  in  the  maternal  plasma,  or  
whether  the  smaller  fragments  we  have  detected  are  derived  from  another  
source. 
By  using  an  approach  which  had  previously  been  used  to  examine  rare  linear  
extra-chomosomal  DNA  species  (21),  whereby  DNA  size  fractionated  by  gel  
electrophoresis  is  subsequently  extracted  and  analysed  by  PCR,    we  made  the  
surprising  finding  that  a  large  discrepancy  existed  in  the  size  of  circulatory  
fetal  and  maternal  DNA  species.    In  this  regard  our  study  indicated  that  fetal  
DNA  molecules  predominantly  have  an  approximate  size  of  300bp  or  less,  
whereas  most  maternally  derived  DNA  molecules  are  considerably  larger  than  
this.  The  fact  that  no  large  circulatory  fetal  DNA  species  are  detected  (i.e.  
greater  than  20  kb)  implies  that  the  mechanism  contributing  to  the  formation  
of  the  large  maternally  derived  DNA  species  is  not  involved  in  the  liberation  
of  circulatory  fetal  DNA.  The  explanation  for  this  difference  could  be  that  
circulatory  fetal  DNA  appears  to  be  exclusively  derived  from  the  placenta  (27),  
whereas  the  vast  proportion  of  normal  circulatory  DNA  is  of  hemopoietic  
origin  (28).   
With  regard  to  the  size  distribution  of  circulatory  maternal  and  fetal  DNA  
species,  our  results  are  remarkably  similar  to  a  recent  observation  made  by  
Chan  and  colleagues  (20),  who  also  observed  that  cell  fetal  DNA  molecules  
were  generally  smaller  than  those  of  maternal  origin.  For  their  study,  they  
made  use  of  differently  sized  PCR  amplicons  ranging  in  size  from  105bp  to  
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798bp  for  the  size  determination  of  predominantly  maternal  derived  DNA  
molecules,  and  107  to  524bp  for  the  examination  of  circulatory  fetal  DNA  
molecules.  Although  their  approach  permitted  a  much  more  precise  delineation  
of  the  size  distribution  of  circulatory  DNA  molecules  within  this  given  range,    
this  study  was  not  able  to  demonstrate  the  existence  of  very  large  (  >10  to  20  
kb)  maternal  circulatory  DNA  species  in  the  way  that  our  analysis  facilitated.   
A  further  important  point  that  the  study  of  Chan  (20)  did  not  address,  and  
which  has  been  the  major  focus  of  our  study,  is  that  this  observation  permits  
the  development  of  a  strategy  facilitating  the  selective  enrichment  of  circulatory  
fetal  DNA  sequences.  The  exploitation  of  this  approach,  in  turn  permits  the  
determination  of  highly  polymorphic  fetal  genetic  traits  not  discernible  from  the  
analysis  of  total  plasma  extracted  circulatory  DNA.  In  this  manner  we  were  
able  to  detect  the  presence  of  both  paternally  and  maternally  inherited  STR  
markers  in  size  separated  circulatory  DNA  fractions,  a  feature  which  was  not  
possible  when  attempting  the  same  analysis  on  un-fractionated  samples  (13,  
14).  Our  study  does,  however,  indicate  that  the  method  we  have  chosen  for  
this  proof-of-concept  study  is  too  imprecise  and  inefficient  to  be  used  for  
potential  clinical  applications.  This  becomes  clear  in  our  analysis  of  paternally  
and  maternally  inherited  polymorphic  markers,  where  it  is  not  possible  to  
determine  the  precise  proportion  that  the  fetal  markers  contribute  to  the  
analysed  pattern.  This  feature  is  very  important,  as  numerous  clinical  studies  
have  clearly  shown  that  the  analysis  of  such  highly  polymorphic  STR  markers  
is  very  useful  for  the  analysis  of  fetal  ploidy  (15).  Hence,  if  our  approach  
using  size-fractionation  were  functioning  in  an  optimal  manner,  it  should  be  
feasible  to  determine  fetal  chromosomal  anomalies  directly  from  maternal  
plasma.  As  our  study  included  one  case  with  a  trisomy  21  fetus,  where  we  
were  not  able  to  determine  fetal  ploidy  from  the  size  fractionated  DNA  sample  
(Figure  6;  Table  4),  this  application  will  have  to  await  developments,  which  
permit  a  more  efficacious  separation  of  maternal  and  fetal  DNA  species.    It  is,  
however,  possible,  that  even  in  it’s  current  form,  that  our  approach  could  be  
used  for  the  non-invasive  determination  of  paternity. 
A  further  important  aspect  of  our  observation  is  that  it  may  in  future  aid  in  
the  examination  of  Mendelian  disorders,  particularly  those  involving  point  
mutations,  as  these  analyses  should  no  longer  be  hindered  by  the  vast  excess  
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of  circulatory  maternal  DNA  sequences  (2,  3).  Indeed,  by  the  use  of  
quantitative  assays  it  may  even  be  possible  to  determine  the  fetal  genotype  in  
those  instances  where  both  partners  are  carriers  for  the  same  disease  allele. 
In  summary,  our  finding  has  shown  that  circulatory  fetal  DNA  molecules  are  
generally  of  a  smaller  size  than  comparable  maternally  derived  sequences,  and  
that  a  selective  enrichment  of  fetal  DNA  sequences  can  be  achieved  using  size  
dependent  separation.  This  latter  feature  permits  the  detection  of  fetal  genetic  
traits  not  possible  from  total  plasma  circulatory  DNA.  For  clinical  applications,  
more  efficacious  separation  modes  will  need  to  be  developed  which  facilitate  a  
better  discrimination  and  recovery  of  fetal  and  maternal  circulatory  DNA  
species.     
 
 
 
 
 
AKNOWLEDGEMENTS 
 
We  thank  Drs.  Monika  Schiesser  (University  Women’s  Hospital,  Basel)  and  
Friedel  Wenzel  (Medical  Genetics,  University  of  Basel)  for  the  generous  
provision  of  archived  culture  samples. 
 
 119
REFERENCES 
 
1. Lo  YM,  Corbetta  N,  Chamberlain  PF,  Rai  V,  Sargent  IL,  Redman  CW,  
et  al.  Presence  of  fetal  DNA  in  maternal  plasma  and  serum.  Lancet  
1997;350:485-7. 
2. Hahn  S,  Holzgreve  W.  Prenatal  diagnosis  using  fetal  cells  and  cell-free  
fetal  DNA  in  maternal  blood:  what  is  currently  feasible?  Clin  Obstet  
Gynecol  2002;45:649-56.   
3. Chiu  RW,  Lo  YM.  Application  of  fetal  DNA  in  maternal  plasma  for  
noninvasive  prenatal  diagnosis.  Expert  Rev  Mol  Diagn  2002;2:32-40. 
4. Lo  YM,  Tein  MS,  Lau  TK,  Haines  CJ,  Leung  TN,  Poon  PM,  et  al.  
Quantitative  analysis  of  fetal  DNA  in  maternal  plasma  and  serum:  
implications  for  noninvasive  prenatal  diagnosis.  Am  J  Hum  Genet  
1998;62:768-75. 
5. Lo  YM,  Leung  TN,  Tein  MS,  Sargent  IL,  Zhang  J,  Lau  TK,  et  al.  
Quantitative  abnormalities  of  fetal  DNA  in  maternal  serum  in  
preeclampsia.  Clin  Chem  1999;45:184-8. 
6. Zhong  XY,  Laivuori  H,  Livingston  JC,  Ylikorkala  O,  Sibai  BM,  
Holzgreve  W,  et  al.  Elevation  of  both  maternal  and  fetal  extracellular  
circulating  deoxyribonucleic  acid  concentrations  in  the  plasma  of  
pregnant  women  with  preeclampsia.  Am  J  Obstet  Gynecol  2001;184:414-
9. 
7. Leung  TN,  Zhang  J,  Lau  TK,  Hjelm  NM,  Lo  YM.  Maternal  plasma  
fetal  DNA  as  a  marker  for  preterm  labour.  Lancet  1998;352:1904-5. 
8. Sugito  Y,  Sekizawa  A,  Farina  A,  Yukimoto  Y,  Saito  H,  Iwasaki  M,  et  
al.  Relationship  between  severity  of  hyperemesis  gravidarum  and  fetal  
DNA  concentration  in  maternal  plasma.  Clin  Chem  2003;49:1667-9. 
9. Lo  YM,  Lau  TK,  Zhang  J,  Leung  TN,  Chang  AM,  Hjelm  NM,  et  al.  
Increased  fetal  DNA  concentrations  in  the  plasma  of  pregnant  women  
carrying  fetuses  with  trisomy  21.  Clin  Chem  1999;45:1747-51. 
10. Zhong  XY,  Burk  MR,  Troeger  C,  Jackson  LR,  Holzgreve  W,  Hahn  S.  
Fetal  DNA  in  maternal  plasma  is  elevated  in  pregnancies  with  aneuploid  
fetuses.  Prenat  Diagn  2000;20:795-8. 
 120
11. Farina  A,  LeShane  ES,  Lambert-Messerlian  GM,  Canick  JA,  Lee  T,  
Neveux  LM,  et  al.  Evaluation  of  cell-free  fetal  DNA  as  a  second-
trimester  maternal  serum  marker  of  Down  syndrome  pregnancy.  Clin  
Chem  2003;49:239-42. 
12. Chiu  RW,  Lau  TK,  Cheung  PT,  Gong  ZQ,  Leung  TN,  Lo  YM.  
Noninvasive  prenatal  exclusion  of  congenital  adrenal  hyperplasia  by  
maternal  plasma  analysis:  a  feasibility  study.  Clin  Chem  2002;48:778-80. 
13. Pertl  B,  Sekizawa  A,  Samura  O,  Orescovic  I,  Rahaim  PT,  Bianchi  DW.  
Detection  of  male  and  female  fetal  DNA  in  maternal  plasma  by  
multiplex  fluorescent  polymerase  chain  reaction  amplification  of  short  
tandem  repeats.  Hum  Genet  2000;106:45-9. 
14. Tang  NL,  Leung  TN,  Zhang  J,  Lau  TK,  Lo  YM.  Detection  of  fetal-
derived  paternally  inherited  X-chromosome  polymorphisms  in  maternal  
plasma.  Clin  Chem  1999;45:2033-5. 
15. Hulten  MA,  Dhanjal  S,  Pertl  B.  Rapid  and  simple  prenatal  diagnosis  of  
common  chromosome  disorders:  advantages  and  disadvantages  of  the  
molecular  methods  FISH  and  QF-PCR.  Reproduction  2003;126:279-97. 
16. Chiu  RW,  Lau  TK,  Leung  TN,  Chow  KC,  Chui  DH,  Lo  YM.  Prenatal  
exclusion  of  beta  thalassaemia  major  by  examination  of  maternal  plasma.  
Lancet  2002;360:998-1000. 
17. Saito  H,  Sekizawa  A,  Morimoto  T,  Suzuki  M,  Yanaihara  T.  Prenatal  
DNA  diagnosis  of  a  single-gene  disorder  from  maternal  plasma.  Lancet  
2000;356:1170. 
18. Chen  CP,  Chern  SR,  Wang  W.  Fetal  DNA  in  maternal  plasma:  the  
prenatal  detection  of  a  paternally  inherited  fetal  aneuploidy.  Prenat  
Diagn  2000;20:355-7. 
19. Houfflin-Debarge  V,  O'Donnell  H,  Overton  T,  Bennett  PR,  Fisk  NM.  
High  sensitivity  of  fetal  DNA  in  plasma  compared  to  serum  and  
nucleated  cells  using  unnested  PCR  in  maternal  blood.  Fetal  Diagn  Ther  
2000;15:102-7. 
20. Chan  KCA,  Zhang  J,  Hui  ABY,  Wong  N,  Lau  TK,  Leung  TN,  Lo  
KW,  Hang  DWS,  Lo  YMD.  Size  distributions  of  maternal  and  fetal  
DNA  in  maternal  plasma.  Clin  Chem  2004;50:88-92. 
 121
21. Saveliev  SV.  PCR-based  detection  of  rare  linear  DNA  in  cell  culture.  
Biol  Proceed  Online  2002;4:70-80. 
22. Sambrook  JR,  D.W.  Molecular  Cloning:  A  Laboratory  Manual.  New  
York:  Cold  Spring  Harbor,  2001. 
23. Nelson  DL,  Ledbetter  SA,  Corbo  L,  Victoria  MF,  Ramirez-Solis  R,  
Webster  TD,  et  al.  Alu  polymerase  chain  reaction:  a  method  for  rapid  
isolation  of  human-specific  sequences  from  complex  DNA  sources.  Proc  
Natl  Acad  Sci  U  S  A  1989;86:6686-90. 
24. Li  Y,  Hahn  D,  Zhong  XY,  Thomson  PD,  Holzgreve  W,  Hahn  S.  
Detection  of  donor-specific  DNA  polymorphisms  in  the  urine  of  renal  
transplant  recipients.  Clin  Chem  2003;49:655-8. 
25. Holdenrieder  S,  Stieber  P,  Forg  T,  Kuhl  M,  Schulz  L,  Busch  M,  et  al.  
Apoptosis  in  serum  of  patients  with  solid  tumours.  Anticancer  Res  
1999;19:2721-4. 
26. Giacona  MB,  Ruben  GC,  Iczkowski  KA,  Roos  TB,  Porter  DM,  
Sorenson  GD.  Cell-free  DNA  in  human  blood  plasma:  length  
measurements  in  patients  with  pancreatic  cancer  and  healthy  controls.  
Pancreas  1998;17:89-97. 
27. Guibert  J,  Benachi  A,  Grebille  AG,  Ernault  P,  Zorn  JR,  Costa  JM.  
Kinetics  of  SRY  gene  appearance  in  maternal  serum:  detection  by  real  
time  PCR  in  early  pregnancy  after  assisted  reproductive  technique.  Hum  
Reprod  2003;18:1733-6. 
28. Lui  YY,  Chik  KW,  Chiu  RW,  Ho  CY,  Lam  CW,  Lo  YM.  Predominant  
hematopoietic  origin  of  cell-free  DNA  in  plasma  and  serum  after  sex-
mismatched  bone  marrow  transplantation.  Clin  Chem  2002;48:421-7. 
 
 122
Chapter 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detection of Paternally Inherited
- Globin Gene Mutations by the Use of
Size-Fractionated Cell-Free DNA 
in Maternal Plasma.
Ying Li,  Edoardo Di Naro*,  Antonio Vitucci°,
Bernhard  Zimmermann, Wolfgang  Holzgreve,  Sinuhe  Hahn
University Women’s Hospital / Department of Research
University of Basel, Basel, Switzerland
* Department of Obstetrics and Gynecology,
 University of Bari, Italy
° Division of Hematology II University of Bari, Italy 
 
 123
Summary 
 
Pregnancies at risk for compound heterozygous single gene disorders, such as the 
hemoglobinopathies, could be screened for by detection of paternally inherited 
mutations. Although fetal DNA can be readily detected in maternal plasma, this 
approach cannot currently be used for the reliable analysis of fetal mutant alleles 
involving single nucleotide changes, as these are masked by circulatory maternal 
DNA. It has recently been described that size-separation of plasma DNA permits the 
ready detection of fetal genetic traits. We now show this method can be used for the 
reliable determination of paternal inheritance of three common point mutations for β 
thalassemia, namely IVSI-110, IVSI-1 and IVSI-6. 
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β thalassemia, characterized by mutations of the β globin gene, is a common 
monogenic disorder 1. Recently fetal DNA in maternal plasma has been used for the 
assessment of pregnancies at risk for β thalassemia major by the determination of fetal 
inheritance of the paternal mutation codon 41/42 2. This analysis can be reliably 
performed as this large 4 base deletion is easily distinguished from the normal 
maternal allele. The similar analysis of fetal mutations involving single base changes, 
which constitute the majority of genetic lesions in the hemoglobinopathies, is more 
complex due to the preponderance of maternal DNA sequences. 
It has recently been shown that circulatory fetal DNA is generally smaller than 
maternal DNA 3,4, and that size-fractionation can be used for a selective enrichment of 
fetal DNA sequences which permits the detection of otherwise masked fetal DNA 
sequences 4. 
We have now examined whether this approach can be used for the determination of 
paternally inherited β globin mutations from maternal plasma. In our study, we 
examined three mutations of the β globin gene which involve single nucleotide 
exchanges,   IVSI-110 (G-A), IVSI-1 (G-A) and IVSI-6 (A-G), which significantly 
contribute to β thalassemia cases in the Mediterranean area 1. Following institutional 
ethical approval and informed consent, blood samples (n=16) were obtained in Bari, 
Italy from pregnancies at risk for β thalassemia, where the father was a carrier for one 
of the three mutations described above and the mother carried another β globin 
mutation. Samples were collected at approximately 12 weeks of gestation prior to an 
invasive procedure, and either whole blood (n=8; shipped at room temperature) or the 
plasma (n=8; at -20ºC) was sent to Basel for blinded analysis.  
Following extraction and size-fractionation 4, the DNA was first amplified in a PCR 
reaction with the PNA (peptide nucleic acid) clamp, which ensures optimal detection 
of the paternal mutant allele by suppressing erroneous amplification of the normal 
allele 5.  Detection of the paternal mutant allele, was then accomplished by allele-
specific real-time PCR (Table 1).  
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Mutations  
 
                 Primers and PNA probes                                                
The conditions of PNA–
Clamping and Real time-allele 
specific -PCR  
IVSI-110 PNA-Clamping: 
             F-Primer: ACT CTT GGG TTT CTG ATA GGC ACT  
             R-Primer: CAG CCT AAG GGT GGG AAA ATA G  
             PNA probe: OO-TAG ACC AAT AGG C 
Allelic specific-real time PCR: 
             F-Primer: ACT CTT GGG TTT CTG ATA GGC ACT  
             IVSI-110/N: CAG CCT AAG GGT GGG AAA ATA CAC C  
             IVSI-110/M: CAG CCT AAG GGT GGG AAA ATA CAC T 
Denatured at 95°C 10min, followed 
by 25cycles of 95°C 15sec, 71°C for 
1min, 62°C for 15sec, 72°C for 30sec, 
final extension at 72°C for 5min 
 
Incubated at 95°C for 10min, followed 
by 40cycles of 95°C for 15sec, 59.5°C 
for 15sec, 72°C for 30sec 
IVSI-1 PNA-Clamping: 
            F-Primer:  GTG AAC GTG GAT GAA GTT GGT  
            R-Primer:  TCT CCT TAA ACC TGT CTT GTA ACC TTC TAT  
            PNA probe:  OO-GAT ACC AAC CTG CCC  
Allelic specific-real time PCR: 
            F-Primer:  GTG AAC GTG GAT GAA GTT GGT  
            IVSI-1/N:  TTA AAC CTG TCT TGT AAC CTT GAT ACG AAC  
            IVSI-1/M : TTA AAC CTG TCT TGT AAC CTT GAT ACG AAT  
Denatured at 95°C for 10min, 
followed by 25cycles of 95°C for 
15sec, 70°C for 1min, 60°C for 15sec, 
72°C for 30sec, final extension at 
72°C for 5min 
 
Incubated at 95°C 10min, followed by 
40cycles of 95°C for 15sec, 63.5°C 
for 15sec, 72°C for 30sec 
IVSI-6 PNA-Clamping: 
            F-Primer:  GTG AAC GTG GAT GAA GTT GGT  
            R-Primer:  CTT AAA CCT GTC TTG TAA CCT TGA    
            PNA probe: OO-GAT ACC AAC CTG CCC 
Allelic specific-real time PCR: 
             F-Primer: GTG AAC GTG GAT GAA GTT GGT  
             IVSI-6/N: CT TAA ACC TGT CTT GTA ACC TTC TAT   
             IVS1-6/M : CT TAA ACC TGT CTT GTA ACC TTC ATG 
Denatured at 95°C for 10min, 
followed by 25cycles of 95°C for 
15sec, 70°C for 1min, 60°C for 15sec, 
72°C for 30sec, final extension at 
72°C for 5min 
 
Incubated at 95°C for 10min, followed 
by 40cycles of 95°C for 15sec, 62.5°C 
for 15sec, 72°C for 30sec 
 
Table: Oligonucleotide sequences and PCR conditions. 
 
The PCR clamping reaction was performed in a total volume of 30µL, consisting of 
1x buffer with 3.5mM Mg2+, 0.2 mM dNTPs, 10µL DNA, 0.13µM of each primer 
(Microsynth, Switzerland), 0.6 U TaqGoldTM DNA polymerase (Applied Biosystems, 
Switzerland), using the following PNA probe concentrations (Applied Biosystems): 
0.67 µM for the IVSI-1 mutation, 0.5µM of PNA in case of IVSI-6 and 1µM l of PNA 
in case of IVSI-110. The real-time allele-specific PCR was then performed using  1µL 
of the PCR clamping product in a total volume of 25 µL containing 1x SYBR Green 
Master Mix and 0.16µM of each primer (Table 1). 
For the reliable determination of the paternal mutant allele, we used a ∆CT system, 
whereby the extent of the amplification of the normal wild-type allele (CTN) was 
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subtracted from that of the mutant allele (CTM). This approach lead to a clear 
discrimination of normal wild-type DNA samples from those heterozygous for the 
mutant allele, even under experimental conditions where the mutant allele constituted 
less than  10% of the total DNA examined. This analysis permitted us to assign 
arbitrary ∆CT (M-N)  cut-off areas for each of the 3 assays for the segregation of normal 
samples from those with the mutant allele (Figure 1).  
 
 
 
The comparison of our blinded analysis of the maternal plasma samples with result of 
the invasive procedure indicated that the presence or absence of a paternal mutant 
allele had been correctly determined in 15  or the 16 cases examined (Figure 1).  One 
false positive result was scored for our analysis of a IVSI-1 mutation (Figure 1). Our 
Figure: Scatter blot of the
real-time PCR analysis for the
IVSI-110, IVSI-1 and IVSI-6
mutations.  By the ?CT (M-N)
analysis we assigned arbitrary
cut-off areas for each
mutation specific assay. For
IVSI-110 these were between
0 and 4, for IVSI-1 between –
2 and 0 and for IVSI-6
between 0 and –1.  Wild type
alleles were grouped above
and mutant allele below these.
Heterozygous DNA
Wild-type controls
Maternal samples
False positive
Cut-off area
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re-analysis of this sample indicated that the total DNA concentration was almost 4 
fold lower than the other samples analyzed. Since wild type samples with similar low 
amounts of total input DNA had the ∆CT(M-N) values close to 0, it is possible that low 
template DNA concentrations lead to anomalies during the PCR clamping step. 
Hence, we recommend that the concentration of input DNA should be within a certain 
range (50-700 genome-equivalents) for the assay to function reliably.  
Although the approach that we have outlined will have to be validated in independent 
and larger studies, our study underscores the validity of approaches enriching fetal 
DNA sequences 4, as our parallel assessment of total plasma DNA samples lead to the 
incorrect evaluation of 3 of 9 cases which had inherited the paternal mutation. 
The advantage of the described method is that it relatively simple and can be 
performed without the need for complex machinery, as it relies on technologies 
consistent with those currently used in routine diagnostic laboratories. Furthermore, it 
can be readily modified to permit a similar non-invasive prenatal assessment of other 
single gene disorders involving compound heterozygous mutations. 
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Abstract 
 
Background: The cell free form of fetal DNA can be found in the plasma of pregnant 
women. The quantitative measurement of fetal DNA by real-time quantitative PCR 
has been applied in many studies to investigate a correlation between increased levels 
and pregnancy related disorders. For example, an increase of fetal DNA has been 
reported in pregnancies with fetal trisomy 21. However, The levels determined are 
close to the detection limit, and the measurements are performed under PCR 
conditions that do not allow accurate measurements. Consequently measurements 
performed by different laboratories lead to results that are not comparable. 
 
Methods: We amended an existing but sub-optimal protocol for the real-time 
quantitative PCR amplification of the DYS14 sequence, which can be found in 
multiple copies on the Y-chromosome. By our analysis of 46 plasma samples of 
pregnancies in the first trimester we show that the method produces better  results 
than currently used single copy sequence targeting protocols.  
 
Results: By our methods, we determined higher circulatory fetal DNA levels than 
previously reported. In 17 male pregnancies of normal outcome the average fetal 
DNA content was 426 genome equivalents per ml plasma.  
 
Conclusion: The determination of low copy numbers is affected by reduced and 
variable amplification. We present a real-time PCR method that increases the 
robustness of male fetal DNA determination by amplifying a sequence that is present 
in multiple copies per male genome.  
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Introduction 
 
Since Lo first described the presence of circulatory free fetal DNA (cffDNA) in the 
maternal circulation in 1998, it’s PCR amplification has emerged as the main strategy 
for the development of non-invasive methods for prenatal diagnosis. One of the main 
clinical applications is the prediction of fetal sex by the real-time quantitative PCR 
technique, as in the assessment of X-linked disorders. Y-chromosome specific 
sequences are also measured to investigate for a correlation between fetal DNA levels 
and pregnancy-associated complications, such as trisomies, preterm labor and 
preeclampsia. The method is only applicable to 50% of the samples due to it’s 
restriction to pregnancies carrying male fetuses.  
As the levels of circulatory fetal DNA in the first and second trimester are very low, 
the quantitation is performed close to the detection limit. The precision and 
reproducibility of the quantitative measurements can greatly be improved by usage of 
Y-specific sequences that are present in more than one copy per Y-chromosome. We 
developed a protocol specific to the multicopy sequence DYS14 and evaluated its 
performance in comparison to our currently used protocol. Our evaluation shows that 
the new protocol performs with an increased accuracy and sensitivity. It greatly 
enhance the quality of studies correlating fetal DNA levels with pregnancy associated 
pathologies. 
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Material and Methods 
 
Genomic reference DNA was extracted from male white blood cells, quantified with a 
spectrophotometer (NanoDrop-1000, Witec AG, Switzerland) and converted into 
genome equivalents (GE) on the basis of 6.6 pg of DNA per cell (1). 
Frozen plasma samples of pregnant women in the 1st trimester were extracted with 
the Roche (Switzerland) high pure PCR template kit. The manufacturers instructions 
were amended in that we extracted 400 µl of plasma, used 40 µl proteinase K for 
digestion, and eluted the DNA into 50 µl of 20% elution buffer (diluted in water). 
Prior to elution, the columns were pre-warmed in a shaker at 70°C for 5 minutes. 
Extracted DNA was stored at 4°C. 
 
Real-time quantitative PCR amplification 
The real-time qPCR was performed in the ABI PRISM 7000 Sequence Detection 
System (Applied Biosystems, ABI). DNA was amplified in volumes of 4 µl, which 
corresponds to the amount of DNA present in 32 µl of maternal plasma. For a single 
copy sequence targeting assay,  this allows for a theoretical detection limit of 31 GE 
per ml. Reactions of 25 µl contained 300 nM of each primer (HPLC purified, 
Microsynth, Switzerland), 200 nM of the MGB probe (ABI), and a 1 x concentration 
of the TaqMan Universal PCR master mix containing Amperase UNG (ABI). Primer 
and probe sequences were as follows: SRY-specific F: TCC TCA AAA GAA ACC 
GTG CAT, R: AGA TTA ATG GTT GCT AAG GAC TGG AT and probe TCC CCA 
CAA CCT CTT; DYS14-specific F: GCC AAT GTT GTA TCC TTC TC, R: CCC 
ATC GGT CAC TTA CAC TTC and probe: TCT AGT GGA GAG GTG CTC. The 
probes were MGB modified and labeled with FAM (SRY) and VIC (DYS14).  
The reactions were prepared on ice. Cycling conditions were 2 min at 50 °C and 10 
min at 95 °C for initial denaturation of the DNA and polymerase activation, followed 
by 50 cycles of 1 min at 60 °C and 15 s at 95 °C. The analysis was performed by the 
ABI Prism 7000 SDS Software with automatic baseline setting.  
For the quantification of DNA from plasma samples we used an approach similar to 
the importing of standard curves (2): We determined the average CT (CT,experiment) of a 
single reference sample of known concentration (540 and 54 GE per PCR for SRY 
and DYS14, respectively). This reference sample was amplified in triplicate in each 
experiment. We calculated  the theoretical CT (CT,cal) for the copy number in the 
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reference sample by the equation of the calibration curve. To use the standard curves 
generated in the assay validation, a correction factor ( CT,cor) was calculated: ( CT,cor = 
CT,experiment – CT,cal). The Intercept of the equation of the calibration curve was corrected 
by this CT,cor to receive the standard curve used for the experiment.  
As replicates with no amplification are not included in the calculations of the SDS 
software, we quantified individual replicates and determined mean, standard deviation 
(SD) and coefficients of variation (CoV = SD / mean) from these quantities.  
For sex determination with the DYS14 protocol we used a cut-off of 1 GE per PCR to 
discriminate between true positives (male) and unspecific amplification (female). 
Reactions were performed in triplicates which all had to indicate the same sex for 
determination. With the SRY protocol sex was determined if all of the three replicates 
either showed amplification or not. 
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Results 
 
In a validation experiment we amplified reference DNA at 5400, 540 and 54 GE / 
PCR  in quadruplicates. Calibration curves were constructed by plotting the CT as a 
function of the log of the template copy number. (SRY: CT = -3.335 x log(copies) + 
39.22 ; DYS14: CT = -3.388 x log(copies) + 36.31). From these curves we determined 
the CT,cal, which was 30.44 for DYS14 and 31.28 for SRY. 
In the same experiment we analyzed twofold dilutions of template DNA between 5.4 
and 0.08 GE per PCR with the DYS14 and SRY specific assays. The results 
demonstrate the increased sensitivity and reproducibility of the DYS14 protocol for 
low copy numbers. The quantitative results determined by the SRY assay deviate 
considerably between replicates, the CoV are greater than 50 %. It is noteworthy that 
many replicates without amplification occur at sample inputs below 5 copies. This 
may be due to amplification failure occurring at very low target amounts or simply 
because no target sequences are present in the reaction mixture. The DYS14 specific 
protocol allowed reproducible amplification of target amounts as low as 0.1 GE. The 
quantification of the low input samples is still precise and reasonably accurate, CoV 
range from 7 to 50 %.  
 
 
Table 1: 2-fold dilution series of reference gDNA, sample input determined by DYS14 and SRY-
specific real-time PCR. Averages with CoV in parentheses. Quantities are in GE. 
 
We compared both assays by analyzing 12 plasma samples of unknown fetal sex 
(gestational age between 11+6 and 13+5 weeks). Each plasma was extracted in 
Input copy 
number 5.4 2.7 1.36 0.68 0.34 0.17 0.08
3.91 3.02 1.15 0.18 0.20 0.18 0.08
3.32 1.78 1.09 1.04 0.18 0.18 0.20
3.31 1.13 0.91 0.58 0.33 0.25 0.08
3.28 1.36 0.96 0.97 0.16 0.15 0.16
averages 3.46 (7.6%) 1.82 (40.3%) 1.03 (9.5%) 0.69 (50.0%) 0.22 (30.0%) 0.19 (19.4%) 0.13 (39.1%)
0.14 1.97 3.41 0 0 0 0
2.32 2.54 0 0.41 0 0 0
2.70 3.35 0 0 0 0 0
3.84 0 0 0 1.25 0 0
averages 2.25 (59.6%) 1.97 (62.9%) 0.85 (173%) 0.10 (173%) 0.31 (173%) 0 0
replicates w/o 
amplification
0 / 4 1 / 4 3 / 4 3 / 4 3 / 4 4 / 4 4 / 4
copy number 
determined by 
DYS14
copy number 
determined by 
SRY
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duplicate and each DNA analyzed individually. Invasive testing identified that 6 
samples were from male and 6 from female pregnancies. The fetal sex of all 24 DNA 
extractions was correctly determined by DYS14 specific real-time PCR. With the 
SRY specific protocol we were able to determine 8 out of 12 male and 11 out of 12 
female DNA samples, the other five did not allow determination. The amplifications 
with the SRY assay were very specific. Only two of 36 replicates from female 
pregnancies amplified with very high CT values (corresponding to 0.8 and 1.8 GE). 
With the DYS14 protocol we observed 13 false amplifications even after extensive 
optimization of the protocol. However, the indicated quantities per PCR are all 
smaller than 0.6 GE which is 10 times less than all results from male pregnancies. 
The measurements of the male pregnancies are very precise with the DYS14 protocol 
(figure 1). The CoV range from 4 to 22 % in 12 triplicate measurements. None of the 
total 36 reactions failed with fetal DNA quantities determined between 5.7 and 19.4 
GE per reaction. The SRY protocol resulted in much greater deviations (CoV between 
26 and 140 %) and 6 negative replicates. For duplicate extractions,  the average CoV 
were 16.9 % (13.8 – 27.8 %) for DYS14 and 74.2 % (63 – 103 %) for SRY. The CoV 
of the duplicate extractions together indicate that the SRY protocol is not more than 
semi-quantitative. Surprisingly the DNA levels determined by the DYS14 protocol 
were 2.5-fold higher than by SRY (range 1.6 – 4.3 fold). 
 Figure 1. Duplicate extractions of samples 1 to 6 quantified by DYS14 (blue) and SRY (red). 
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To investigate the discrepancy between the copy numbers determined by both assays, 
we amplified genomic DNA dilutions in triplicate with DYS14 and SRY. With these 
amplifications we constructed new calibration curves and quantified 4 male plasma 
extracts. In three samples both assays determined the same copy number, while in one 
sample the SRY-result was three times lower (3.7 versus 11.2 GE per PCR). The old 
and new standard curves generated for the DYS14 protocol were very similar. In 
contrast the SRY curves. We plotted the old standard curve A, which we used for the 
quantification by a single reference sample, and the fresh curve B (figure 2). While 
the average CT of the reference samples with copy numbers of 5400 and 540 GE are 
within 0.1 cycles, the curves diverge due to the differences of the 54 GE standard. The 
differences in the CT of this concentration result in a difference of more than one cycle 
at the intercept. Using B instead of A for the imported standard curve would result in 
two-fold greater template numbers in reactions with less than 10 GE. This would lead 
to similar determinations by SRY and DYS14 in the plasma samples. However, the R2 
for A is much better than for B. The problem is, that the determinations of the lowest 
standard are too imprecise to allow correct quantification. The deviations increase for 
measurements of lower copy numbers, which will be skewed by random variability. 
The implication is that copy numbers for the plasma samples as provided by the SRY 
protocol can only be considered a rough estimate. The copy numbers we determine by 
the SRY assay could be just as well twice their value. By using new standard curves 
with every run, the inter-assay comparability of results would be reduced and no 
B: y = -3.68x + 40.39
R2 = 0.9816
A: y = -3.34x + 39.22
R2 = 0.9934
25
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accuracy gained. Standards of adequate concentration have similar copy numbers as 
the samples. However, with the SRY protocol neither can be measured accurately. 
We further tetsed the specificity of the DYS14 protocol on 34 plasma samples at a 
gestational age of 11+6 to 13+6 weeks in a blinded manner. Again the sex of all 
samples was correctly determined.  
Overall, 25 male plasma DNA samples were quantified between 3.4 and 31.5 GE per 
PCR with CoV between 7 and 27 %. In the 33 extractions of female pregnancies we 
observed amplification curves in 36 of 99 reactions. All these were indicative for less 
than 0.9 GE per PCR. As we applied a cut-off of 1.0 GE for the sex determination, 
none of the female replicates was assessed to be male. 
We  achieved a specificity and senstivity of 100% for sex determination by the novel 
DYS14 specific assay in 58 DNA samples from plasma (46 different pregnancies). In 
the 17 male pregnancies of normal outcome, with gestational ages from 11+6 to 13+6 
weeks, the average fetal DNA content was 426 GE per ml plasma (108 – 983). In the 
sample cohort, 2 pregnancies were trisomy 21 affected, their fetal DNA levels were 
333 and 750 GE at 13 and 12 weeks of pregnancy.  
The quantitative and qualitative limits of the novel assay are both around 1 GE per 
reaction, which is a clear advancement in comparison to the assay targeting the single 
copy gene SRY. 
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Discussion 
 
The measurement of circulatory fetal DNA has been shown to correlate with certain 
pregnancy associated disorders (3). It is to be expected that in the near future large 
studies will be performed to assess the suitability of cffDNA as a marker for first and 
second trimester screening. The measurement of male fetal DNA levels is considered 
to be a simple procedure. However, as we could observe in a recent comparison study 
between five laboratories, quantitative data collected can differ significantly between 
sites (4). Even the use of the identical sample material and implementation of the 
same DNA extraction and real-time quantitative PCR procedures resulted in major 
differences of the finalized data. In the comparison of numerical values from different 
studies with varying protocols, major discrepancies can be expected. This lead to the 
pessimistic suggestion that absolute fetal DNA levels as determined by different sites 
might not be comparable even with a highly standardized protocol. 
We show that when using a single copy gene locus as amplification target, the 
determination of fetal circulatory DNA levels of less than 10 GE per PCR cannot be 
considered quantitative. CoV from such reactions can reach over 100 %, which 
evidently does not allow a credible determination of two-fold differences. Our 
judgment is supported by the recent reporting of reduced reproducibility in samples 
with 10 copies and inconsistent detection and loss of linearity in samples with single 
copies (5).  
However, a review of the literature has revealed that template numbers from reports 
of increased cffDNA levels in pregnancies with trisomy 21 fetuses as well as those 
disputing this finding are in the range of reduced quantitativity (6) (table 2).(7-10) In 
all these studies, no mention of precision of the copy number determinations is 
included. However, judging from our evaluation, the single measurements contain a 
high degree of uncertainty, and the data from these studies at most allow to observe 
trends for elevation. To determine if the cffDNA level of an individual sample can be 
used for the assessment of the risk for trisomy, quantification needs to be precise and 
strategies need to be optimized. To perform evaluation of cffDNA levels as a 
screening marker from such data seems premature and will probably underestimate 
the suitability of the approach (11). In addition, in many reports measuring plasma 
DNA levels it is difficult to determine the exact detection limit of the PCR in GE per 
milliliter plasma from the abbreviated protocols. This shortcoming makes the 
evaluation of results cumbersome if not impossible. 
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Table 2. Literature of extraction protocols, real-time PCR detection limits and median 
cffDNA levels reported in control and trisomy 21 pregnancies. Underlined numbers 
are used for our calculations. Volumes are in microliter. a: mean. * as reported in:Lo et 
al, Clin. Chem 1999;45:184-8; ** "similar to"  Bianchi et al, Clin Chem 
2001;47:1867-9; § as determined from figures. 
 
 
More than 10 target sequences need to be present per reaction to generate sound data. 
This can be accomplished by increasing either the volume of plasma extracted or the 
copy number of target sequences per genome. Consequently, reference reactions for 
quantification should contain more than 10 target sequences and variability in 
replicate amplifications should be minimal. At the same time, copy numbers should 
be in the range of the samples to be quantified.  
When we compared the plasma DNA levels determined by both assays, we made the 
surprising observation that levels determined by the DYS14 protocol are generally 
two times greater than levels determined by SRY. These discrepancies are a 
consequence of the great variability of the SRY based measurements. This finding 
revealed another flaw of the single copy SRY protocol: As the number of template 
sequences per reaction is very low, several factors can lead to less efficient 
amplification and a resulting underestimation of the copy number: amplification 
failure and a lag in the initial cycles and increased variability will result in the 
determination of lower amounts than actually in the reaction (5). Especially the 
relatively high background of maternal DNA and formation of primer dimers can 
generate a decreased efficiency or even amplification failure (12). These problems are 
effectuated by PCR competition from amplifications of unspecific artefacts. 
Author
extracted 
Plasma
elution 
volume
DNA per 
PCR
Plasma per 
PCR
Detection Limit 
(GE/ml plasma)
median        
GE/ml plasma 
controls
median          
GE/ml plasma 
trisomy 21 gest age
Lo 400 - 800 50 5 * 80 12.5 16.3 (n=18) 48.2 (n=6) 17.2 / 18.0
Zhong 400 50 2 16 62.5 83.1a (n=29) 185.6a (n=15) 14+4
Lee 400 100 ** 5-10** 40 25 ~10-30 §(n=55) ~15-25 §(n=11) 15-19
Hromadnikova 400 50 2.5 20 50 24.5 (n=13) 23.3 (n=11) 15-22
Spencer 400 50 5 40 25 34.1 (n=10) 32.0 (n=10) 15
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Moreover, the levels determined in our study are also markedly higher as compared to 
those in the literature. This is partially due to the low amount of template affecting the 
enumeration. Additionally, since all samples were from patients with an increased risk 
for chromosomal aberrations as determined by first trimester prenatal screening, our 
cohort might have higher levels than in inconspicuous pregnancies. Importantly, a 
more efficient DNA elution may have lead to higher DNA recovery, as we took care 
to solubilize the DNA under heated conditions prior to elution from the filter (4). 
Consequently, for quantitative studies it will be important to monitor the DNA 
recovery. Additionally, we aimed to reduce loss of fetal DNA in the extracted 
solutions to a minimum and avoided freezing the extracts (13). 
Finally, quantitative differences can arise from the absolute quantification by real-
time PCR: Standard samples used can introduce discrepancies by differing 
determination of concentration, presence of inhibitors, use of different concentrations 
for the standard curve or reference sample. Also the slopes of standard curves can 
largely be affected by amplification variability. 
When we performed a BLAST search with the primer and probe sequences from the 
original DYS14 targeting protocol, we observed considerable homologies to 
sequences on chromosomes other than Y (14); (15), which would lead to unspecific 
amplification from the maternal background DNA. This is probably the reason why 
the assay has only been applied to samples of confirmed pregnancy with a male fetus. 
However, unspecific amplifications at high rates might even affect quantification in 
extreme cases, for example when the background of maternal DNA is very high.  It 
proved to be very difficult to develop an assay without any unspecific amplification, 
as homologies to sequences on other chromosomes could not be avoided fully. 
Although the assay was not designed for the determination of fetal sex, the 
susceptibility of the assay for unspecific amplification can be overcome by selecting a 
cut-off at 1.0 GE per PCR. By this approach we were able to exclude false male 
interpretations, as we showed in our blind analysis of totally 58 plasma extractions. 
Fetal sex determination may be possible at even earlier stages of gestation than 
reported with single copy locus specific assays (Rijnders 2001).  
Here we present an approach to address one of the major hindrances in the generation 
of precise and relevant data, the scarce nature of the material to be quantified. We 
describe an assay with a ten times increased detection and quantitative limit as 
compared to the single copy sequence targetting protocol. This approach will be 
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useful in large studies for the assessment of cffDNA levels as possible marker of 
pregnancy associated disorders. 
In the context of clinical application it will be important to standardize all procedural 
steps that lead to variability of the quantitative data. For large studies, thoroughly 
evaluated and optimized protocols need to be established. With a detailed description 
and discussion of procedures we try to highlight several important points to generate 
accurate data. Results should be reported in more detail. It is essential that in addition 
to the results in copy number and their CoV, detection and quantification limits 
should be included, as only these data allow assessment of the validity of the results. 
Further statistical analysis of the data only makes sense when one is aware of it’s 
quantitative value.  
In conclusion, the measurement of multicopy Y-specific sequences by real-time 
quantitative PCR is an optimal tool for the assessment of male fetal DNA 
concentration in maternal plasma. With the assay here presented the investigation of 
elevated cffDNA levels under a variety of pregnancy-related pathologies can be 
conducted in a quantitative manner. 
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To the Editor of the Journal of the American Medical Association:  
The discovery of cell free fetal DNA in maternal plasma opened a new avenue for the 
risk free assessment of fetal genetic traits 1. As the detection of fetal genetic loci 
completely absent from the maternal genome has proven to be highly specific, 
reproducible and quite facile, this method is already being used clinically for the 
determination of the fetal Rhesus status 2. 
The analysis of other fetal genetic loci not completely disparate from the mother has, 
however, proven to be very problematic, as their detection is masked by the vast 
abundance of maternal DNA sequences 2. In this context, Dr. Dhallan and colleagues 
recently described a procedure whereby maternal blood samples were treated with 
formaldehyde 3. This was suggested to stabilize maternal blood cells, preventing the 
release of their DNA, thereby significantly enhancing the proportion of fetal DNA in 
maternal plasma samples. It was also suggested that this could form the basis for 
future investigations examining complex fetal traits, such as aneuploidies or single 
gene disorders.  
Intrigued by this finding we have attempted to verify it. In our examination of 21 
maternal blood samples, we performed a side-by-side analysis of plasma prepared by 
our standard protocol, (1600 x g for 10’ at 4oC & 16,000 x g for 10’ at RT) and by the 
formaldehyde method 3. The concentration of cell free maternal DNA was then 
determined by real-time PCR in each of these paired plasma samples. This analysis 
indicated that the concentration of maternal DNA was not significantly (p= 0.32) 
reduced by formaldehyde treatment (mean = 4286 copies/ ml plasma) when compared 
to conventionally prepared samples (mean = 4737 copies/ ml plasma). 
It is, therefore, highly unlikely that the method proposed by Dhallan and colleagues 3 
will lead to a preferential change in the ratio of fetal to maternal DNA. Instead, it 
appears that a misinterpretation of the data may have occurred by the use of an 
inappropriate PCR assay. In this regard, this report serves to highlight a recent finding 
made during the large scale NICHD “NIFTY” study, in that considerable care should 
be exercised when performing quantitative analysis of cell free DNA4.  
Other strategies will, hence, have to be explored for the analysis of complex fetal 
genetic traits, such as the use of size-fractionated plasma DNA, whereby fetal 
sequences are preferentially enriched for on the basis of their smaller size than 
maternal ones 5. 
 146
References 
 
1. Lo YM, Corbetta N, Chamberlain PF et al., Presence of fetal DNA in maternal 
plasma and serum. Lancet. 1997;350:485-487. 
2. Hahn S, Holzgreve W. Prenatal diagnosis using fetal cells and cell-free fetal 
DNA in maternal blood: what is currently feasible? Clin Obstet Gynecol. 
2002;45:649-656. 
3. Dhallan R, Au WC, Mattagajasingh S et al., Methods to increase the 
percentage of free fetal DNA recovered from the maternal circulation. JAMA 
2004;291:1114-1119. 
4. Johnson KL, Dukes KA, Vidaver J et al., Interlaboratory comparison of fetal 
male DNA detection from common maternal plasma samples by real-time 
PCR. Clin Chem. 2004;50:516-521. 
5. Li Y, Zimmermann B, Rusterholz C et al., Size separation of circulatory DNA 
in maternal plasma permits ready detection of fetal DNA polymorphisms. Clin 
Chem. 2004;50:1002-1011. 
 
 147
Chapter 12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nucleic Acid Based Biosensors:
the Desires of the User.
Sinuhe  Hahn, Susanne Mergenthaler,
Bernhard Zimmermann, Wolfgang Holzgreve
University Women’s Hospital / Department of Research
University of Basel, Basel, Switzerland
 
Written for Biochemistry
 148
ABSTRACT 
 
The need for nucleic acid based diagnostic tests has increased enormously in the last 
few years.  On the one hand this has been stimulated by the discovery of new 
hereditary genetic disease loci following the completion of the Human Genome 
Project, but also by the presence of new rapidly spreading viral threats, such as that of 
the SARS epidemic, or even micro-organisms released for the purpose of biological 
warfare. As in many instances rapid diagnoses of specific target genetic loci is 
required, new strategies have to be developed which will allow this to be achieved 
directly at the point-of-care setting. One of these avenues being explored is that of 
biosensors. In this review, we provide an overview of the current state of the art 
concerning the high-throughput analysis of nucleic acids, and address future 
requirements, which will hopefully be met by new biosensor-based developments. 
 
Key words: DNA biosensor diagnosis PCR microarray 
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INTRODUCTION 
 
Probably no event has altered clinical analysis of DNA and RNA such as the 
development of PCR (polymerase chain reaction) (1). The introduction of this  
technology permitted a examination of small quantities of material, even as little as a  
few or single cells, with the result being obtained within hours.  This was in stark 
contrast to methods used till then, such as Southern (for DNA) or Northern (for 
mRNA) blot analysis which relied on microgram quantities of pure nucleic acids, and 
where a result was usually obtained only after a few days or even weeks. 
It is therefore little wonder that PCR was readily seized upon by diagnostic or clinical 
laboratories, and that these in turn introduced many of the “cutting edge” applications, 
which later found widespread use in the bio-medical research community. Examples 
of this are single cell PCR (SC-PCR), which was pioneered for pre-implantation 
genetic diagnosis (PGD) (2), and allele-specific PCR, which permitted the rapid 
determination of mutant loci, which frequently differ by only a single base change 
from the normal allele. 
The elucidation of genetic loci implicated in hereditary genetic disorders (e.g. cystic 
fibrosis), or those which were associated with a risk for a particular disease later in 
life, (e.g., the BRCA1 and 2 genes and the development of breast cancer), has driven 
the development of new PCR-based technologies which permit a high-throughput 
analysis of the numerous mutant alleles associated with such disorders. Of these 
technologies, probably the most promising is the use of high density nucleic acid 
arrays (3), also termed DNA Chip Technology, which permits the simultaneous 
assessment of numerous genetic alleles or loci.  
A further technological development of the PCR process, which has found widespread 
clinical applicability, was the advent of real-time PCR, which facilitated the highly 
accurate quantitation of nucleic acids (4). This technology has rapidly been applied to 
clinical settings, especially in oncology, where it is used for the determination of gene 
dosage or the associated level of gene expression of genes implicated in the 
malignancy. It has, however, also been widely used in the examination of infectious 
diseases, for instance in monitoring the viral burden in HIV infected individuals 
undergoing a variety of treatment regimens, to assess drug efficacy. 
Although the development of PCR, in all its various forms, has completely altered the 
analysis of nucleic acids for diagnostic purposes, it is to be expected that the next 
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technological revolution will equally transform applications as we know them today. 
It is to be expected that this new revolution will again be driven by the requirements 
of the end-user, which amongst others are:  
• cheap, rapid, simple,  
• high-throughput 
• ability to be used directly at the point-of-care setting by staff with no laboratory 
training. 
This latter point is gaining in importance as many clinical or other analytical 
applications increasingly rely on near-instantaneous answers directly at the point- of-
care or point-of-entry setting. Examples of these include: 
• The rapid identification of infected individuals or carriers for a new viral epidemic 
e.g., SARS, directly at the point-of-entry into a country. 
• Rapid assessment of the fetal genotype in prenatal diagnosis.  
• Rapid assessment of the oncological status of a malignant lesion directly in the 
surgery. 
• Viral load response to drug treatment. 
• Detection of genetically modified organisms or foodstuffs. 
• Detection of bacterially contaminants during food processing. 
• Detection of biological agents used for germ warfare. 
These facets will permit much more rapid therapeutic or intervensive strategies 
leading to better and more cost-effective healthcare management. 
These few scenarios do, however, imply that this next phase cannot be addressed by 
current technologies, and that new tools will have to be developed which are as simple 
to use as current technologies permitting diabetics to monitor their own blood sugar 
levels in a minimally invasive manner. In as much as such glucose monitoring devices 
rely on biosensor technologies, it is hoped that the new revolution of nucleic acid 
analysis will similarly be introduced by novel DNA-based biosensors. 
 
CURRENT STATE OF THE ART OF HIGH DENSITY DNA ARRAYS  
 
Microarrays are miniaturised analytical systems emerging from traditional 
biochemical assays such  Southern, Northern or Western blotting (5, 6). According to 
these conventional assays different branches of microarrays evolved which can be 
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applied in a complementary fashion to achieve a comprehensive global view of genes 
and gene expression, posttranslational modifications and protein status. The 
miniaturisation of the assay systems enables the simultaneous interrogation of  either 
many different events within one biological sample e.g. a specific cell population 
under certain stimuli, or the testing of a multitude of samples in parallel for the same 
event. Both variants provide a high throughput analysis tool which can be adapted to 
most different types of experimental questions and customer needs. 
Application fields for micro-arrays include diagnostics with genotyping applied to 
either mutation detection in specific human disease-related genes or identification 
processes in microbiological tasks, or gene profiling for predictive medicine. In the 
latter scenario, transcription patterns are correlated with different pathophysiological 
conditions, prognoses and disease progressions. Consequently the technology can be 
used for superior patient-tailored treatment based upon recognition of specific 
aberrant signalling pathways and expression patterns. A second field encompasses the 
identification of novel biomarkers and new targets for drug therapeutics as well as 
monitoring their effects e.g., efficacy and toxicity, on the organism.  
The fundamental basis of the microarray technology is a process of hybridisation 
where two biological molecule pair together in dependence of their complementary 
sequences or structures: DNA/DNA, cDNA/RNA, protein/antibody. The application 
of more novel interactions, such as those with aptamers, affibodies or glyoproteins for 
microarray applications is currently being explored.  
Technically advanced robots permit the disposition of probe molecules 
(oligonucleotides, PCR-amplified cDNA-fragments, proteins, antibodies) in 
micrometer distances onto the array surface, thereby facilitating the immobilisation of  
many different probes in a high density array on small surfaces of e.g. one square 
centimeter. The oligonucleotide probes can either be synthesised step by step in silico 
using photolithographie (allowing for a density of 106 different oligonucleotides per 
cm2) or they are pre-synthesised in vitro and subsequently spotted onto the array 
surface (10000 – 30000 spots per slide); this surface usually consists of  nylon 
membranes or glass slides coated with various agents providing immobilisation while 
maintaining probe native structures. The generation of oligonucleotide or cDNA 
arrays requires highly sophisticated bio-informatics systems as care needs to be taken 
that the maximum hybridisation-potential for every single array-probe-sample is 
achieved.  
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For the analysis of gene-expression, also termed gene-profiling, the sample RNA is 
generally converted into stable cDNA, using approximately 5-10 ug total RNA as 
starting material. Amplification of this sample material is usually achieved by in-vitro 
transcription or PCR. During this procedure the sample is also labelled with a 
fluorophore used for the identification of target-probe interactions in the subsequent 
hybridisation process. Quantitative analysis can either be obtained using a single 
colour scheme, where the fluorescently labelled sample is hybridised to different gene 
arrays, or by the use of multi-colour settings, whereby two samples which are to be 
compared are labelled with different  flourophores and co-hybridised to the same 
array. 
As these high-density arrays permit the simultaneous examination of several thousand 
loci,  new bio-informatic tools have had to be developed in order to facilitate useful 
data mining, which by careful correlation with the underlying physiological processes 
will lead to the extraction of biologically important information from this wealth of 
data. 
Although a major application to date of such high density arrays has been for the 
purpose of gene profiling, great strides have recently been made in applying this 
technology for genotyping or disease loci or of single nucleotide polymorphisms in 
order to determine disease associated patterns (7).  
 
CURRENT STATE OF THE ART OF REAL-TIME PCR 
 
Traditionally, PCR was a qualitative method, that was rendered semi-quantitative by 
ingenious reaction set-ups, such as competitive PCR where standards of known 
amount are co-amplified with the sample or quantitative fluorescent PCR.  
This deficit has been completely changed by the introduction of real-time PCR 
analysis (4), which has revolutionized the quantitative analysis of DNA and RNA. In 
real-time PCR reactions the concentration of the input template nucleic acid is 
accurately determined by the accumulated emission of a fluorescent signal during 
each cycle of the PCR reaction. This system permits the accurate quantitation of 
sample concentration over a dynamic range of several orders of magnitude. 
Furthermore, the system has proven to be very reliable and sensitive, being capable of 
detecting small amounts of target in the order of 1 to 10 copies. It is suitable for the 
determination of small differences in copy numbers, as witnessed from our recent 
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description of an assay which permits the detection of fetal aneuploidies (8), where 
only a 50% increase in target template occurs. 
A significant advantage of real-time PCR is that no post PCR handling is required, 
such as gel electrophoretic analysis of the PCR products, which effectively eliminates 
the risk of carry-over contamination, a vitally important feature for clinical settings. 
As the assay can be accessed in real-time, several quality controls can be integrated to 
monitor the efficacy of the PCR assay, such as final fluorescence, replicate 
uniformity, slope of the fluorescence curve and melting curve analysis.  
Furthermore, full advantage can be made of the fluorescent signal detection system, in 
that currently up to 4 different fluorophores (including a passive loading control) can 
be monitored simultaneously. In addition the system is very amenable to automation 
and is constantly being adapted to new formats which permit high-throughput, such as  
the recently developed 384 well format, which requires very little reagent chemistry 
(as little as 5-20µl) and permits a very rapid PCR cycles. This implies that by the use 
of 4 different fluorophores,  1536 different targets can be simultaneously analysed in a 
real-time setting, with a result being obtained in as little as 10 minutes. 
It is hence, no wonder that since its introduction a few years ago that real-time PCR 
has been used for a myriad of applications including, gene profiling, mutation and 
SNP analysis, monitoring of viral load, to the analysis of cell free DNA 
concentrations in a variety of disorders (9-10). 
It is, hence, to be expected that real-time PCR will continue to spearhead 
developments concerning the rapid and highly precise analysis of nucleic acids. 
 
BIOSENSORS: WHERE DO WE STAND FROM A USERS POINT OF VIEW? 
 
It readily becomes apparent from a quick perusal of the current literature that 
numerous DNA-based biosensor systems are being evaluated, and that new formats 
are almost being added on a daily basis. As these are being addressed in much greater 
depth in other contributions to this volume, we shall only briefly describe a few here 
and elude to current constraints limiting their immediate or near future use in a 
clinical or diagnostic setting. 
In general the underlying physical properties of the various types of sensors use the 
following modes of detection:  fluorescence, electrochemical or altered surface 
properties.  
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One of the most promising approaches for the fluorescent detection of nucleic acids 
appears to be the use of fibre optic systems, where in the interim it has become 
possible to coat pits chemically etched into individual optic fibres with a single 
sequence specific probe, thereby in essence permitting the analysis of single molecule 
– target sequence interactions (11). A highly sensitive CCD camera is used to monitor 
sequence specific hybridisation on the fibre bundle, which have been arranged into 
block-matrixes, to facilitate large scale parallel analysis. By using such an approach it 
has recently been possible to profile transcript differences  in a panel of human cancer 
cell lines, using starting material from as few as 10 cells. 
Electrochemical applications are also being intensively explored, as these are 
potentially cheaper to operate and maintain than the more complex systems required 
for the analysis of fluorescent signals. In these approaches both the analysis of nano-
particles as well as solid phase array biochips is being explored. 
In the former approach, DNA oligonucleotides are spotted in arrays which are flanked 
by electrodes (12).  Following hybridisation of the target sequence, the combined 
probe-target sequence is then recognised by gold nanoparticles coupled to specific 
oligonucleotides, which is used to trigger an electrical signal in combination with a 
reactive silver nitrate solution. By using this approach highly specific sequence 
detection with femtomolar sensitivity were reported. 
In parallel developments electrical biochip technologies are also being explored (13). 
In these systems, ELISA-based enzymatic redox reactions, such as the conversion of 
the substrate p-aminophenyl phosphate to the electroactive p-aminophenyl by alkaline 
phosphatase, are used to register the binding of specific target molecules. Potential 
applications of this technology which are under investigation include the monitoring 
of vial infections. Advantages of electrical biochips are that this technology is readily 
adaptable for a variety of biological targets, such as nucleic acids, metabolites 
(glucose) or proteins (antigens). Furthermore these devices are highly sensitive, do not 
require mechanical adjustments, are simple to use and readily miniaturised. 
Other research avenues include the use of quantum dots (14) and nanomechanical 
cantilever arrays (15, 16). Quantum dots are generated from discretely sized 
nanocrystals of cadnium selenide capped with zinc sulfide (14). The advantage of 
these dots is that they have unique optical properties, such as the ability to emit single 
colour signals at different wavelengths depending on the size of the dot. Furthermore, 
even if the dots are close proximity of each other no FRET (fluoresce resonance 
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energy transfer) effect occurs. This implies that highly dense arrays in the nano or 
micrometer scale are possible. The advantage of these dots is that as they very small, 
they can be incorporated in a vast array of combinations into polymer microbeads. By 
labelling each of these microbeads with a sequence specific oligonucleotide, this 
system permits rapid and efficient gene profiling.  
Nanomechanical cantilever arrays, on the other hand, make use of physical changes in 
surface structure, such as the bending of a micro-cantilever upon the specific binding 
of a target molecule (15, 16). The sensitivity of this system can be significantly 
improved by the inclusion of a magnetic control system. In this manner the deflection 
of the cantilever is enhanced by the application of an external magnetic field which 
acts on target sequences bound to the cantilever, which have been tagged with 
oligonucleotides labelled with magnetic particles. 
Although these approaches are all very promising, their current sensitivity is in the 
nanomolar range. Furthermore, most experiments have been restricted to the detection 
of artificial oligonucleotide mixtures, and the specificity of these detection systems 
has not be tested under “real-life” conditions where the vast amount of nucleic acids 
do not correspond to the target sequence. 
 
CONCLUSIONS 
 
From this overview it should be clear that significant strides are not only being made 
with new biosensor technologies for the analysis of nucleic acids, but that 
considerable advances have been made with more conventional PCR-based 
approaches. This is evident from new developments in real-time PCR, where results 
can be obtained in a matter of a few minutes, or from DNA arrays where thousands of 
alleles can be examined simultaneously. 
On the other hand, DNA sensor technologies, while promising, still need to bridge the 
gap between experimental status and the harder reality of clinical / diagnostic 
applications. Nevertheless, it is to be hoped that these technologies will lead to the 
development of new tools which are simple and cheap enough to be used at point-of-
care sites, thereby addressing a real need which cannot be met by current PCR-based 
platforms. 
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As most of my work involved the fascinating method of real-time quantitative PCR, I 
will also in the future address several projects involving prenatal diagnosis and PCR: 
• A major focus will be to follow up on the real-time PCR method for the detection 
of aneuploidies. We will test the novel real-time PCR instrument GeneXpert ® of 
Cepheid for it’s suitability to perform the diagnosis. In combination with their 
cartridge-based automatic sample preparation system it could be feasible to 
perform a rapid test that gives a diagnostic result within minutes of the invasive 
sampling. This test could be performed at the point of care without the 
requirement for technical staff or further laboratory equipment . 
• The concept to enrich the fetal fraction of the plasma DNA is one of the most 
promising approaches for non-invasive prenatal diagnosis. We will search for 
methods that permit a more straightforward enrichment with higher recoveries 
than the gel-based method. We will also try to develop novel methods for the 
prenatal detection of mutations, similar to the β thalassemia assays. With the 
implementation of real-time quantitative PCR or the more conventional 
quantitative fluorescent PCR even aneuploidy detection in a non-invasive manner 
is thinkable. 
• Real-time quantitative PCR is a method of tremendous potential. The detection 
and quantification of low copy numbers and in multiplexed amplifications require 
optimal reaction conditions and analysis. In this respect I will further investigate 
the phenomenon of PCR bias, which I discovered during my large trisomies study. 
I will also search for reaction conditions that allow more specific, highly sensitive 
and cheaper detection of sequences. Similarly, new concepts to thoroughly 
evaluate and compare different reaction conditions need to be established. 
• We already started a large study for the evaluation of fetal DNA levels in maternal 
plasma with the novel multicopy-sequence targetting DYS14 assay. In this work 
we will also aim to further monitor and  standardise DNA recovery and 
quantification. 
• The most recent candidate as a marker for pregnancy-related disorders is particle 
associated mRNA of placental origin in the maternal circulation. We will establish 
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experimental procedures for the measurement of promising gene-transcripts, and 
evaluate their usefulness for prenatal screening. 
